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Objetives
White adipose tissue and skeletal muscle are the largest organs 
in the body and both are composed of distinct cell types with a 
common origin, the mesenchymal steam cells. The adipose tissue 
is composed by the adipocyte while myocyte are the defining 
cell of skeletal muscle. Both adipocyte and myocyte secrete a 
range of bioactive molecules that are involved in local autocrine/
paracrine interactions as well as in an endocrine cross-talk with 
other tissues. Based on it, the main aim of the present work was 
to explore and to validate the role of the obestatin/GPR39 system 
in the differentiation program that determines adipogenesis and 
myogenesis. This aim was divided in the following points: 
1.  To determine the role of the obestatina/GPR39 system, as 
autocrine/paracrine signal, in the adipogenic program.
2.  To determine the role of the obestatina/GPR39 system on 
adipocyte metabolism. 
3.  To establish the role of the obestatin/GPR39 system as 
autocrine/paracrine signal in the myogenesis.
4.  To ascertain the role of the obestatina/GPR39 system on muscle 
metabolism. 
5.  To validate the use of obestatin as a potential therapeutic 
peptide for skeletal muscle regeneration.
6.  To determine the action of obestatin in the activation and 
differentiation of satellite stem cells from skeletal muscle.

INTRODUCTION
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Introduction A common origin for adipocytes and muscle
A COMMON OrIgIN FOr ADIpOCYTES AND 
MUSCLE
The embryonic development compromises different well orches-
tred processes that need to be switched on for organulogenesis1. 
Three are the germ layers that are implicated in the development 
of the different internal organs. The endoderm produces tissue 
within the lungs, thyroid, and pancreas. The ectoderm produces 
tissues within the epidermis and aids in the formation of neurons 
within the brain, and melanocytes. The mesoderm aids in the pro-
duction of muscle and adipose tissue, tissues within the kidneys, 
and red blood cells. All of the many different kinds of specialized 
cells that make up the body are derived from one of these germ 
layers2. The term stem cell is used to describe progenitors that 
give rise to cells derived from these three embryonic germ layers. 
Stem cells are capable of self-renewal and multilineage differen-
tiation through a process of asymmetric mitosis that leads to two 
daughter cells, one identical to the stem cell and one capable of 
differentiation into more mature cells.  Depending on its differen-
tiation capacity, stem cells are classified in: 
 1. Totipotent, i. e. early embryonic cells (1-3 days from 
oocyte fertilization), which can give rise to all the 
embryonic tissues and placenta.
 2. pluripotent, i. e. embryonic cells from blastocysts (days 
4-14 after oocyte fertilization), which can differentiate 
only into embryonic tissues belonging to the inner cell 
mass (ectoderm, mesoderm, and endoderm).
 3. Multipotent, i. e. embryonic cells from the 14
th day 
onwards, fetal stem cells, cord blood stem cells, and adult 
stem cells, which can give rise only to tissues belonging 
to one embryonic germ layer (ectoderm or mesoderm or 
endoderm)3.
Among the three embryonic germ layers, the mesoderm is a 
major source of the mesenchymal precursors giving rise to most 
mesodermal tissues. Consequently, growth and development 
of fat and muscle tissues have a common embryonic origin, the 
mesenchymal stem cells (MSCs) from the mesoderm4. MSCs are 
a versatile group of non-hematopoietic stem cells with high 
1. Slack, J. M. Origin of stem cells in organogenesis. Science. 2008; 322 (5907): 1498-501. 
2. Bongso, A. et al. History and perspective of stem cell research. Best Pract. Res. Clin. Obstet. 
Gynaecol. 2004; 18 (6): 827-34.
3. Hochedlinger, K. et al. Epigenetic reprogramming and induced pluripotency. Development. 
2009; 136: 509-3. 
4. Vodyanik, M.A. et al. A mesoderm-derived precursor for mesenchymal stem and endothelial 
cells. Cell Stem Cell. 2010; 7 (6): 718-29.
potency of proliferation and multipotency of the mesodermal 
lineage, such as adipocytes, myocytes, osteocytes, as well as other 
embryonic lineages5. MSCs are abundant in the skeletal muscle 
at early developmental stages, especially during the fetal and 
neonatal stages. While most of the MSCs develop into myogenic 
cells, a small portion of these cells differentiates into adipocytes6 
(SCHEME-1). The mesoderm is not the only germ-layer source of 
mesenchymal cells. In the head, for example, the facial bones, 
jaws and associated connective tissues have been shown to de-
rive from the neural crest (NC). The NC is a vertebrate cell popula-
tion that arises from the neuroectoderm7.
MSCs are not only involved in embryonic development and 
pre-natal stages. In addition, different mammal adult tissues 
harbour small amounts of MSCs, which have the potential to 
give a rise to all cell types of the specific tissue in which they 
reside aiming to repair, replace damaged tissue or to expand in 
response to chronic energy overload; dividing essentially without 
limit to replenish other cells as long as the person or animal is still 
alive. Depending on the type of host tissue, as well as age and 
state of the donor’s health, the plasticity can vary considerably8. 
This process is regulated by means of complex and incompletely 
understood mechanisms of communication among cells. MSCs 
were found mostly in human adult bone marrow but they are also 
found in muscle, fat, brain, cartilage, dental pulp, etc. Numerous 
publications have demonstrated the broad therapeutic poten-
tial of MSCs, due to their ability to differentiate towards multi-
ple adult cell types under appropriate conditions after birth9. 
Therefore, it is necessary further investigations to elucidate the 
complex mechanisms involved in the differentiation process of 
the different MSCs derived cells. The study of different signals will 
amplify the broad of new therapeutic targets in order to improve 
the knowledge and treatment of different pathologies related 
with differentiation cell processes abnormalities.
5. Krampera, M. et al. Mesenchymal stem cells: from biology to clinical use. Blood Transfus. 2007; 
5: 120-9.
6. Dodson, M. V. et al. Skeletal Muscle Stem Cells from Animals I. Basic Cell Biology. Int. J. Biol. 
Sci. 2010; 6 (5): 465-74.
7. Billon, N. et al. The generation of adipocytes by the neural crest. Development. 2007; 134: 
2283-92.
8. Xiang, X. et al. mTOR and the differentiation of mesenchymal stem cells. Acta Biochim. Biophys. 
Sin. 2011; 43 (7): 501-10.
9. Malek, A. et al. Human placental stem cells: biomedical potential and clinical relevance. J. 
Stem Cells. 2011; 6 (2): 75-92.
28
Introduction Adipogenesis
SCHEME-1. Diagram of the common embryonic origin of myocytes and 
adipocytes. After fertilization of the ovum and mitotic divisions of the zygote, 
the subsequent pluripotent stem cells give rise to endoderm, ectoderm, 
and mesoderm. The mesoderm may differentiate into hematopoietic tissue, 
kidney, and sex organs, as well as mesenchymal stem cells. Mesenchymal 
stem cells may differentiate into skeletal myoblasts and adipocytes, as well 
as osteoblasts, chondroblasts, tenoblasts, marrow stromal cells, neuron-like 
cells, and into cardiomyocytes. Through the formation of mesenchymal stem 
cells, both myocytes and adipocytes share a common genetic lineage (Figure 
extracted from J. Am. Coll. Cardiol. 2011; 57: 2461-73)
ADIpOgENESIS 
Types of tissues, characteristics and different 
functions
Two functionally different types of adipose tissues are classi-
cally described in mammals, which differ in several important 
properties: brown adipose tissue (BAT) and white adipose tissue 
(WAT)10. Both are involved in energy balance, but assume oppo-
site functions, even if they have a similar genetic content. BAT is 
specialized in energy dissipation as heat during cold and diet-in-
duced thermogenesis, whereas WAT is mainly involved in energy 
storage, and mobilization in the form of triacylglycerol. BAT stores 
less lipid and have more mitochondrias than WAT. BAT express-
es almost all the genes that are expressed in WAT, but it also 
expresses some distinct genes, including uncoupling protein-1 
(UCP1), which allows energy to be dissipated as heat without 
generating adenosine triphosphate (ATP)11,12 (SCHEME-2). Most BAT 
in rodents is localized in the interscapular region. Humans have 
large depots of BAT during infancy, but only small amounts that 
are dispersed throughout depots of WAT persist in adults. WAT is 
found in several depots throughout the body, and location varies 
between species. For mammals and birds, the largest fat tissues 
are intra-abdominal and subcutaneous, but it can also be found 
in other areas, such as the face and extremities, and within bone 
marrow. WAT from different locations have distinct molecular 
and physiological properties13. WAT is distributed throughout 
the body in the form of two major types: subcutaneous adipose 
tissue (SWAT) and the intra-abdominal visceral adipose tissue 
(VWAT). VWAT tissue is associated with insulin resistance, diabe-
tes mellitus, dyslipidemia, hypertension, atherosclerosis, hepat-
ic steatosis, and overall mortality. Subcutaneous and visceral 
adipocytes derive from different progenitor cells that exhibit a 
different gene expression pattern. SWAT responds better to the 
antilipolytic effects of insulin and other hormones, secrets more 
adiponectin and less inflammatory cytokines, and is differentially 
affected by molecules involved in signal transduction as well as 
drugs compared with VWAT. For example, adipocytes in visceral 
depots are less sensitive to lipolytic stimuli, whereas adipocytes 
from structural depots, such as around the eyes and in the heel 
pads, do not release stored lipid easily. Increased visceral adipose 
tissue is associated with an increased risk of insulin resistance and 
cardiovascular disease, whereas increased subcutaneous adipose 
tissue is not. Therefore it is necessary to distinguish properly be-
tween subcutaneous and visceral adipose tissue and its different 
10.  Saely, C. H. Brown versus white adipose tissue: A Mini-Review. Gerontology. 2012; 58: 15-23.
11.  Christodoulides, C. Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 2009; 20 
(1): 16-24. 
12.  Enerbäck, S. The origins of brown adipose tissue. N. Engl. J. Med. 2009; 360: 2021-3. 
13.  Rosen, E. D. et al. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006; 
7 (12): 885-96.  
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physiological implications14,15. 
SCHEME-2. Electronic micrograph  comparing cross-sections from BAT 
and WAT adipose tissues. In contrast to WAT, which stores triglycerides in 
a single lipid droplet, BAT contains numerous smaller droplets and a much 
higher number of (iron-containing) mitochondria, which make it brown. BAT 
also contains more capillaries than WAT, since it has a greater need for oxygen 
than most tissues. (Figure extracted from http://thepsychologyoffitness.
com/2012/03/01/the-science-of-fat-loss-part-1-different-types-of-body-fat/) 
The adipogenic differentiation process
Whereas the development of BAT takes place mainly during 
the embryonic/fetal period, the development of WAT can be 
understood as a continuous process throughout life16. In rodents, 
WAT develops mainly after birth, first in the perigonadal and 
subcutaneous depots, and only later in the omental depot. In 
humans, WAT formation begins during the second trimester 
of gestation and by birth both the visceral and subcutaneous 
depots are apparent. The fact developing further adipose tissue 
after birth, reflects the need of the newborn to survive in a new 
environment and to adapt to new intervals between nutrient 
intake17. Strikingly, the study of the developmental origin of fat 
tissues has received very little attention until now. Adipocytes, 
14.  Gil, A. et al. Is adipose tissue metabolically different at different sites? Int. J. Pediatr. Obes. 
2011; 6 (1): 13-20.
15.  Montague, C. T. et al. The perils of portliness: causes  and consequences of visceral adiposi-
ty. Diabetes. 2009; 49: 883-8. 
16.  Ailhaud, G. et al. Hormonal regulation of adipose differentiation. Trends Endocrinol.  Metab. 
1994; 5: 132-6. 
17.  MacDougald, O. A. et al. Transcriptional regulation of gene expression during adipocyte 
differentiation. Annu. Rev. of Biochem. 1995; 64: 345-73.
similar to muscle and bone cells, are derived from MSCs, which 
themselves are thought to arise from mesoderm. However, 
studies to define MSCs precise lineage origin and development of 
adipocytes during embryogenesis have not been performed18,19. 
Initially it was thought that we were born with all the fat cells we 
shall ever have, and that obesity resulted solely from adipocyte 
hypertrophy. In vivo studies showed that Zucker rats display 
adipocyte hypertrophy until a crucial cell size is reached, after 
which they further expand fat mass by adipocyte hyperplasia20. 
We also know that pre-adipocytes from elderly humans retain 
the capacity to differentiate in vitro21. Even at the adult stage, 
the potential to generate new fat cells persists22. Adipogenesis 
probably continues throughout life at a low rate until energy-
storage demand promotes further differentiation, although 
crucial data in humans are lacking on this point23. Excessive caloric 
intake without a rise in energy expenditure promotes adipocyte 
hyperplasia and hypertrophy after birth. As mature adipocytes 
do not divide, regeneration of adipocytes and the increase in 
adipocyte number depend on self-renewal of a pool of adipocyte 
precursors that remains present during adult life and that can be 
recruited to form new fat cells. The rise in adipocyte number is 
triggered by signalling factors that induce conversion of MSCs that 
differentiate into adipocytes. MSCs are recruited from the vascular 
stroma of adipose tissue as from the bone marrow24. 
The adipogenic process is divided in two main phases: determi-
nation and terminal differentiation. Determination results in the 
conversion of the stem cell to preadipocytes, which cannot be 
distinguished morphologically from its precursor cell but has lost 
the potential to differentiate into other cell types. Recruitment to 
this lineage gives rise to preadipocytes, which, when induced, un-
dergoes multiple rounds of mitosis (mitotic clonal expansion) and 
then differentiate into adipocytes. Whether ‘mitotic clonal expan-
sion’ is required for differentiation is controversial25; however, it is 
18.  Dani, C. et al. Adipocyte Precursors: Developmental Origins, Self-Renewal, and Plasticity. Adi-
pose Tissue Biology, 1. Ed. M.E. Symonds , Springer. (New York, USA). 2012. 
19.  Billion, N. et al. Developmental origin of adipocytes-new insights into a pending question. 
Biol. Cell. 2008; 100 (10): 563-75.
20.  Cleary, M. P. et al. Developmental changes in thymidine kinase, DNA, and fat cellularity in 
Zucker rats. Am. J. Physiol. 1979; 236: E508-E513.
21.  Hauner, H. et al. Promoting effect of glucocorticoids on the differentiation of human adipo-
cyte precursor cells cultured in a chemically defined medium. J. Clin. Invest. 1989; 84: 1663-70.
22.  Gregoire, F. M. et al. Understanding adipocyte differentiation. Physiol. Rev. 1998; 78 (3): 783-809.
23.  Rosen, E. D. et al. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006; 
7 (12): 885-96.
24.  Spalding, K. L. et al. Dynamics of fat cell turnover in humans. Nature. 2008; 453: 783-7.
25.  Otto, T. C. et al. Adipose development: from stem cell to adipocyte. Crit. Rev.  Biochem. Mol. 
Biol. 2005; 40: 229-42. 
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clear that some of the checkpoint proteins for mitosis also regu-
late aspects of adipogenesis. For instance, expression of cell cycle 
regulators, like p21 Waf1/Cip1 or p27 Kip1 are reduced during the 
clonal expansion26. Correlating with this, loss of p21 Waf1/Cip1 
and/or p27 Kip1produced adipocyte hyperplasia and obesity27. In 
the second phase, terminal differentiation, preadipocytes takes 
on the characteristics of the mature adipocyte, it acquires the ma-
chinery that is necessary for lipid transport and synthesis, insulin 
sensitivity and the secretion of adipocyte-specific proteins. Much 
progress has been made in defining the transcriptional networks 
controlling the terminal differentiation of preadipocytes into 
mature adipocytes; however, the early steps of adipocyte devel-
opment origin of this lineage remain poorly known28.
Several factors have been identified that commit the conver-
sion of multipotent stem cells to produce preadipocytes. These 
include bone morphogenetic proteins (BMP)29, Wingless-type 
mouse mammary tumor virus (MMTV) integration site family 
members (Wnt)30,31. BMP proteins, include BMP4, BMP2; the BMP 
receptors, BMPr2 and BMPr1a; and SMAD-1, -5, -8. Binding of 
BMP to the BMPr1: BMPr2 complex induces phosphorylation 
and, thus, activation of the BMPr1 kinase, that phosphorylates 
SMAD-1, -5, -8, which forms a complex with SMAD4 that trans-
locate into the nucleus and regulates the transcription of target 
genes32. Exposure of dividing C3H10T1/2 stem cells to either 
BMP4 or BMP2 gives rise to preadipocyte-like cells which, when 
treated at growth arrest with differentiation inducers, enter the 
adipose development pathway, express adipocyte markers, and 
acquire the adipocyte phenotype33. The Wnts comprise a family 
of secreted signalling glycoproteins whose effects are mediated 
through the Frizzled Receptor and low-density lipoprotein-re-
26.  Morrison, R. F. et al. Role of PPARγ in regulating a cascade expression of cyclin-dependent 
kinase inhibitors, p18 (INK4c) and p21 (Waf1/ Cip1), during adipogenesis. J. Biol. Chem. 1999; 
274: 17088-97.
27.  Naaz, A. et al. Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia 
and obesity. FASEB J. 2004; 18: 1925-7.
28.  Billion, N. et al. Developmental origin of adipocytes-new insights into a pending question. 
Biol. Cell. 2008; 100 (10): 563-75.
29.  Bowers, R. R. et al. Stable stem cell commitment to the adipocyte lineage  by inhibition of 
DNA methylation: role of the BMP-4 gene. Proc. Natl. Acad. Sci. USA. 2006; 103: 13022-7. 
30.  Ross, S. E. et al. Inhibition of adipogenesis by Wnt signalling. Science.  2000; 289: 950-3. 
31.  Bowers, R. R. et al. Wnt signalling and adipocyte lineage commitment. Cell Cycle.  2008; 7: 
1191-6. 
32.  Huang, H. Y. et al. BMP signalling pathway is required for commitment  of  C3H10T1/2 pluri-
potent stem cells to the adipocyte lineage. Proc. Natl. Acad. Sci. USA. 2009; 106: 12670-5. 
33.  Tang, Q. Q. et al. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. 
Proc. Natl. Acad. Sci. USA. 2004; 101: 9607-11. 
lated protein 5/6 co-receptor34. Surprisingly, the Wnts act at 
two points in the adipose development program, early in the 
program as an activator of lineage commitment and late in the 
program as an inhibitor of adipocyte differentiation, perhaps 
through the actions of different Wnt proteins35. Wnts exert their 
effects by signalling through multiple so-called ‘canonical’ and 
‘non-canonical’ pathways to control cell proliferation, survival, 
fate and behavior. Canonical Wnt signalling regulates mesen-
chymal stem cell fate36. Activation of Wnt/β-catenin signalling 
promotes differentiation of mesenchymal precursor cells into 
myocytes and osteocytes while suppressing commitment to 
the adipocytic lineage and terminal differentiation. Late Wnt 
signalling restrains adipocyte differentiation by inhibiting the 
expression of nuclear peroxisome proliferator–activated recep-
tor-γ (PPARγ), transcription factors cytidine-cytidine-adeno-
sine-thymidine (CCAT) and the complexes formed by CCAT and 
different enhancer-binding protein (EBP),  CCAT/EBP (C/EBP),  
the central regulators of adipogenesis. These transcription 
factors are induced directly by C/EBPβ and C/EBPδ in response 
to adipogenic stimuli, which also serve to switch off the 
canonical Wnt pathway. PPARγ and C/EBPα subsequently feed 
back to induce their own expression, in addition to activating 
many downstream target genes whose expression defines 
the adipocyte. Conversely, there are some works that assert, 
Wnt signalling serves to increase the number of preadipocytes 
during commitment and mitotic clonal expansion, versus a 
“non-canonical” pathway37 (SCHEME-3). 
Following commitment, adipocyte precursors re-entry 
into the cell cycle (mitotic clonal expansion) and undergo 
approximately two rounds of division, is a prerequisite for 
differentiation. Early markers of differentiation, such as 
lipoprotein lipase (LPL), are then expressed, and these cells are 
known as preadipocytes38. In the case of in vitro differentiation 
it is necessary a cocktail of inducers, including an agent to 
elevate cellular cyclic adenosine monophosphate (cAMP) in 
34.  Komiya, Y. et al. Wnt signal transduction pathways. Organogenesis. 2008; 4: 68-75. 
35.  Ross, S. E. et al. Inhibition of adipogenesis by Wnt signalling. Science. 2000; 289: 950-3. 
36.  Kang, S. et al. Wnt signalling stimulates osteoblastogenesis of mesenchymal precursors 
by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activa-
ted receptor gamma. J. Biol. Chem. 2007; 282(19): 14515-24 .
37.  Bowers, R. et al. Wnt signalling and adipocyte lineage commitment. Cell. Cycle. 2008; 7: 
1191-6. 
38.  Kokta, T. A. et al. Intercellular signalling  between adipose tissue and muscle tissue. Do-
mest. Anim. Endocrinol. 2004; 27: 303-31.
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fetal bovine serum (FBS) containing medium, like 3-isobutyl-1-
methylxanthine (IBMX), dexamethasone (DEX), as well as a high 
level of insulin or low level of insulin growth factor I (IGF-I)39, 
a hormone similar in molecular structure to insulin that has a 
considerable homology to insulin. Circulating IGF-I is synthesized 
primarily in the liver but also by adipocytes, suggesting 
autocrine/paracrine effects40. These inducers activate IGF-I, 
glucocorticoids, and cAMP-signalling pathways, respectively. In 
the early stages of adipogenesis, insulin functions predominantly 
through IGF-I receptor signalling, as preadipocytes express 
many more receptors for IGF-I than for insulin, although this 
ratio shifts as differentiation proceeds41. It has been established 
that the IGF-I, rather than insulin, is the true inducer ligand. IGF-I 
binds∼100-fold more tightly than insulin to the IGF receptor42.
Mitotic clonal expansion involves a transcription factor cascade, 
followed by the expression of adipocyte genes that triggers the 
differentiation of preadipocytes to adipocytes. Over the past 
two decades, attention was centered on the role of PPARγ and 
members of the family C/EBP. Immediately after induction of 
differentiation, cAMP response element-binding protein (CREB) 
becomes phosphorylated and activates the expression of C/
EBPβ43,44. However, at this point, C/EBPβ lacks DNA-binding 
activity. At 14–16 h after induction, dual phosphorylation on T188 
by mitogen-activated protein kinase (MAPK) and on S184 or T179 
by glycogen synthase kinase 3β (GSK3β), induced conformational 
changes in C/EBPβ that promotes dimerization and gives rise 
to DNA binding activity as the preadipocytes reenter the cell 
cycle. Beginning 18-24h,  C/EBPβ triggers transcription of 
PPARγ and C/EBPα, which, in turn, coordinately activate genes 
whose expression produces the adipocyte phenotype. C/EBPα 
and PPARγ function together as pleiotropic transcriptional 
activators of the large group of genes that produce the adipocyte 
39.  MacDougald, O. A. et al. Transcriptional regulation of gene expression during adipocyte  di-
fferentiation. Annu. Rev. Biochem. 1995; 64: 345-73. 
40.  Peter, M. A. et al. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins 
by growth hormone in rate white adipose tissue. Endocrinology. 1993; 133: 2624-31. 
41.  Smith, P. J. et al. Insulin-like growth factor-I is an essential regulator of the differentiation of 
3T3-L1 adipocytes. J. Biol. Chem. 1988; 263: 9402-8.
42.  Otto, T. C. et al. Adipose development: from stem cell to adipocyte. Crit. Rev. Biochem. Mol. 
Biol. 2005; 40: 229-42. 
43.  Zhang, J. W. et al. Role of CREB in transcriptional regulation of CCAAT/enhancer-binding 
protein beta gene during adipogenesis. J. Biol. Chem. 2004; 279: 4471-8. 
44.  Zhang, Jm W. et al. Dominant-negative C/EBP disrupts mitotic clonal expansion and diffe-
rentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA. 2004; 101: 43-7. 
phenotype45,46,47. Within their proximal promoters, both the C/
EBPα and PPARγ genes possess C/EBP regulatory elements at 
which C/EBPβ binds to coordinately activate transcription48,49,50,51. 
Once expressed, PPARγ and C/EBPα positively cross-activate 
each other through their respective C/EBP regulatory elements. 
Presumably, this action perpetuates the adipocyte phenotype in 
the mature adipocyte52,53.
After preadipocytes stop proliferating, late markers of differenti-
ation, such as glycerol-3-phosphate dehydrogenase (GPDH) and 
fatty acid synthetase (FAS) are detected. Cells then begin lipid 
accumulation in the cytosol at which time cells are called adipo-
cytes. Terminal adipocyte differentiation is seen as the accumula-
tion of lipid so that the nucleus is displaced from the center to the 
periphery of the cell54. Likewise, numerous regulatory proteins, 
characteristic of adipocytes in situ, are coordinately expressed, 
including insulin receptors, the insulin- responsive glucose trans-
porter, leptin, and others55,56.
45.  MacDougald, O. A. et al. Transcriptional regulation of gene expression during adipocyte  di-
fferentiation. Annu. Rev. Biochem. 1995; 64: 345-73. 
46.  Hwang, C. S. et al. Adipocyte differentiation and leptin expression. Annu. Rev. Cell Dev. Biol. 
1997; 13: 231-59. 
47.  Rosen, E. D. et al. Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 2000, 16: 
145-71. 
48.  Lane, M. D. et al. Role of C/EBPα in adipocyte differentiation. In Nutrition Genetics Obesity: 
Pennington Center Nutrition Series. Ed. GA Bray, DH Ryan. (Lousiana, USA) 1999. 
49.  Christy, R. J. et al. CCAAT/enhancer binding protein gene promoter: binding of nuclear fac-
tors during differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci.  USA. 1991; 88: 2593-7. 
50.  Abboud, T. K. et al. Desflurane: a new volatile anesthetic for cesarean section. Maternal and 
neonatal effects. Acta Anaesthesiol. Scand. 1995; 39: 723-6. 
51.  Clarke, S. L. et al. CAAT/enhancer binding proteins directly modulate transcription from 
the peroxisome proliferator-activated receptor gamma 2 promoter. Biochem. Biophys. Res. Com-
mun. 1997; 240: 99-103. 
52.  Date, T. et al. Bone morphogenetic protein-2 induces differentiation of multipotent 
C3H10T1/2 cells into osteoblasts, chondrocytes, and adipocytes in vivo and in vitro. J. Orthop. 
Sci. 2004; 9: 503-8. 
53.  Elberg, G. et al. Modulation of the murine peroxisome proliferator-activated receptor gam-
ma 2 promoter activity by CCAAT/enhancer-binding proteins. J. Biol. Chem. 2000; 275: 27815-22. 
54.  Giorgino, F. et al. Regional differences of insulin action in adipose tissue: insights from in 
vivo and in vitro studies. Acta Physiol. Scand. 2005: 183: 13-30. 
55.  Taylor-Jones, J. M. et al. Activation of an adipogenic program in adult myoblasts with age. 
Mech. Ageing Dev. 2002; 123: 649-61.
56.  Rosen, E. D. et al. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006; 
7 (12): 885-96.  
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SCHEME-3. Intracellular signalling pathways involved in adipogenesis. 
Canonical WNT signalling regulates mesenchymal stem cell fate. Activation of 
WNT/β-catenin signalling promotes differentiation of mesenchymal precursor 
cells into myocytes and osteocytes while suppressing commitment to the 
adipocytic lineage and terminal differentiation. WNT signalling restrains 
adipocyte differentiation by inhibiting the expression of PPARγ and C/EBPα, 
the central regulators of adipogenesis. These transcription factors are induced 
directly by C/EBPβ and C/EBPδ in response to adipogenic stimuli, which also 
serve to switch off the canonical WNT pathway. PPARγ and C/EBPα A subse-
quently feed back to induce their own expression, in addition to activating 
many downstream target genes whose expression defines the adipocyte. 
Autocrine and paracrine factors regulating 
adipogenic differentiation
WAT it is not only a site of energy storage providing a massive 
energy reserve that could be mobilized upon demand, with 
considerable capacity to expand, making it perhaps the only 
tissue in the body with the ability to increase in size so drastically 
without underlying transformation of the cellular phenotype57. 
The discovery of PPARγ and the C/EBPs gave the field a starting 
point, but it is becoming clear that the participation of these 
57.  Blüher, S. Insulin-like growth factor I, growth hormone and insulin in white adipose tissue. 
Best Pract. Res. Clin. Endocrinol. Metab. 2005; 19 (4): 577-87.
factors do not fully explain the transcriptional basis of adipocyte 
differentiation. Recent studies have revealed that WAT acts as 
an autocrine/paracrine organ that releases different hormones, 
adipokines and new transcription factors, in addition to a 
complex and interleaving set of cofactors, that act locally or 
in an endocrine manner, playing key roles in global energy 
metabolism58,59. Adiponectin avoids insulin resistance. Although 
it circulates in high concentrations, adiponectin levels are lower 
in obese subjects than in lean subjects, and are also reduced in 
association with insulin resistance and diabetes type II60. Leptin, 
which is expressed and secreted by adipocytes in proportion to 
adipose tissue mass, is anorectic and acts to limit energy storage 
when adipose tissue reserves have been filled. Leptin interacts 
with specific receptors in the hypothalamus to reduce food 
intake. In the obese state, however, resistance to leptin occurs, 
limiting its effectiveness. It also promotes angiogenesis in adipose 
tissue, to prevent adipocyte hypoxia61. Omentin, which is also 
preferentially expressed and release by visceral adipose tissue, 
appears to increase adipocyte insulin sensitivity and promote 
insulin- stimulated glucose uptake, via stimulation of Akt signalling 
pathway62. Chemerin promotes insulin receptor substrate-1 
(IRS-1) phosphorylation and concomitantly enhances glucose 
uptake in 3T3-L1 adipocytes63. Pre-adipocytes and adipocytes 
express and secrete high amounts of IGF-I in humans and several 
animal models. The production rate increases during adipocyte 
differentiation, suggesting an autocrine/paracrine action of IGF-I 
during adipose tissue development64. IGF-I increases glucose 
transport and lipogenesis and inhibits lipolysis65. 
Adipose tissue is also under the control of the central nervous 
system because it is innervated by neurons of the sympathetic 
nervous system that secrete adrenergic hormones (epinephrine/
58.  Saltiel, A. R. You are what you secrete. Nature Medicine. 2001; 7: 887-8. 
59.  Kratchmarova, I. et al. A proteomic approach for identification of secreted proteins  during 
the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol. Cell Proteomics. 2002; 1: 213-22.
60.  Lihn, A. S. et al. Adiponectin: action, regulation and association to insulin sensitivity. Obes. 
Rev. 2005; 6 (1): 13-21.
61.  Friedman, J. M. Leptin, leptin receptors and the control of body weight. Eur. J. Med. Res. 
1997; 2: 7-13. 
62.  Yang, R. Z. et al. Identification of omentin as a novel depot- specific adipokine in human 
adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 2006; 
290: E1253-E1261.
63.  Takahashi, M. et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte 
metabolism. FEBS Lett. 2008; 282: 573-8.
64.  Gaskin, H. R. et al. Regulation of insulin-like growth factor-Iribonucleicadic expression, 
polypeptide secretion, and binding protein activity by growth hormone in porcine preadipo-
cyte cultures. Endocrinology .1990; 126: 622-30. 
65.  Wabitsch, M. et al. The role of growth hormone/insulin-like growth factors in adipocyte 
differentiation. Metabolism. 1995; 44: 45-9. 
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norepinephrine) that promote fat mobilization66,67. The cyclin 
dependent-3/cyclin-dependent kinase-6 (CDK6) complex binds to 
and phosphorylates PPARγ resulting in increased transcriptional 
activity of PPARγ, which promotes adipogenesis68. Cyclin-depend-
ent kinase-4 (CDK4) also interacts with and activates PPARγ; this 
interaction requires the kinase domain of CDK4 but does not seem 
to involve direct phosphorylation of PPARγ69. Conversely, cyclin D1 
represses PPARγ activity and inhibits adipocyte differentiation70. 
Circulating free fatty acids (FFAs) derived from adipocytes are 
elevated in obesity states and have been suggested to contribute 
to the insulin resistance of diabetes and obesity by inhibiting 
glucose uptake, glycogen synthesis and glucose oxidation, by 
increasing hepatic glucose output71.
Molecular mechanisms implicated in adipogenic 
differentiation
As discussed above, the program of adipogenesis is modeled 
by the sequential activation of transcription factors. These 
transcription factors function as a downstream of signalling 
pathways that transduce information about the suitability of 
intracellular and extracellular conditions for differentiation72. 
Two kinase systems, mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol 3-kinase (PI3K)- Akt/protein kinase 
B (PKB), in 3T3-L1 cells can be activated by insulin, the main 
adipogenic hormone73. Several studies have looked at the 
effects of MAPK family members on adipogenesis with 
conflicting results74. The weight of evidence favors a role 
for extracellular signal-regulated kinase-1 (ERK1) and p38 
in adipocyte differentiation, with confusion stemming from 
66.  Rodbell, M. The metabolism of isolated fat cells. IV. Regulation of release of protein by li-
polytic hormones and insulin. J. Biol. Chem.  1966; 241: 3909-17. 
67.  Karastergiou, K. et al. The autocrine and paracrine roles of adipokines. Mol. Cell. Endocrinol. 
2010; 318: 69-78.
68.  Sarruf, D. A. et al. Cyclin D3 promotes adipogenesis through activation of peroxisome proli-
ferator-activated receptor. Mol. Cell. Biol. 2005; 25: 9985-95. 
69.  Abella, A. et al. Cdk4 promotes adipogenesis through PPARγ activation. Cell Metab. 2005; 
2: 239-49. 
70. Fu, M. et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor γ-mediated adipo-
genesis through histone deacetylase recruitment. J. Biol. Chem. 2005; 280, 16934-41. 
71.  Bergman, R. N. et al. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends 
Endocrinol. Metab. 2000; 11: 351-6.
72.  Rosen, E. D. et al. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006; 
7 (12): 885-96.
73.  Jinfei, X. et al. PKB/Akt Plays Pivotal Role in IGF-I Adipocyte Differentiation. J. Biol. Chem. 
2004; 279 (20): 35914-22.
74.  Bost, F. et al. The role of MAPKs in adipocyte differentiation and obesity. Biochimie. 2005; 
87: 51-6.
divergent effects in different phases of differentiation. ERK1, for 
example, is required in the proliferative phase of differentiation, 
and blockade of ERK activity in 3T3-L1 cells, or in mice inhibits 
adipogenesis. By contrast, in the terminal differentiation phase, 
ERK1 activity leads to phosphorylation of PPARγ, which inhibits 
differentiation. This implies that ERK1 activity has to be reduced 
after proliferation so that differentiation can proceed; this 
reduction is mediated in part by MAPK phosphatase-1 (MAPKP-
1)75. Data in 3T3-L1 cells indicated that p38 might be required 
for adipogenesis; however, loss of p38 seems to promote 
differentiation in primary pre-adipocytes, ES cells and p38-
/- MEFs. The answer to this paradox seems to lie within 3T3-L1 
cells, in which p38 has a unique pro-adipogenic effect that is 
not seen in other cell models76. Downstream components of the 
insulin-IGF-I signalling cascade are also crucially important for 
adipogenesis. The loss of individual insulin-receptor substrate 
(IRS) proteins inhibits adipogenesis, because it promotes CREB 
phosphorylation77. 
Moving down the insulin-signalling cascade, PI3K as well as 
Akt play an essential role in adipogenesis. PI3K/Akt signalling 
acts as the node for multiple growth factors and their cellular 
responses78. RNAi-mediated decrease in Akt1 was found to block 
the differentiation of 3T3- L1 cells79. Constitutively active Akt can 
promote the differentiation of 3T3-L1 cells into adipocytes, even 
in the absence of other inputs80. Furthermore, mouse embryonic 
fibroblasts (MEFs) and 3T3-L1 lacking Akt1 display an inability to 
differentiate into adipocytes81, this defect stems from an inability 
to induce PPARγ expression at the initiation of the adipogenesis 
program82, 83. The PPARγ transcription factor is the master regu-
75.  Sakaue, H. et al. Role of MAPK phosphatase-1 (MKP-1) in adipocyte differentiation. J. Biol. 
Chem. 2004; 279: 39951-7.
76.  Aouadi, M. et al. Inhibition of p38MAPK increases adipogenesis from embryonic to adult 
stages. Diabetes. 2006; 55: 281-9.
77.  Cypess, A. M. et al. Insulin/IGF-I regulation of Necdin and Brown Adipocyte Differentiation 
Via CREB- and FoxO1- Associated Pathways. Endocrinology. 2011; 152 (10): 3680-9.
78.  Jinfei, X. et al. PKB/Akt Plays pivotal role in IGF-I adipocyte differentiation. J. Biol Chem. 2004; 
279 (20): 35914-22.
79.  Xu, J. et al. Protein kinase B/Akt 1 plays a pivotal role in insulin-like growth factor-1 receptor 
signalling induced 3T3-L1 adipocyte differentiation. J. Biol. Chem. 2004; 279: 35914-22. 
80.  Kohn, A. D. et al. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipo-
cytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 1996; 
271 (49): 31372-8. 
81.  Baudry, A. et al. PKBα is required for adipose differentiation of mouse embryonic fibroblasts. 
J. Cell Sci. 2006; 119: 889-97.
82.  Peng, X. D. et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone de-
velopment, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003; 17: 1352-65. 
83.  Yun, S. J. et al. Isoform- specific regulation of adipocyte differentiation by Akt/protein kinase 
B α. Biochem. Biophys. Res. Commun. 2008; 371: 138-43. 
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lator of adipocyte differentiation, as well as Akt84. While it is clear 
from these studies that Akt is both necessary and sufficient to 
drive adipogenesis, its downstream targets involved in regulating 
this differentiation program are not well understood85. 
The forkhead box O1 (FoxO1) family of transcription factors 
are phosphorylated and inhibited by Akt, exporting it out 
of the nucleus because its presence in the nucleus strongly 
attenuates adipocyte differentiation86. FoxO1 expression is 
highest in adipose tissue, but FoxO1 appears to be a strong 
inhibitor of adipocyte differentiation87. Furthermore, FoxO1 has 
been proposed to directly repress PPARγ transcription88. Taken 
together, these studies suggest that Akt-mediated inhibition 
of FoxO1 is one mechanism by which Akt induces PPARγ and 
subsequent adipocyte differentiation89. It could be expected that 
the activation of PKB/Akt by the IGF-I receptor signal leads to 
the phosphorylation and inactivation of FoxO and removes its 
braking effect on the adipogenic transcription factors90.
Other downstream signal of Akt involved in adipogenesis is the 
mammalian target of rapamycin (mTOR)91, a critical regulator 
of mRNA translation and cell growth92. Using mTOR-specific 
inhibitor rapamycin, several studies have concluded that mTOR 
activity is required for proper differentiation of preadipocyte 
cell lines and primary cultures93,94. The effects of rapamycin were 
found to correlate with a reduction in PPARγ mRNA and protein 
84.  Rosen, E. D. et al. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. 
J. Biol. Chem. 2001; 276: 37731-4. 
85.  Zhang, H. H. et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. 
PLoS One. 2009; 10; 4 (7): E6189.
86.  Yun, S. J. et al. Isoform- specific regulation of adipocyte differentiation by Akt/protein kinase 
B α. Biochem. Biophys. Res. Commun. 2008; 371: 138-43. 
87.  Nakae, J. et al. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. 
Dev. Cell. 2003; 4: 119-29.
88.  Armoni, M. et al. FoxO1 represses peroxisome proliferator-activated receptor-gamma1 and 
-gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensiti-
vity. J. Biol. Chem. 2006; 281: 19881-91.
89.  Wolfrum, C. et al. Role of Foxa-2 in adipocyte metabolism and differentiation. J. Clin. Invest. 
2003; 112: 345-56.
90.  Jinfei, X. et al. PKB/Akt Plays Pivotal Role in IGF-I Adipocyte Differentiation. J. Biol. Chem. 
2004; 279 (20): 35914-22.
91.  Kim, J. E. et al. Regulation of peroxisome proliferator-activated receptor-γ activity by mam-
malian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004; 53: 2748-56.
92.  Wullschleger, S. et al. TOR signalling in growth and metabolism. Cell. 2006; 124: 471-84.
93.  Bell, A. et al. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes. 
Res. 2000; 8: 249-54.
94.  Yeh, W. C. et al. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-
L1 cells. Proc. Natl. Acad. Sci. USA. 1995; 92: 11086-90.
levels95,96,97,98. Akt activity results in downstream activation 
of mTOR complex 1 (mTORC1), which is acutely sensitive to 
rapamycin. A second mTOR-containing protein complex, 
mTORC2, lies upstream of Akt and contributes to Akt activation 
by insulin and growth factors by phosphorylating S473 in its 
hydrophobic regulatory motif99. mTORC2 is resistant to the acute 
effects of rapamycin, but prolonged treatment with rapamycin 
disrupts mTORC2 and in some lines results in loss of Akt 
phosphorylation100,101,102. 
Another target of Akt-mediated phosphorylation is GATA2, a 
transcription factor specifically expressed in the stromal vascular 
fraction of the adipose tissue where preadipocytes reside. In fact, 
GATA2 blocks the transition from preadipocyte to adipocyte in 
part through suppression of PPAR-γ2 expression after being phos-
phorylated by PI3K/Akt103, 104.
95.  Cho, H. J. et al. Regulation of adipocyte differentiation and insulin action with rapamycin. 
Biochem. Biophys. Res. Commun. 2004; 321: 942-8.
96.  Gagnon, A. et al. Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after 
clonal expansion. J. Cell. Physiol. 2001; 189: 14-22.  
97.  El-Chaar, D. et al. Inhibition of insulin signalling and adipogenesis by rapamycin: effect on 
phosphorylation of p70 S6 kinase vs eIF4E- BP1. Int. J. Obes. Relat. Metab. Disord. 2004; 28: 191-8.
98.  Kim, J. E. et al. Regulation of peroxisome proliferator-activated receptor- gamma activity by 
mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004; 53: 2748-56.
99.  Sarbassov, D. D. et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR com-
plex. Science. 2005; 307: 1098-101. 
100.  Sarbassov, D, D, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/
PKB. Mol Cell, 2006; 22:159-68.
101.  Hahn-Windgassen, A. et al. Akt activates the mammalian target of rapamycin by regulating 
cellular ATP level and AMPK activity. J. Biol. Chem. 2005; 280: 32081-9. 
102.  Zhang, H. H. et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 path-
way. PLoS One. 2009; 10; 4 (7): E6189.
103.  Tong, Q. et al. Function of GATA transcription factors in preadipocyte-adipocyte transition. 
Science. 2000; 290: 134-8.
104.  Menghini, R. et al. Phosphorylation of GATA2 by Akt increases adipose tissue differen-
tiation and reduces adipose tissue−related Inflammation: a novel pathway linking obesity to 
atherosclerosis. Circulation. 2005; 111: 1946-53.
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SCHEME-4. Molecular mechanisms implicated in the Akt/mTOr signalling 
pathway. mTOR promotes mRNAtranslation (a) and inhibits autophagy (b), 
by integrating nutrient signals that are generated by amino acids (c), growth 
factors such as insulin and IGFs (d), energy signals that act through AMPK 
(e) and various stressors including hypoxia (f), and DNA damage (g). Akt 
and ERK1/2 phosphorylate TSC2 inhibiting the GAP activity of TSC1–TSC2 
towards Ras homologue enriched in brain (RHEB). By contrast, phosphoryla-
tion of TSC2 by AMPK and GSK3β results in the activation of TSC1–TSC2. The 
hypoxic factor protein regulated in development and DNA damage response 
1 (REDD1; also known as DDIT4) promotes the assembly and activation of 
TSC1–TSC2. A second level of integration occurs at the lysosome: the Rag 
GTPases [which are held in place by the Ragulator, which consists of p18, p14 
and MAPK scaffold protein 1 (MP1)] recruit mTORC1 to the lysosomal surface 
in response to amino acids (c); in turn, lysosomal recruitment enables mTORC1 
to interact with GTP-bound RHEB, the end point of growth factor (d), energy 
(e) and stress (f,g) inputs. Growth factor receptors activate mTORC2 near the 
plasma membrane (d), where mTORC2 may be recruited through binding of 
mammalian stress-activated map kinase-interacting protein 1 (mSIN1; also 
known as MAPKAP1) to phospholipids. Because of its role in phosphorylating 
and activating Akt, mTORC2 forms a core component of the phosphoinositide 
3-kinase (PI3K) pathway. (Figure extracted from Nat. Rev. Mol. Cell Biol. 2011; 
12: 21-35)
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MYOgENESIS 
Types of tissues, characteristics and different 
functions
There are three major types of muscle structure in our body 
(SCHEME-5): 
 1. Skeletal muscle/voluntary muscle, responsible 
for skeletal movement such as locomotion and in 
maintaining posture and it is the most abundant.
 2. Smooth muscle, found within the walls of organs and 
blood vessels, it is not under conscious control.
 3. Cardiac muscle, an involuntary muscle and is found only 
in the heart.
Skeletal muscle exhibits a distinctive banding pattern when 
viewed under the microscope due to the arrangement of cy-
toskeletal elements in the cytoplasm of the muscle fibers. The 
structural and functional element of skeletal muscle is the 
myofiber. Each myofiber is surrounded by the endomysium, 
also called the basement membrane or basal lamina. Bundles of 
myofibers are surrounded by the perimysium, while the entire 
muscle is contained within the epimysium. Each myofiber is 
anchored at its extremities to tendons or tendon-like fascia at 
the myotendinous junctions (MTJs). Myofibers are composed 
mainly of actin and myosin myofibrils (also known as thick and 
thin filaments, respectively) repeated as a sarcomere, which is the 
basic functional unit of skeletal muscle. Responding to the signals 
from motor neurons, myofibers depolarize and release calcium 
from the sarcoplasmic reticulum (SR). This drives the movement 
of actin and myosin filaments relative to one another and leads to 
sarcomere shortening and muscle contraction105.
105.  Scott, W. et al. Human skeletal muscle fiber type classifications. Phys. Ther. 2001; 81 (11): 
1810-6.
SCHEME-5. Types and anatomical description of the muscle. (A) Anatomi-
cal location and description of the three main types of muscle: Cardiac muscle 
located in the heart walls has striated, tubular and branched uninucleated 
fibers; skeletal muscle is usually attached to skeleton and has striated, tubular 
and multinucleated fibers; smooth muscle located in walls of internal organs 
and blood vessels, it has narrow and tapered rod-shaped cells, as well as 
non striated and uninucleated fibers. (B) Scheme of the different parts that 
conform the skeletal muscle.
Based on their physiological properties, skeletal muscle fibers can 
be grouped into106:
 1. Fast-contracting, fatigue-susceptible type.  
 2. Slow-contracting, fatigue-resistant type. 
Myofibers also vary in terms of their myosin heavy chain (MHC) 
isoforms (fast or slow) and metabolism types (oxidative or glyc-
olytic), the proportion of each fiber type within a muscle deter-
mines its overall contractile property107. 
106.  Zierath, J. R. et al. Skeletal muscle fiber type: influence on contractile and metabolic pro-
perties. PLoS Biol. 2004; 2 (10): E348.  
107.  Yin, H. et al. Satellite cells and the muscle stem cell niche. Physiol. Rev. 2013; 93: 23-67.
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SCHEME-6. Histological section showing the different pattern of fibers 
distribution. The slow contracting soleus muscle is rich in myofibers 
expressing the slow type I MHC isoform as illustrated by the mosaic pattern 
displayed following immunostaining with an antibody specific to slow myosin 
heavy chain (arrows), whereas the fast contracting plantaris muscle is devoid 
of slow type I myofibers. (Figure extracted from Physiol. Rev. 2004; 84: 209-38)
Skeletal muscle tissue embryonic origin
In mammals, all axial and limb skeletal muscle derives from 
progenitors originating in the mesoderm, all are finalized 
during the fetal stage of development. These progenitors arise 
from the dorsal portion of the somite, the dermomyotome, an 
epithelial structure formed on the dorsal part of the somite. The 
dermomyotome contains multipotent progenitor cells, which 
eventually give rise to multiple adult tissues/cell types. The cell 
fate decisions largely depend on the relative position of these 
multipotent progenitor cells with respect to adjacent tissues 
(notochord, neural tube, dorsal ectoderm, and myotome) that 
contain the morphogenes that qualitatively trigger different 
cellular behavioral responses108. These cells destined for a muscle 
fate then undergo the process of myogenesis, it takes place 
in two successive stages109. Briefly, primary myofibers are first 
formed in the embryonic stage. Later, other signals stimulate 
a wave of proliferation giving rise to a population of so-called 
secondary myoblasts that will differentiate to form secondary 
fibers in the mid and late gestation in humans, and late and 
neonatal stages in mice110. The formation of secondary myofibers 
overlaps with adipogenesis, and fibrogenesis, which are initiated 
108.  Buckingham, M. Myogenic progenitor cells and skeletal myogenesis in vertebrates. Curr. 
Opin. Genet. Dev. 2006; 16: 525-32.
109.  Buckingham, M. et al. The formation of skeletal muscle- from somite to limb. J. Anat. 2003; 
202: 59-68.
110.  Ross, J. J. et al. Formation of primary and secondary myotubes in rat lumbrical muscles. 
Development. 1987; 100: 383-94.
at mid-gestation in humans and late gestation in rodents111,112 
(SCHEME-7).
Summarizing, during myogenesis the progenitors become 
specified and determined as myoblasts, which in turn 
differentiate into postmitotic mononuclear myocytes, and these 
myocytes fuse to one another to form multinucleated myofibers 
that will be fused among them to assemble the final muscle 
structure113. All along this process different specific factors 
are expressed: Paired-Homebox Transcription Factors (Pax3/
Pax7) are express in the course of the myogenic progenitors 
development, and basic helix-loop-helix (bHLH) myogenic 
regulatory factors (MRFs) during the next steps of differentiation. 
Pax3-positive cells are founder cells, forming a template of initial 
fibers in the limb to which Pax7-positive cells then contribute by 
forming secondary fibers114,115. The MRFs consist of four proteins: 
myogenic factor 5 (Myf5), myoblast determination protein 1 
(MyoD), Mrf4 (also called Myf6), and myogenin. These factors 
were originally identified by their in vitro ability to convert 10T1/ 
2 fibroblasts to a myogenic fate116. Myf5, MyoD, and Mrf4 are 
expressed in myoblasts117,118,119, while myogenin is expressed in 
myocytes120,121,122. In addition, MyoD, Mrf4, and myogenin are all 
expressed in the myonuclei of differentiated myofibers123,124,125.  
111. Michael, V. Dodson, et al. Skeletal muscle stem cells from animals I. Basic Cell Biology. Int. 
J. Biol. Sci. 2010; 6 (5): 465-74.
112.  Du, M. et al. Fetal muscle development, mesenchymal multipotent cell differentiation, and 
associated signalling pathways. J. Anim. Sci. 2011; 89: 583-90.
113.  Murphy, M. et al. Origin of vertebrate limb muscle- the role of progenitor and myoblast 
populations. Curr. Top. Dev. Biol. 2011; 96: 1-32.
114.  McMahon, J. A. et al. Noggin-mediated antagonism of BMP signalling is required for grow-
th and patterning of the neural tube and somite. Genes Dev. 1998; 12: 1438-52.
115.  Bentzinger, C. F. et al. Building Muscle- Molecular Regulation of Myogenesis. Cold Spring 
Harb. Perspect. Biol. 2012; 4: A008342.
116.  Weintraub, H. et al. The myoD gene family: Nodal point during specification of the muscle 
cell lineage. Science. 1991; 251: 761-6.
117.  Biressi, S. et al. Intrinsic phenotypic diversity of embryonic and fetal myoblasts is revealed 
by genome-wide gene expression analysis on purified cells. Dev. Biol. 2007; 304: 633-51.
118.  Kassar-Duchossoy, L. et al. Mrf4 determines skeletal muscle identity in Myf5: MyoD dou-
ble-mutant mice. Nature. 2004; 431: 466-71.
119.  Sassoon, D. et al. Expression of two myogenic regulatory factors myogenin and MyoD1 
during mouse embryogenesis. Nature. 1989; 341: 303-7.
120.  Ontell, M. et al. Contractile protein gene expression in primary myotubes of embryonic 
mouse hind limb muscles. Development. 1993; 117: 1435-44.
121.  Ontell, M. P. et al. Modulation of contractile protein gene expression in fetal murine crural 
muscles: emergence of muscle diversity. Dev. Dyn. 1993; 198: 203-13.
122.  Ott, M. O. et al. Early expression of the myogenic regulatory gene, myf-5, in precursor cells 
of skeletal muscle in the mouse embryo. Development. 1991; 111: 1097-107.
123.  Bober, E. et al. The muscle regulatory gene, Myf-6, has a biphasic pattern of expression 
during early mouse development. J. Cell Biol. 1991; 113; 1255-65.
124.  Hinterberger, T. J. et al. Expression of the muscle regulatory factor MRF4 during somite and 
skeletal myofiber development. Dev. Biol. 1991; 147: 144-56.
125.  Voytik, S. L. et al. Differential expression of muscle regulatory factor genes in normal and 
denervated adult rat hind limb muscles. Dev. Dyn. 1993; 198: 214-24.
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Identification of these molecular markers of the different stages 
of myogenic cells has been essential for reconstructing how 
myogenesis occurs. 
SCHEME-7. Formation and origin of trunk and hind limb mice muscles. 
Skeletal muscle is established in successive steps involving different types 
of muscle progenitors: embryonic/primary and fetal/secondary progenitors 
during development, and SCs in the adult. In mouse embryos, embryonic 
myogenesis occurs from E9.5 (embryonic day 9.5) to E16.5. From E16.5 to 
E18.5, fetal myogenesis allows muscle growth in the embryo. From E18.5, SCs 
appear that are responsible for perinatal growth and muscle regeneration. 
From 3 weeks postnatal, satellite cells are quiescent. Muscle progenitors that 
are involved in embryonic muscle differentiation skip the quiescent SCs stage 
and directly become myoblasts. Some progenitors remain as SCs in postnatal 
muscle and form a heterogeneous population of stem and committed cells. 
Activated committed satellite cells (myoblasts) can eventually return to the 
quiescent state. Six1/4 and Pax3/7 are master regulators of early lineage spec-
ification, whereas Myf5 and MyoD commit cells to the myogenic program. 
Expression of the terminal differentiation genes, required for the fusion of 
myocytes and the formation of myotubes, are performed by both myogenin 
and MRF4. 
Satellite cells and muscle regeneration 
It has been known for more than a century that skeletal muscle 
has the ability to regenerate new muscle fibers switching on 
myogenesis process, after it has been damaged by injury or as a 
consequence of disease such as muscular dystrophy126. Recent 
studies have revealed striking similarities in the mechanisms and 
the mediators of skeletal myogenesis in the embryo and in adult 
life127. Although skeletal muscle fibers are post-mitotic and unable 
to divide, a class of steam cells residing on the periphery of the 
fiber maintains the capacity for tissue remodeling and muscle 
regeneration128,129,130,131. Half a century ago, Alexander Mauro ob-
served a group of mononucleated cells at the periphery of adult 
skeletal muscle myofibers by electron microscopy132. These cells 
were named satellite cells (SCs) due to their sublaminar location 
and intimate association with the plasma membrane of myofib-
ers. They reside beneath the surrounding basal lamina and out-
side the myofiber plasma membrane. The direct juxtaposition of 
satellite cells and myofibers immediately raised a hypothesis that 
these progenitors cells may be involved in skeletal muscle growth 
and regeneration (SCHEME-8). In intact muscle, SCs are sublaminal 
and mitotically quiescent (G
o
 phase). Quiescent SCs are charac-
terized by the expression of Pax7 but not MyoD or myogenin133. 
Accumulating evidence indicates that adult SCs originate from 
the dermomyotome as all the other myogenic cell lineages. 
Pax3+/Pax7+ embryonic progenitor cells are the major source of 
adult SCs in trunk and limb muscles134. The quantity of SCs differs 
between muscles, myofiber types, developmental stages, and 
species. In general, SCs account for 30–35% of the sublaminal 
nuclei on myofibers in early post-natal murine muscles, and this 
number declines to 2-7% in adult muscles135,136,137,138. Within the 
same muscle, the number of SCs found on slow muscle myofibers 
126.  Tedesco, F. S. et al. Repairing skeletal muscle- regenerative potential of skeletal muscle 
stem cells. J. Clin. Invest. 2010; 120: 11-9.
127.  Palacios, D. et al. The epigenetic network regulating muscle development and regenera-
tion. J. Cell Physiol. 2006; 207 (1): 1-11.
128.  Seale, P. et al. A new look at the origin, function, and “stem-cell” status of muscle satellite 
cells. Dev. Biol. 2000; 218: 115-24.
129.  Charge, S. B. et al. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 
2004; 84: 209-38.
130.  Zammit, P. S. et al. The skeletal muscle satellite cell: the stem cell that came in from the 
cold. J. Histochem. Cytochem. 2006; 54: 1177-91.
131.  Mckay, B. R. et al. Satellite cell number and cell cycle kinetics in response to acute myotrau-
ma in humans: immunohistochemistry versus flow cytometry. J. Physiol. 2010; 588 (17): 3307-20. 
132.  Mauro, A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 1961; 9: 493-5.
133.  Yin, H. et al. Satellite cells and the muscle stem cell niche. Physiol. Rev. 2013; 93: 23-67.
134.  Horst, D. et al. Comparative expression analysis of Pax3 and Pax7 during mouse myogene-
sis. Int. J. Dev. Biol. 2006; 50 (1): 47-54.
135.  Allbrook, D. B. et al. Population of muscle satellite cells in relation to age and mitotic acti-
vity. Pathology. 1971; 3: 223-43. 
136.  Hellmuth, A. E. et al. Muscle satellite cell numbers during the postnatal period. J. Anat. 
1971; 110: 503. 
137.  Rudnicki, M. A. et al. The molecular regulation of muscle stem cell function. Cold Spring 
Harb. Symp. Quant Biol. 2008; 73: 323-31.
138.  Schultz, E. A. et al. Quantitative study of the satellite cell population in postnatal mouse 
lumbrical muscle. Anat. Rec. 1974; 180: 589-95.
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(type I) is generally higher than those on fast myofibers (type IIa 
and type IIb)139,140,141. It has been reported that the density of SCs 
is higher at the ends of the myofibers, where the longitudinal 
growth of skeletal muscle happens142. Moreover, SCs have been 
observed in close proximity to capillaries143. 
A HEALTH (EM) B INJURED CTX (H&E) C REST EXERCISE
(EM)
(H&E)
SCHEME-8. Muscle sections showing the different fibers distribution 
between health and injured muscle. (A) Adult skeletal muscle contains 
a population of SCs, closely associated with myofibers, located within the 
same basal lamina as seen by electron microscopy. SCs (violet arrow) can be 
distinguished from myonuclei (pink arrow) by their abundant heterochroma-
tin reflecting their mitotic quiescence. (B-C). Cardiotoxin versus exercise‐in-
duced damage. The extreme nature of the damage caused by cardiotoxin can 
be easily observed by H&E staining, with an almost complete loss of muscle 
fibers in the injured area at 4 days post-injection. Contrast with the lower 
damage caused via exercise observed in C. The electronic microscopy images 
show a clear disruption of Z‐bands, indicating damage, which is also clear 
from the H&E.
Muscle regeneration occurs in three sequential but overlapping 
stages after a pharmacological or physical damage, excessive 
exercise or a specific pathology (SCHEME-9):  
1. Inflammatory response. 
2. Activation, division, migration of SCs.
3. Differentiation and fusion of myotubes.
4. Maturation and remodeling of newly formed myofibers.
139.  Gibson, M. C. et al. The distribution of satellite cells and their relationship to specific fiber 
types in soleus and extensor digitorum longus muscles. Anat. Rec. 1982; 202: 329-37.
140.  Mackey, A. L. et al. Assessment of satellite cell number and activity status in human skeletal 
muscle biopsies. Muscle Nerve. 2009; 40: 455-65.
141.  Okada, S. et al. Muscle fiber type differentiation and satellite cell populations in normally 
grown and neonatally denervated muscles in the rat. Acta Neuropathol. 1984; 65: 90-8. 
142.  Allouh, M.Z. et al. Pax7 reveals a greater frequency and concentration of satellite cells at 
the ends of growing skeletal muscle fibers. J. Histochem. Cytochem. 2008; 56: 77-87. 
143.  Christov, C. et al. Muscle satellite cells and endothelial cells: close neighbors and privileged 
partners. Mol. Biol. Cell. 2007; 18: 1397-409. 
SCHEME-9. Muscle regeneration in adult mouse muscle. Left panel. 
Each myofiber in adult muscle is surrounded by a basal lamina sheath 
underneath which lie SCs in close apposition to the fiber. In response to injury, 
segmental necrosis of the myofiber occurs and SCs begin to proliferate and 
form myoblasts. These myoblasts differentiate and then migrate, adhere and 
fuse with one another to form multiple myotubes within the basal lamina 
sheath. Myoblasts/myotubes fuse with the stumps of the surviving myofiber 
and myotubes also fuse with each other to repair the injured myofiber. 
right panel. Regenerated myofibers are easily identified by the presence of 
centrally located nuclei. For each stage of regeneration in the schematic, a 
representative mouse muscle section is shown in cross-section and stained 
with H&E to illustrate the morphological features of the tissue. (Figure 
extracted from Development. 2012; 139: 641-56).
Muscle degeneration begins with necrosis of damaged muscle 
fibers. This event is initiated by dissolution of the myofiber 
sarcolemma, which leads to increased myofiber permeability. 
Disruption of myofiber integrity is reflected by increased 
plasma levels of muscle proteins and microRNAs, such as 
creatine kinase (CK)144 and miR-133a145, which are usually 
144.  Angelini, C. et al. Relationship of serum enzyme changes to muscle damage in vitamin E 
deficiency of the rabbit. Sperimentale. 1968; 118: 349-69.
145.  Laterza, O. F. et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. 
Clin. Chem. 2009; 55: 1977-83.
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restricted to the myofiber cytosol. Moreover, myofiber necrosis 
is accompanied by increased calcium influx or calcium release 
from the sarcoplasmatic reticulum (SR), which, in turn, activates 
calcium-dependent proteolysis and drives tissue degeneration. 
In this process, calpain, a calcium-activated protease, has been 
shown to cleave myofibrillar and other cytoskeletal proteins. 
Myofiber necrosis also activates the complement cascade and 
induces inflammatory responses146. Subsequent to inflammatory 
responses, chemotactic recruitment of circulating leukocytes 
occurs at local sites of damage. Neutrophils are the first 
inflammatory cells to infiltrate the damaged muscle, with a 
significant increase in their number being observed as early as 
1–6 h after myotoxin- or exercise-induced muscle damage147. 
Following neutrophil infiltration, two distinct subpopulations 
of macrophages (MPs) sequentially invade the injured muscle 
and become the predominant inflammatory cells148. The early 
invading MPs, characterized by the surface markers cluster of 
differentiation 68+ and 163-(CD68+/CD163-), reach their highest 
concentration in damaged muscle at 24 h after the onset of 
injury and thereafter rapidly decline. These CD68+/CD163-MPs 
secrete proinflammatory cytokines, such as tumor necrosis 
factor-α (TNF-α) and interleukin-1 (IL-1), and are responsible for 
the phagocytosis of cellular debris. A second population of MPs, 
containing CD68+/CD163-, reaches their peak at 2–4 days after 
injury. These MPs secrete anti-inflammatory cytokines, such as 
interleukin-10 (IL-10), and persist in damaged muscle until the 
termination of inflammation. Notably, the CD68+/CD163--MPs 
also reportedly facilitate the proliferation and differentiation of 
SCs149,150,151,152.
Following muscle damage, SCs activate and undergo rounds 
of proliferation before differentiating and fusing with existing 
146.  Orimo, S. et al. Analysis of inflammatory cells and complement C3 in bupivacaine-induced 
myonecrosis. Muscle Nerve. 1991; 14: 515-20. 
147.  Fielding, R. A. et al. Acute phase response in exercise. III. Neutrophil and IL-1 beta accu-
mulation in skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol.  1993; 265: R166-R172. 
148.  Chazaud, B. et al. Dual and beneficial roles of macrophages during skeletal muscle regene-
ration. Exerc. Sport. Sci. Rev. 2009; 37: 18-22. 
149.  Cantini. M, et al. Macrophage-secreted myogenic factors: a promising tool for greatly en-
hancing the proliferative capacity of myoblasts in vitro and in vivo. Neurol. Sci. 2002; 23: 189-94.
150.  Lescaudron, L. et al. Blood borne macrophages are essential for the triggering of muscle 
regeneration following muscle transplant. Neuromuscul. Disord. 1999; 9: 72-80. 
151.  Merly, F. et al. Macrophages enhance muscle satellite cell proliferation and delay their 
differentiation. Muscle Nerve. 1999; 22: 724-32. 
152.  Sonnet, C. et al. Human macrophages rescue myoblasts and myotubes from apoptosis 
through a set of adhesion molecular systems. J. Cell Sci. 2006; 119:  2497-507.
myofibers153,154. SCs activation is not only restricted to the site of 
muscle damage. In fact, localized damage at one end of a muscle 
fiber leads to the activation of all satellite cells along the same 
myofiber and migration of these SCs to the regeneration site155. 
It has been observed that SCs can migrate between myofibers 
and even muscles across barriers of basal lamina and connective 
tissues during muscle development, growth, and regeneration 
156,157,158. Recently, sialomucin CD34, whose expression is high 
on quiescent SCs but dramatically reduced during satellite cell 
activation, was demonstrated to act as an antiadhesive molecule 
to facilitate migration and promote the proliferation at very early 
stages of muscle regeneration159. In addition, dynamic regulation 
of ephrin receptors and ephrin ligands have been shown to 
direct SCs migration160. Progression of SCs through the myogenic 
program is controlled by the coordinated up- and down-
regulation of MRFs. The upregulation of Myf5 marks the earliest 
phase of myogenic commitment followed by the concomitant 
expression of MyoD, which together mark the majority of newly 
activated SCs (myoblasts). Following proliferation, these cells 
express markers of myoblast differentiation (MRF4 and myogenin) 
giving rise to nascent myotubes, that will be fused to form new 
myofibers, aiding in the repair process161,162. 
Similar to embryonic myogenesis, de novo formation of myofibers 
during muscle regeneration happens in two stages. In the first 
stage, individual differentiated myoblasts fuse to one another and 
generate nascent myotubes with few nuclei. In the second phase, 
additional myoblasts incorporate into the nascent myotubes, 
forming a mature myofiber with increased size and expression 
of contractile proteins (SCHEME-10). In recent years, studies in 
153.  Holterman, C. E. et al. Molecular regulation of satellite cell function. Semin. Cell Dev. Biol. 
2005; 16: 575-84.
154.  Le Grand, F. et al. Skeletal muscle satellite cells and adult myogenesis. Curr. Opin. Cell. Biol. 
2007; 19: 628-33.
155.  Schultz, E. et al. Response of satellite cell stofocal skeletal muscle injury. Muscle Nerve. 
1985; 8: 217-22. 
156.  Hughes, S. M. et al. Migration of myoblasts across basal lamina during skeletal muscle 
development. Nature. 1990; 345: 350-3.
157.  Jockusch, H. et al. Migration of adult myogenic precursor cells as revealed by GFP/nLacZ 
labelling of mouse transplantation chimeras. J. Cell. Sci. 2003; 116: 1611-6.
158.  Watt, D. J. et al. The movement of muscle precursor cells between adjacent regenerating 
muscles in the mouse. Anat. Embryol. 1987; 175: 527-36. 
159.  Alfaro, L. A. et al. CD34 promotes satellite cell motility and entry into proliferation to facili-
tate efficient skeletal muscle regeneration. Stem Cells. 2011; 29: 2030-41. 
160.  Stark, D. A. et al. Eph/ephrin interactions modulate muscle satellite cell motility and patter-
ning. Development. 2011; 138: 5279-89.
161.  Charge, S. B. et al. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 
2004; 84: 209-38.
162.  Dhawan, J. et al. Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell 
quiescence, activation and replenishment. Trends Cell. Biol. 2005; 15:  666-73.
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myoblast fusion in vitro have identified a cadre of cell surface, 
extracellular, and intracellular molecules, which are important 
for these two stages of myogenic cell fusion. For example, cell 
membrane proteins β 1-integrin163, very late antigen-4 integrin 
(VLA-4), integrin receptor V-CAM164, caveolin-3165, and transcrip-
tion factor Forkhead in human rhabdomyosarcoma (FKHR) also 
called FoxO1a have been shown to act in myoblast-to-myoblast 
fusion. Whereas the cytokine interleukin-4 (IL-4)166 and calcium 
and calmodulin activated nuclear factor of activated T cells iso-
forms (NFATC2) pathway is critical for the fusion of myoblasts with 
nascent myotubes167.
Muscle regeneration can be characterized by a series of mor-
phological characteristics based on histological and immuno-
fluorescence staining. On muscle cross-sections, newly formed 
myofibers can be readily distinguished by their small caliber and 
centrally located myonuclei. These myofibers are often basophilic 
in the beginning of regeneration due to protein synthesis and the 
expression of embryonic/developmental forms of MHC168,169. On 
muscle longitudinal sections and on isolated single myofibers, the 
centrally localized myonuclei were observed in discrete segments 
of regenerating myofibers or along the entire new myofiber, 
which suggests that cell fusion during regeneration happens in a 
focal, rather than diffuse, manner170. Once the regeneration pro-
cess is completed, the nuclei of new myofibers will move towards 
the sides, as they reside in the mature fibers. 
Skeletal muscle is a dynamic tissue composed of numerous 
elements including vascular, nervous and connective tissue. It is 
during skeletal muscle development and regeneration that these 
elements need to grow or repair in conjunction with the muscle 
163.  Schwander, M. et al. Beta1 integrins regulate myoblast fusion and sarcomere assembly. 
Dev. Cell. 2003; 4: 673-85. 
164.  Rosen, G. D. et al. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myoge-
nesis. Cell. 1992; 69: 1107-19.
165.  Galbiati, F. et al. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube 
formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated 
protein kinase is required for induction of caveolin-3 expression and subsequent myotube for-
mation. J. Biol. Chem. 1999; 274: 30315-21. 
166.  Horsley, V. et al. Forming a multinucleated cell: molecules that regulate myoblast fusion. 
Cells Tissues Organs. 2004; 176: 67-78.
167.  Horsley, V. Regulation of the growth of multinucleated muscle cells by an NFATC2-depen-
dent pathway. J. Cell. Biol. 2001; 153: 329-38.
168.  Hall-Craggs, E. C. et al. Histochemical changes in innervated and denervated skeletal mus-
cle fibers following treatment with bupivacaine (marcain). Exp. Neurol. 1975; 46: 345-4. 
169.  Wheeler, E. F. et al. Spatio temporal patterns of expression of NGF and the low-affinity NGF 
receptor in rat embryos suggest functional roles in tissue morphogenesis and myogenesis. J. 
Neurosci. 1992; 12: 930-45. 
170.  Blaveri, K. et al. Patterns of repair of dystrophic mouse muscle: studies on isolated fibers. 
Dev. Dyn. 1999; 216: 244-56. 
fibers in order to produce a fully functional unit171. Numerous 
studies further revealed that the proliferation and differentiation 
of SCs during muscle regeneration is profoundly influenced 
by innervation, the vasculature, hormones, nutrition, and the 
extent of tissue injury172,173,174,175,176,177,178. Therefore in vitro and in 
vivo research is focused on trying to mimic the environment of 
the muscle regeneration process, using different approaches, 
surgical techniques, implants and co-cultures, with the challenge 
to get a therapeutic alternative. Several publications have 
demonstrated the effectiveness in vitro and in vivo of co-culture 
rat skeletal muscle SCs and micro vascular fragments (MVF) or 
MSCs179 . Other challenge is the transplantation of SCs, a solution 
after a muscle damaged180,181,182. Transplantation of the cultured 
primary myoblasts into regenerating muscle typically results in 
extensive loss of the transplanted cells, terminal differentiation 
of the surviving cells, and virtually no contribution to the 
SCs compartment183,184, 185,186,187,188. By contrast, experiments 
171.  Dodson, M. V. et al. Skeletal Muscle Stem Cells from Animals I. Basic Cell Biology. Int. J. Biol. 
Sci. 2010; 6 (5): 465-74.
172.  D’Albis, A. et al. Regulation by thyroid hormones of terminal differentiation in the skeletal 
dorsal muscle. I. Neonate mouse. Dev. Biol. 1987; 123: 25-32.
173.  Hansen-Smith, F. M. et al. Muscle satellite cells in malnourished and nutritionally rehabili-
tated children. J. Neurol. Sci. 1979; 41: 207-21. 
174.  Jirmanova, I. et al. Ultra structural study of experimental muscle degeneration and regene-
ration in the adult rat. Z. Zellforsch. Mikrosk. Anat. 1972; 131: 77-97.
175.  McGeachie, J. K. et al. Initiation and duration of muscle precursor replication after mild 
and severe injury to skeletal muscle of mice. An auto radiographic study. Cell. Tissue Res. 1987; 
248: 125-30.
176.  Mulvaney, D. R. et al. Proliferation of skeletal muscle satellite cells after castration and 
administration of testosterone propionate. Proc. Soc. Exp. Biol. Med.  1988; 188: 40-5.
177.  Phillips, W. D. et al. Elimination of distributed synaptic acetylcholine receptor clusters on 
developing avian fast-twitch muscle fibers accompanies loss of polyneuronal innervation. J. 
Neurocytol. 1987; 16: 785-97.
178.  Yinm H. et al. Satellite cells and the muscle stem cell niche. Physiol. Rev. 2013; 93: 23-67.
179. Rhoads, R. P. et al.  Satellite cell-mediated angiogenesis in vitro coincides with a functional 
hypoxia-inducible factor pathway. Am. J. Physiol. Cell. Physiol. 2009; 296: C1321-C1328.
180.  Wallace, G. Q. et al.  Long-Term survival of transplanted stem cells in immunocompetent 
mice with muscular dystrophy. Am. J. Pathol. 2008;  173 (3): 792-802.
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involving transplant of intact fibers carrying SCs189or fresh 
isolated SCs190 have suggested that at least some portion of 
SCs have the capacity to repopulate the SCs compartment as 
well as extensively contribute to regenerating muscle. All of 
these findings led to an intriguing notion that SCs reside in a 
especial microenvironment in vivo, which profoundly affects 
their behavior, their niche is completely crucial for the correct SCs 
homeostasis191. 
SCHEME-10. Model of adult stem cell-mediated muscle regeneration. 
Schematic model outlining the different stages (text in blue) of muscle regen-
eration. At first, activated SCs proliferate, then fuse with existing myofibers, 
repairing damaged muscle fibers or alternatively fuse to each other to form 
new myofibers, participating to muscle regeneration and repair. SCs express 
specific markers during the different stages of muscle regeneration. It is 
important to note that while these markers are all effective for identifying SCs, 
most of them are not selectively expressed by SCs (e. g. CD34, syndecan 3 and 
4).  (Figure extracted from Ageing Res. Rev. 2011; 10 (1): 35-42)
189.  Collins, C. A. et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells 
from the adult muscle satellite cell niche. Cell. 2005; 122: 289-301.
190.  Montarras, D. et al. Direct isolation of satellite cells for skeletal muscle regeneration. Scien-
ce. 2005; 309: 2064-7.
191.   Kuang, S. et al. Asymmetric self-Renewal and commitment of satellite stem cells in muscle. 
Cell. 2007; 129; 999-1010.
Self-renewal and commitment of SCs
SCs are crucial for regeneration following injury but they 
also have the maintaining muscle homeostasis role, by self-
renewing192. The fate of daughter cell is determined by their 
relative orientation within the SCs compartment. Theoretically, 
sister cells can either be in a planar orientation where both 
cells remain in direct contact with the basal lamina and host 
myofiber or in an apical-basal orientation where one daughter 
cell is pushed toward the basal lamina and the other cell apically 
toward the host myofiber. Apical-basal location determines self-
renewal versus differentiation193 (SCHEME-11). During regeneration 
both types of orientation were founded, but doublets are 
predominantly planar (91%). Planar divisions were observed to 
give rise almost exclusively to identical daughter cells, trough 
symmetric division. Apical-basal orientation is performed trough 
asymmetric division principally194. Results regarding asymmetric 
division revealed that majority of apical-basal oriented doublets 
contained a Pax7+/Myf5- cell against the basal surface and a 
Pax7+/Myf5+ cell located on the apical side against the muscle 
fiber. The daughter cell attached to the basal lamina remains 
Myf5-, whereas the daughter that loses contact with the basal 
lamina upregulates Myf5 and becomes a committed myogenic 
cell. Presumably, Myf 5 is a marker of SCs commitment. So apical-
basal division usually gives rise to two different cells, they divided 
in an asymmetric mode, allowing to stem cell self- renewal. 
This finding strongly argues that satellite cell self-renewal 
is governed by the structure and signalling present in their 
immediate niche195. Trough asymmetric division, satellite stem 
cells self-renew to replenish the stem cell poll and produce more 
committed myogenic progenitors that participate in skeletal 
muscle growth and regeneration. Further investigation has 
revealed an important role for Wnt7a signalling trough the planar 
cell polarity pathway, controlling the homeostatic level of satellite 
steam cells and hence regulates the regenerative potential 
muscle self-renewal196,197. 
192.  Watt, F. M. et al. Out of Eden: stem cells and their niches. Science. 2000; 287: 1427-30.
193.  Yin, H. et al. Satellite cells and the muscle stem cell niche. Physiol. Rev. 2013; 93: 23-67.
194.  Cossu, G. et al. Oriented cell divisions and muscle satellite cell heterogeneity. Cell. 2007; 
129 (5): 859-61.
195.  Kuang, S. et al. Asymmetric self-renewal and commitment of satellite stem cells in muscle. 
Cell. 2007; 129: 999-1010.
196.  Cossu, G. et al. Oriented cell Divisions and Muscle satellite cell Heterogeneity. Cell. 2007; 
129 (5): 859-61.
197.  Le Grand, F. et al. Wnt7a Activates the Planar Cell Polarity Pathway to Drive the Symmetric 
Expansion of Satellite Stem Cells. Cell. Stem. Cell. 2009; 4 (6): 535-47.
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SCHEME-11. Symmetric and asymmetric division of muscle SCs. Asymmet-
ric division of stem cells generates self-renewing and committed daughter 
cells. Symmetric divisions generate either two self-renewing cells that are 
Pax7+/Myf5− (green) or two committed cells that are Pax7+/Myf5+ (red). In 
adult skeletal muscle, symmetric divisions (where the mitotic spindle is ori-
ented parallel to the muscle fiber axis) generate two identical (either stem or 
committed progenitor) daughter cells that both contact the basal lamina and 
the plasmalemma. Asymmetric division (where the mitotic spindle is oriented 
perpendicular to the fiber axis) generates one self-renewing cell (Pax7+/
Myf5−) that remains in contact with the basal lamina and one committed cell 
(Pax7+/Myf5+) that is adjacent to the plasmalemma but has lost contact with 
the basal lamina. (Figure extracted from Cell. 2007; 129: 999-1001)
Autocrine/paracrine factors involved in myogenesis
Given that skeletal muscle is the largest organ in the human body, 
the discovery of muscle as a producing organ revealed a whole 
new paradigm: skeletal muscle is an endocrine organ, which by 
secretion of hormone-like factors may influence metabolism 
in tissues and organs. Cytokines and other peptides that are 
produced, expressed and released by muscle fibers and exert 
autocrine, paracrine or endocrine effects should be classified 
as myokines198. Myostatin, was the first secreted muscle factor 
discovered to fulfill the criteria of a myokine199. Myostatin is a 
highly conserved member of the TGFα superfamily, is secreted 
and processed by protein binding and proteolitic cleavage 
before the active protein can execute its effects by preventing 
myoblast hyperplasia via the cell cycle progression, and thereby 
reduce muscle size200. Knock-out of the GDF8 gene encoding 
this protein promotes extensive skeletal muscle hypertrophy in 
198.  Trayhurn, P. et al. Secreted proteins from adipose tissue and skeletal muscle-adipokines, 
myokines and adipose/muscle cross-talk. Arch. Physiol. Biochem. 2011; 117 (2): 47-56.
199.  Kocamis, H. et al. Myostatin expression and possible functions in animal muscle growth. 
Domest. Anim. Endocrinol. 2002; 23 (4): 447-54.
200.  Rodgers, B. et al. Clinical, agricultural, and evolutionary biology of myostatin: a comparati-
ve review. Endocr. Rev. 2008; 29: 513-34.
mice, cattle and humans201. Contracting human skeletal muscle 
releases significant amounts of interleukin-6 (IL-6) into the 
circulation during prolonged single-limb exercise without any 
sign of muscle damage202 (SCHEME-12). Muscle fibers express 
the myokine IL-6, which subsequently exerts its effects both, 
locally within the muscle (e. g. through activation of AMPK) and 
when released into the circulation peripherally in several organs 
in a hormone-like fashion. Research during subsequent years 
highlighted the fact that muscle-derived IL-6 is an important 
player in metabolism. Moreover, IL-6 increased insulin-stimulated 
glucose uptake in muscle cells in vitro203. Specifically in skeletal 
muscle, IL-6 acts in an autocrine or paracrine manner to signal 
through a gp130R/IL-6R homodimer, resulting in the activation of 
AMPK and/or PI3K to increase glucose uptake and fat oxidation204. 
Another interleukin involved in myogenesis is interleukin-7 
(IL-7). During differentiation of human myoblasts IL-7 induces 
a reduction in mRNA levels of the terminal myogenic markers 
myosin heavy chain 2 and myogenin205. There are also other 
cytokines involved in muscle regeneration in a less manner as 
IL-8206 implicated in the further vascularization after muscle 
damaged, and interleukin-15 (IL-15), that also plays a role in the 
metabolic relation muscle-adipose tissues207. Other molecules 
were identified as novel muscle secreted factors which enhance 
muscle regeneration by stimulating the fusion of myoblasts 
with myotubes208.They include several growth factors and other 
molecules as:  IGF-I209,210; FGF-21211,212; vascular endothelial growth 
201.  McPherron, A. et al. Regulation of skeletal muscle mass in mice by a new TGF-α superfamily 
member. Nature. 1997; 387: 83-90.
202.  Steensberg, A. et al. Production of interleukin-6 in contracting human skeletal muscles 
can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 2000; 529 (1): 
237-42. 
203.  Pedersen, B. K. et al. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. 
Physiol. Rev. 2008; 88: 1379-406.
204.  Pedersen, B. K. et al. Point: Interleukin-6 does have a beneficial role in insulin sensitivity 
and glucose homeostasis. J. Appl. Physiol. 2007; 102: 814-6.
205.  Haugen, F. et al. IL-7 is expressed and secreted by human skeletal muscle cells Am. J. Phy-
siol. Cell Physiol. 2010; 298: C807-16.
206.  Keane, M. P. et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idio-
pathic pulmonary fibrosis. J. Immunol. 1997; 159: 1437-43.
207.  Nielsen, A. R. et al. Expression of interleukin-15 in human skeletal muscle effect of exercise 
and muscle fiber type composition. J. Physiol. 2007; 584: 305-12.
208.  Pedersen, B. K. et al. Muscles, exercise and obesity skeletal muscle as a secretory organ. 
Nat. Rev. Endocrinol. 2012; 8: 457-65.
209.   Jacquemin, V. et al. IGF -1 induces human myotube hypertrophy by increasing cell recruit-
ment. Exp. Cell. Res. 2004; 299  (1): 148-58.
210.  Musaro, A. et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of 
insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA. 2004; 101 (5): 1206-10. 
211.  Dogra, C. et al. Fibroblast growth factor inducible 14 (Fn14) is required for the expression 
of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for 
TWEAK-independent functions of Fn14 during myogenesis. J. Biol. Chem. 2007; 282 (20): 15000-10.
212.  Hojman, P. et al. Fibroblast growth factor-21 is induced in human skeletal muscles by 
hyperinsulinemia. Diabetes. 2009; 58: 2797-801.
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factor (VEGF)213,214; hepatocitic growth factor (HGF)215; TNF-α216 , 
and its regulation by tissue inhibitor of metalloproteinase (TIMP-
3) is directly implicated in muscle regeneration217; brain-derived 
neurotrophic factor (BDNF)218; vasopressin receptor (V1a-R)219; 
hexamethylene bis-acetamide inducible (HEXIM1)220 ; follistatin-
related protein 1221.
SCHEME-12. Biological role of contraction-induced IL-6. Skeletal muscle 
expresses and releases myokines into the circulation. In response to muscle 
contractions, both type I and type II muscle fibers express the myokine 
IL-6, which subsequently exerts its effects both locally within the muscle 
(e.g. through activation of AMPK) and when released into the circulation 
peripherally in several organs in a hormone-like fashion (Figure extracted 
from J. Exp. Biol. 2011; 214: 337-46).
213.  Germani, A. et al. Vascular endothelial growth factor modulates skeletal myoblast func-
tion. Am. J. Pathol. 2003; 163: 1417-28. 
214.  Bryan, B. A. Coordinated vascular endothelial growth factor expression and signalling du-
ring skeletal myogenic differentiation. Mol. Biol. Cell. 2008; 19 (3): 994-1006. 
215.  Sugiura, T. et al. Increased HGF and c-Met in muscle tissues of polymyositis and derma-
tomyositis patients: beneficial roles of HGF in muscle regeneration. Clin. Immunol. 2010; 136 
(3): 387-99. 
216.  Chen, S. E. et al. TNF-alpha regulates myogenesis and muscle regeneration by activating 
p38 MAPK.  Am. J. Physiol. Cell. Physiol. 2007; 292 (5): C1660-71.
217.  Liu, H. et al. TIMP3: a physiological regulator of adult myogenesis. J. Cell. Sci.  2010; 123 
(17): 2914-21.
218.  Miura, P. et al. Brain-derived neurotrophic factor expression is repressed during myogenic 
differentiation by miR-206. J. Neurochem. 2012; 120 (2): 230-8.
219.  Toschi, A. et al. Skeletal muscle regeneration in mice is stimulated by local overexpression 
of V1a-vasopressin receptor. Mol. Endocrinol. 2011; 25: 1661-73.
220.  Hong, P. et al. HEXIM1 controls satellite cell expansion after injury to regulate skeletal 
muscle regeneration. J. Clin. Invest. 2012; 122 (11): 3873-87.
221.  Ouchi, N. et al. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell func-
tion and revascularization in ischemic tissue through a nitric-oxide synthase-dependent me-
chanism. J. Biol. Chem. 2008; 283: 32802-11. 
gLUCOSE METABOLISM OF MUSCLE AND ADIpOSSE 
TISSUE
Development and growth of the different tissues are intimately 
bounded programs. The role of energy is fundamental to such 
biological processes, life is dependent on energy transformations, 
from a variety of metabolic pathways and chemical bonds are 
broken and made as part of the exchange and transformation 
of energy. Mammals must consume organic compounds to get 
energy, these are mostly carbohydrates, fats and proteins222.
Mammals possess highly integrated systems to regulate energy 
storage and expenditure. These systems have evolved to promote 
energy storage during periods of food surplus and mobilization 
of these stores when food is scarce223. Such systems are regulated 
both at the cellular level and in the whole organism by the coordi-
nated actions of circulating hormones and efferent neural signals 
from the central nervous system both to higher brain centers 
and to peripheral tissues, including the liver, muscle, and adipose 
tissue224. When food is abundant, carbohydrates are stored as 
small reserves of glycogen in the liver and muscle and as a much 
larger reserve as triglycerides in adipocytes. When food is limited, 
these stores are mobilized in catabolic pathways to meet energy 
needs225,226.
Glucose up-take occurs by diffusion and is mediated by glucose 
transporters (GLUT). There are over 10 different types of glucose 
transporters; however, the most significant for study are GLUT1-
4227.
 1. gLUT1 and gLUT3 are located in the plasma membrane 
of cells throughout the body, as they are responsible for 
maintaining a constant basal rate of glucose uptake.
 2. gLUT2 are located in the plasma membranes of hepato-
cytes and pancreatic beta cells, and they have a lower 
affinity for glucose.
222.  Lehninger, A. L. Bioenergetics: The Molecular Basis of Biological Energy Transformations . 
Ed. Addison-Wesley. (Indiana, USA) 1971 
223.  Wahren, J. et al. Splanchnic regulation of glucose production. Annu. Rev. Nutr. 2007; 27: 
329-45. 
224.  Wolfgang, M. J. et al. The role of hypothalamic malonyl-CoA in energy homeostasis. J. Biol. 
Chem. 2006; 281: 37265-9. 
225.  Otto, T. C. et al. Adipose development: from stem cell to adipocyte. Crit. Rev. Biochem. Mol. 
Biol. 2005; 40: 229-42.
226.  Cahill, G. F. Jr. Fuel metabolism in starvation. Annu. Rev. Nutr. 2006; 26: 1-22.
227.  Joost, H. et al. The extended GLUT-family of sugar/polyol transport facilitators: nomencla-
ture, sequence characteristics, and potential function of its novel members. Mol. Membr. Biol. 
2001; 18 (4): 247-56.  
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 3. gLUT4 are found in muscle and adipose tissue, it is in-
volved in post-prandial uptake of excess glucose from 
the bloodstream.
During fasting, some GLUT4 transporters will be expressed at 
the surface of the cell. However, most will be found within the 
plasma membranes of cytoplasmic vesicles within the cell. Upon 
reaching the plasmalemma, the vesicles fuse with the membrane, 
increasing the number of GLUT4 transporters expressed at the 
cell surface, and hence increasing glucose uptake. GLUT4 pro-
teins transport glucose and related hexoses according to a model 
of alternate conformation, which predicts that the transporter 
exposes a single substrate binding site toward either the outside 
or the inside of the cell. Binding of glucose to one site provokes 
a conformational change associated with transport, and releases 
glucose to the other side of the membrane228.
Insulin is the most potent anabolic hormone known, it stimulates 
the uptake of glucose, amino acids and fatty acids into cells, and 
increases the expression or activity of enzymes that catalyze 
glycogen, lipid and protein synthesis, while inhibiting the activity 
or expression of those that catalyze degradation229.Up to 75% 
of insulin-dependent glucose disposal occurs in skeletal mus-
cle, whereas adipose tissue accounts for only a small fraction230. 
Insulin regulates the amount of trafficking GLUT from intracellular 
compartments to the plasma membrane (PM) 231 (SCHEME-13). 
There are also references of GLUT translocation to the membrane 
after acute exercise232. Numerous references reflect the effect of 
different drugs in GLUT4 membrane translocation, 4-Hydroxyiso-
leucine233, triglitazone234. Akt is a key node for insulin and glucose 
metabolism with its consequently redistribution of GLUT4 to the 
cell. Although the precise molecular mechanisms by which Akt 
stimulates GLUT4 translocation are still being intensely studied. 
The Rab GTPase-acting protein (GAP) Akt substrate (AS160), also 
228.  Bell, G. et al. Molecular biology of mammalian glucose transporters. Diabetes Care.  1990; 
13 (3): 198-208. 
229.  Saltiel, A. R. et al. Insulin signalling and the regulation of glucose and lipid metabolism. 
Nature. 2001; 414 (6865): 799-806.
230.  Klip, A. et al. Glucose transport and glucose transporters in muscle and their metabolic 
regulation. Diabetes Care. 1990; 13: 228-43.
231.  Pessin, J. E. et al. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! 
Location! Location! J. Biol. Chem. 1999; 274: 2593-6.
232.  Kennedy, J. W. et al. Acute exercise induces GLUT4 translocation in skeletal muscle of nor-
mal human subjects and subjects with type 2 diabetes. Diabetes. 1999; 48 (5): 1192-7.
233.  Jaiswal, N. et al. 4-Hydroxyisoleucine stimulates glucose uptake by increasing surface 
GLUT4 level in skeletal muscle cells via phosphatidylinositol-3-kinase-dependent pathway. Eur. 
J. Nutr. 2012; 51 (7): 893-8.
234.  Yonemitsu, S. et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes. 
2001; 50 (5): 1093-101.
known as TBC1 domain family member 4 (TBC1D4) has emerged 
as an important direct target of Akt involved in this process235. 
Five putative Akt sites are phosphorylated on AS160 in response 
to insulin, of which S588 and T642 are the most important 
binding sites for its bioactivity. Importantly, mutation of these 
two sites to alanine significantly blocks insulin-stimulated GLUT4 
translocation236. The current model is that Akt-mediated phos-
phorylation of some combination of the sites on AS160 inhibits its 
GAP activity; thereby allowing a GAP to become GTP loaded and 
stimulate GLUT4 vesicle translocation.
Inside the cell, depending on the homeostasis, glucose is converted 
to glucose 6-phosphate that can be stored by conversion to 
glycogen in the muscle, or catabolized to produce cellular energy 
trough glycolysis, to pyruvate, which then enters the Krebs cycle 
in the mitochondria and is catabolized to acetyl-CoA-carboxilase 
(ACC), which is a feed stock for the fatty acid synthesis pathway, 
so they stored by conversion to triglycerides in the adipocytes, 
or in case, catabolized until the end of the catabolic process to 
get energy in form of ATP, all these processes under the control 
of Akt signalling237. Glycogen storage needs phosphorylation 
and consequent inactivation of GSK3 α/β. This inactivation leads 
to a decrease in the phosphorylation of glycogen synthase (GS) 
resulting in its activation, thereby stimulating glycogen synthesis238. 
Apart from GS, eukaryotic translation initiation factor 2B (eIF2B) 
can be also activated in a similar way leading to an increase in 
the glycogen synthesis and the protein synthesis239. Furthermore, 
inactivation of GSK3 has been shown to avoid degradation of the 
sterol regulatory element-binding proteins (SREBPs), which are 
transcription factors that trigger the expression of genes involved 
in cholesterol and fatty acid biosynthesis240. 
Storage in the adipose tissue as triglycerides is an important 
source of energy because they are both reduced and anhydrous. 
The energy yield from a gram of fatty acids is approximately 9 
Kcal (37 kJ), compared to 4 Kcal/g (17 kJ/g) for carbohydrates241. 
235.  Eguez, L. et al. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating 
protein. Cell Metab. 2005; 2: 263-72.
236.  Sano, H. et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regu-
lates GLUT4 translocation. J. Biol. Chem. 2003; 278: 14599-602.
237.  Manning, B. D. et al. Akt/PKB signalling: navigating downstream. Cell. 2007; 129: 1261-74.
238.  Kim, Y. M. et al. Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senes-
cence. Ann. NY Acad. Sci. 2010; 1201: 65-71.
239.  Rayasam, G. V. et al. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 
2009; 156: 885-98.
240.  Sundqvist, A. et al. Control of lipid metabolism by phosphorylation-dependent degra-
dation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005; 1: 379-91.
241.  Zechner, R. et al. Lipolysis: pathway under construction. Curr. Opin. Lipidol. 2005; 16: 333-40.
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Triglycerides storage is regulated by adenosine monophosphate-
activated protein kinase (AMPK) pathway, a serine/threonine 
protein kinase that senses the immediate availability of 
cellular energy. AMPK is switched on when the ratio ADP: ATP 
is decreased, to get energy and consequently switching on 
catabolic pathways and switching off anabolic pathways242. 
However, in case of overfeeding conditions, the glucose up-take 
is very high, there is an increase of ATP, so energy needs to be 
storage. This situation triggers out the dephosphorylation of 
AMPK that leads to a reduction in ACC phosphorylation, and 
thus an increase in the activity of this enzyme. Enhanced ACC 
activity consequently leads to increased malonyl Co-A levels, 
which mediate an inhibitory effect on cholinephosphotransferase 
1 (CPT-1), preventing fatty acid transport into mitochondria 
and fatty acid oxidation, promoting fatty acid synthesis and the 
consequently adipogenesis243. Therefore, both Akt and AMPK 
are involved in glucose metabolism, but their expression in 
overfeeding conditions is inverse, Akt regulates the intracellular 
ATP level and acts as a negative regulator of AMPK244. Akt has 
been shown to be an upstream negative regulator of AMPK 
and tuberous sclerosis protein 2 (TSC2) and, in that capacity, 
induces the full inhibition of TSC2 and activation of mTOR in 
lung cancer245. Conversely, Akt dephosphorylation often occurs 
concomitantly with AMPK activation when cells are treated with 
phenformin, an anti-diabetic drug, suggesting that these drugs 
do not only affect AMPK but also cause a coordinated inverse 
regulation of AMPK and Akt246.
Both pathways, GS or AMPK, favor glycogen/fat deposition 
respectively, with the consequent inhibition of breakdown plus 
burning stored energy and reduction of body weight. There is 
a main difference between muscle and adipose tissue glucose 
metabolism. In the first case, muscle metabolism does not 
implicate myogenesis, however in adipose tissue, an increase 
in glucose uptake involve the adipogenesis process and the 
consequently enhance of adipose tissue size. Despite these 
control mechanisms to survive feast or famine situations, lifestyles 
242.  Osawa, Y.  et al. Acid sphingomyelinase regulates glucose and lipid metabolism in hepa-
tocytes through Akt activation and amp-activated protein kinase suppression. FASEB J. 2011; 
25 (4): 1133-44.
243.  Munday, M. R. Regulation of mammalian acetyl-CoA carboxylase. Biochem. Soc. Trans. 
2002; 30: 1059-64.
244.  Hahn-Windgassen, A. et al. Akt activates the mammalian target of rapamycin by regulating 
cellular ATP level and AMPK activity. J. Biol. Chem. 2005; 280 (37): 32081-9.
245.   Quanri, J. et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in 
lung cancer chemopreventive activities of deguelin. Cancer Res. 2007; 67 (24): 11630-9. 
246.  King, T. D. et al. AMP-activated protein kinase (AMPK) activating agents cause dephos-
phorylation of Akt and glycogen synthase kinase-3. Biochem. Pharmacol. 2006; 71 (11): 1637-47.
in developed societies have led to excessive consumption of 
energy rich foods and sedentary behavior. Accumulation of 
excess fat in visceral compartment, even if subcutaneous fat 
mass is normal, carries greater metabolic risk as consequence of 
obesity, and its accompanying pathological consequences, most 
notably insulin resistance, the precursor to type 2 diabetes, and 
heart disease, that have become serious medical problems247. 
Conversely, in comparison with visceral adipose tissue, the 
subcutaneous depots appear less metabolically active248. When 
the capacity of WAT to store FFAs is exceeded, as occurs in some 
forms of obesity (when WAT expandability is exhausted) or in 
lipodystrophy (when WAT is partially or completely absent), extra-
adipose lipid accumulation, lipotoxicity, insulin resistance and 
ectopic lipid accumulation ensues249.
 The increase of intermuscular adipose tissue (IMAT) could play 
a crucial pathogenic role and represents a negative prognostic 
factor for several myopathies, metabolic diseases, and aging. 
Therefore, the origin and biology of this adipose depot could 
represent a promising pharmacological target.  It is possible 
to speculate that a primary insult to the muscle could induce 
its differentiation toward adipose tissue. In fact, high-glucose-
induced muscle stem cell to enter the adipogenic lineage250. 
On the other hand, the expansion of IMAT could induce 
some changes in muscle metabolism and insulin sensitivity 
because of the release of adipokines and metabolites from fat 
cells surrounding muscle fibers. There are clear evidences of 
signalling interaction between myogenic cells and adipocytes, 
playing a significant role in the rate and extent of adipogenesis, 
myogenesis, and lipogenesis/lipolysis 251,252,253. A fibro/adipogenic 
progenitor cell population may exist in skeletal muscle, having 
impacts on intramuscular fat accumulation as well as fibrosis in 
disease states254. Switching the commitment of these stem cells 
from myogenesis to adipogenesis in pathological situations, 
may increase intramuscular fat, an event associated with muscle 
247.  Wolfgang, M. J. et al.. Control of energy homeostasis: role of enzymes and intermediates of 
fatty acid metabolism in the central nervous system. Annu. Rev. Nutr. 2006; 26: 23-44. 
248. Tang, Q. Q. et al. Adipogenesis: From Stem Cell to Adipocyte. Annu. Rev. Biochem. 2012; 81: 
715-36.
249.  Christodoulides, C. et al. Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 2009; 
20 (1): 16-24. 
250.  Aguiari, P. et al. High glucose induces adipogenic differentiation of muscle-derived stem 
cells. Proc. Natl. Acad. Sci. USA. 2008; 105: 1226-31.
251.  Boone, C. et al. The adipose conversion process: regulation by extracellular and intracellu-
lar factors. Reprod. Nutr. Dev. 2000; 40: 325-58. 
252.  Diamond, F. The endocrine function of adipose tissue. Growth Genet. Hormones. 2002; 18: 17-23. 
253.  Fruhbeck, G. et al. The adipocyte: a model for integration of  endocrine and metabolic 
signalling in energy metabolism regulation. Am. J. Physiol. 2001; 280: E827-47. 
254.  Pisani, D. F. et al. Isolation of a highly myogenic CD34-negative subset of human skeletal 
muscle cells free of adipogenic potential. Stem Cells. 2010; 28:753-64.
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insulin resistance due to the paracrine effect of intramuscular 
adipocytes255,256,257. Because of their particular position close to 
muscle fibers, it is possible to hypothesize that the biology of 
intramuscular adipocytes may differ from that of adipocytes 
from other sites, but only a few data have been reported in 
animals258,259 , and no data are available in humans260.
SCHEME-13. glucose uptake and metabolism in the different organs. In 
normal individuals, binding of insulin to its receptor on the cell membrane 
stimulates glucose uptake into muscle and fat cells through the GLUT4 
transporter. It also inhibits glucose production in liver, thereby maintaining 
normal glucose levels in the blood. In adipose tissue, glucose provides fuel for 
the synthesis of fat stores, which serve as the body’s main energy reservoir. 
In muscle glucose provides energy and it is storage as glycogen, as a first 
energy source. Summarizing glucose uptake by insulin activates lipogenesis 
in adipose tissue, glycogenesis in muscle tissue and inhibits gluconeogenesis 
in liver (Figure extracted from Nature. 2005; 436:337-338).
255.  Uezumi, A. et al. Mesenchymal progenitors distinct from satellite cells contribute to ecto-
pic fat cell formation in skeletal muscle. Nat. Cell Biol. 2010; 12: 143-52.
256.  Joe, A. W. et al. Muscle injury activates resident fibro/dipogenic progenitors that facilitate 
myogenesis. Nat. Cell Biol. 2010; 12: 153-63.
257.  Kokta, T. A. et al. Intracellular signalling between adipose tissue and muscle tissue. Domest. 
Anim. Endocrinol. 2004; 27: 303-31.
258.  Pond, C. M. et al. The effects of noradrenaline and insulin on lipolysis in adipocytes isolated 
from nine different adipose depots of guinea-pigs. Int. J. Obes. 1991; 15: 609-18.
259.  Gardan, D. et al. Lipid metabolism and secretory function of porcine intramuscular adipo-
cytes compared with subcutane- ous and perirenal adipocytes. Am. J. Physiol. Endocrinol. Metab. 
2006; 291: E372-E380.
260.  Vettor, R. The origin of intermuscular adipose tissue and its pathophysiological implica-
tions. Am. J. Physiol. Endocrinol. Metab. 2009; 297: E987-E998.
OBESTATIN, THE grEAT MISSUNDErSTOOD
preproghrelin, the origin
Preproghrelin is a polypeptide encoded by the gene GHRL, which 
is located on chromosome 3, band p25–26, and it has 4 exons 
and 3 introns261. It is composed of 117 amino acids, with 23 amino 
acids conforming the signal sequence and 94 the proghrelin 
(SCHEME-14). After translation, the signal sequence is eliminated 
subsequently in the endoplasmatic reticulum (ER) and then a 
proteolitic processing occurs giving two mature peptides:  ghrelin 
and obestatin262. It has been identified and described different 
and multiple ghrelin-derived molecules produced by post-trans-
lational processing, on the basis of amino acid length and by type 
of acylation at serine 263.
SCHEME-14. The sequences of obestatin and ghrelin. A. Comparison of 
amino acid sequences of human, rat, mouse, chicken obestatin and ghrelin 
peptides. B. Amino acid segments and receptors of obestatin and ghrelin. 
A: Amino acid segment of ghrelin; B: Amino acid segment of obestatin. 
Conserved amino acids in all species are represented as red letters. (Figure 
extracted from Peptides. 2008; 29: 639-45)
261.  Kojima, M. et al. Ghrelin: structure and function. Physiol. Rev. 2005; 85: 495-522. 
262.  Gualillo, O. One ancestor, several peptides post-translational modifications of preproghrelin 
generate several peptides with antithetical effects. Mol. Cell. Endocrinol. 2006; 256: 1-8.
263.  Hosoda, H. et al. Structural divergence of human ghrelin. Identification of multiple 
ghrelin-derived molecules produced by post-traslational processing. J. Biol. Chem. 2003; 278: 
64-70.
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ghrelin and its receptor
The ghrelin hormone was discovered in gastric extracts as the 
natural ligand of the orphan growth hormone secretagogue 
receptor type 1a (GHSR1a) using reverse pharmacology264. Ghrelin 
is a 28 amino acidic peptide hormone, mainly produced in the 
stomach by the enteroendocrine X/A-like cells in the oxyntic 
mucosa265, in other organs and tissues, to a lesser extent, as 
other parts of gastrointestinal tract, pancreas, kidney, pituitary 
and hypothalamus266.  Additionally, to increase food intake 
and body weight in rodents after central as well as peripheral 
administration267, ghrelin possess other no endocrine activities 
such as the control of body energy, gastric motility, acid-gastric 
secretion, influence on pancreatic activity and glucose metabolism, 
reproductively, cardiovascular effects and proliferative and 
antiproliferative effects on different cell lines268,269. 
Ghrelin undergoes a post-translational modification, O-n-
octanoylation at Ser 3, essential for the binding to the GHSR-1a, 
for the release of growth hormone (GH) both in vivo and in vitro 
and for the most of the other endocrine actions270. Recently, the 
enzyme that catalyzes ghrelin acylation has been discovered 
using a bioinformatics approach. The ghrelin O-acyl transferase 
(GOAT) belongs to the membrane bound O-acyl transferases 
(MBOAT), specifically MBOAT4271(SCHEME-15). In mouse, GOAT is 
located in the ER and its distribution is well defined across the 
gastrointestinal tract and testis. In humans, it is expressed in 
stomach and pancreas272. Another difference between rodents 
and humans is that GOAT catalyzes the binding of n-octanoic 
acid to the Ser 3 in a specific way in the former one, meanwhile 
in humans this binding can occur with other different fatty 
acids273. The acylation occurs before pro-ghrelin is transported 
to the Golgi and it starts after the signal sequence is cleaved by 
a signal peptide peptidase. Then, GOAT, which is located in the 
264.  Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. 
Nature. 1999; 402: 656-60.
265.  Kojima, M. et al. Ghrelin: discovery of the natural endogenous ligand for the growth hor-
mone secretagogue receptor. Trends Endocrinol. Metab. 2001; 12: 118-22.
266.  Horvath, T. L. et al. Minireview: ghrelin and the regulation of energy balance: a hypotha-
lamic perspective. Endocrinology. 2001; 142: 4163-9. 
267.  Inui, A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat. Rev. 2001; 
2: 551-60. 
268.  García, M. C. et al. Role of ghrelin in reproduction. Reproduction. 2007; 133: 531-40.
269.  Camina, J. P. Cell biology of the ghrelin receptor. J. Neuroendocrinol. 2006; 18:  65-76.
270.  Kojima, M. et al. Ghrelin: discovery of the natural endogenous ligand for the growth hor-
mone secretagogue receptor. Trends Endocrinol. Metab. 2001; 12: 118-22.
271.  Yang, J. et al. Identification of the acyltransferase that octanoylates ghrelin, an appe-
tite-stimulating peptide hormone. Cell. 2008; 132: 387-96.
272.  Sakata, I. et al. Colocalization of ghrelin O-acyltransferase and ghrelin in gastric mucosal 
cells. Am. J. Physiol. Endocrinol. Metab. 2009; 297 (1): E134-E141.
273.  Gutierrez, J. A. et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc. 
Natl. Acad. Sci. USA. 2008; 105: 6320-5.
membrane of the ER compartment, mediates the translocation of 
the octanoyl-CoA from the cytosolic side to the ER lumen. Once 
the pro-ghrelin precursor reaches the trans-Golgi compartment, 
it is cleaved by prohormone convertase 1/3 (PC1/3), releasing the 
ghrelin peptide to the blood stream274. In addition to this acylated 
ghrelin, exists another form of ghrelin, commonly named des-acyl 
ghrelin or unacylated ghrelin (UAG), which circulates in a greater 
amount respect to acylated ghrelin (AG), it does not present the 
acylation on Ser 3 but nevertheless it has biological functions275. 
Des-acyl ghrelin has different no endocrine functions like 
cardiovascular and antiproliferative effects276, 277 and numerous 
reports point to the existence of another receptor, different to the 
GHSR-1a, for the des-acyl ghrelin278,279.
SCHEME-15. posttranslational processing of the different peptides that 
are cleaved from preproghrelin. The figure represents the posttranslational 
processing and acylation of the pro-ghrelin peptide. The acylation of pro-gh-
relin occurs after the signal sequence is cleaved by a signal peptide peptidase. 
GOAT seems to be located at the ER compartment and mediates the transloca-
tion of the octanoyl-CoA from the cytosolic side. Once the pro-ghrelin precursor 
reaches the trans-Golgi compartment, it might be cleaved by PC1/3 convertase, 
packaged in vesicles, and released to the blood. Different forms of ghrelin are 
released to the circulation: acylated, unacylated, and other shorter forms whose 
role is still unknown (Figure extracted from Eur. J. Endocrinol. 2010; 163(1):1-8).
274.  Romero, A. et al. GOAT: the master switch for the ghrelin system? Eur. J. Endocrinol. 2010; 
163: 1-8.
275.  Cederberg, H. et al. Unacylated ghrelin is associated with changes in insulin sensitivity and 
lipid profile during an exercise intervention. Clin. Endocrinol. 2012; 76 (1): 39-45.
276.  Korbonits, M. et al. Ghrelin: a hormone with multiple functions. Front. Neuroendocrinol. 
2004; 25: 27-68.
277.  Bowers, C. Y. Unnatural growth hormone-releasing peptide begets natural ghrelin. J. Clin. 
Endocrinol. Metab. 2001; 86: 1464-69.
278.  Baldanzi, G. et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and 
endothelial cells through ERK1/2 and PI 3-kinase/Akt. J. Cell Biol. 2002; 159: 1029-37.
279.  Toshinai, K. et al. Des-acyl ghrelin induces food intake by a mechanism independent of the 
growth hormone secretagogue receptor. Endocrinology. 2006; 147:  2306-14. 
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Obestatin discovery
In 2005, based on bioinformatic predictions, Zhang and col-
leagues discovered that the ghrelin gene encoded another 
secreted and bioactive peptide280. They isolated a peptide called 
obestatin, a contraction of obese, from the Latin “obedere,” 
meaning to devour, and “statin,” denoting suppression.  It showed 
actions opposite to ghrelin on food intake, body weight, and gas-
tric emptying. This peptide derived from proghrelin (amino acids 
76-98) has 23 amino acids with a glycine residue on the carboxy-
terminal domain that can be amidated. Obestatin was originally 
isolated from stomach, showing to be a circulating peptide whose 
secretion is pulsatile and displays an ultradian rhythmicity similar 
to ghrelin and GH secretion281. Concentrating immunoreactive 
obestatin from the stomach of 30 rats and verifying its unique 
sequence according to Edman sequencing282, it was found that in 
the first 20 amino acids sequenced, two residues are distinct from 
those of human obestatin and matched with the rat sequence. 
At the time, no rodent obestatin was synthesized283. Although 
a recent report could not detect endogenous immunoreactive 
obestatin in rat stomach extracts284, another study demonstrated 
the existence of alternatively spliced ghrelin transcripts in the 
human stomach, encoding exclusively obestatin together with a 
signal peptide for secretion285. Future studies are needed to reveal 
the regulation of obestatin biosynthesis, processing, and secre-
tion. Further investigations, found expression in other tissues as 
small intestines, stomach, spleen, cerebral cortex of rats286, perina-
tal rat pancreas287, myenteric plexus, and in the Leydig cells of the 
testis in mice/ rats with in vivo and in vitro techniques288,289. 
280.  Zhang, J. V. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s 
effects on food intake. Science. 2005; 310: 996-9.
281.  Zhu, X. et al. On the processing of proghrelin to ghrelin. J. Biol. Chem. 2006; 281: 38867-70.
282.  Zhang, J. V. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s 
effects on food intake. Science. 2005; 310: 996-9.
283.  Zhang, J. V. et al. Obestatin induction of early-response gene expression in gastrointestinal 
and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol. Endo-
crinol. 2008; 22: 1464-75. 
284.  Bang, A. S. et al. Characterization of proghrelin peptides in mammalian tissue and plasma. 
J. Endocrinol. 2007; 192: 313-23.
285.  Seim, I. et al. Revised genomic structure of the human ghrelin gene and identification of 
novel exons, alternative splice variants and natural antisense transcripts. BMC Genomics. 2007; 
8: 298-314.
286.  Zhang, J. V. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s 
effects on food intake. Science. 2005; 310: 996-9.
287.  Chanoine, J. P. et al. Obestatin acylated and total ghrelin concentrations in the perinatal rat 
pancreas. Horm. Res. 2006; 66 (2): 81-8.
288.  Dun, S. L. et al. Distribution and biological action of obestatin in the rat. J. Endocrinol. 2006; 
191: 481-9. 
289.  Grönberg, M. et al. Distribution of obestatin and ghrelin in human tissues: immunoreactive 
cells in the gastrointestinal tract, pancreas, and mammary glands. J. Histochem. Cytochem. 2008; 
56: 793-801.
Obestatin and its receptor
Obestatin was originally reported to be the ligand for the orphan 
receptor GPR39290. GPR39 was first cloned in 1997, before obesta-
tin discovery, from a fetal brain cDNA library, by hybridization at 
low stringency. Due to the sequence similarity, GPR39, along with 
another GPCR cloned at that time, was considered related to the 
GHSR1a, the motilin receptor (GPR38, cloned at the same time 
as GPR39), neurotensin receptors or neuromedin-U receptors, 
whose agonists included synthetic peptides and non-peptide GH 
secretagogues291. Later the natural endogenous ligand for GHS-R 
was discovered, named ghrelin292,
 
and GPR39 was speculated to 
have a ligand of a peptide regulating gastrointestinal functions, 
since all the other receptors homologous to GHS-R have such 
ligands293.
 
GPR39 had been considered, however, an orphan GPCR 
until 2005, when Zhang and colleagues discovered obestatin 
encoded by the ghrelin gene. Based on the data of radiolabeled 
ligand binding assays, it was proposed that the new hormone was 
a cognate ligand of GPR39294. 
The human GPR39 is 435-amino acid long and has seven-
transmembrane helices. Its gene is located in chromosome 2, 
band q21–q22, consisting of two exons295.The first exon encodes 
residues 1 to 285, corresponding to the N-terminal region and 
the first five transmembrane helices, and the second exon 
encodes residues 286 to 435, corresponding to the last two 
transmembrane helices and the C-terminal region. Between 
the two exons there is an intron as large as 200 kb, whose 
analogue appears in the genes of the ghrelin receptor and the 
motilin receptor. The second exon of GPR39 shares a segment 
of DNA with LYPD1 gene: GPR39 is encoded by the forward 
strand of DNA, while LYPD1 is transcribed from the reverse 
strand. The two-exon structure and LYPD1 gene-overlapping 
pattern are conserved among several species.
 
The maximal 
promoter activity resides in the 5’-UTR region. Such a region 
in U-138 cell lines was reported to be from 673 to 14 from the 
290.  Zhang, J. V. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s 
effects on food intake. Science. 2005; 310: 996-9.
291.  McKee, K. K. et al. Cloning and characterization of two human G protein-coupled receptor 
genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin re-
ceptors. Genomics. 1997; 46: 426-34.
292.  Kojima, M. et al. Ghrelin: discovery of the natural endogenous ligand for the growth hor-
mone secretagogue receptor. Trends Endocrinol. Metab. 2001; 12: 118-22.
293.  Kojima, M. et al. Ghrelin: structure and function. Physiol. Rev. 2005; 85: 495-522. 
294.  Zhang, J. V. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s 
effects on food intake. Science. 2005; 310: 996-9.
295.  Nogueiras, R. et al. Biomedicine. Separation of conjoined hormones yields appetite rivals. 
Science. 2005; 310: 985-6. 
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translation initiation codon, while in HepG2 cell from “573 
to“14.
 
Although the negative regulatory elements have not 
yet been determined, there was such an element from 673 to 
573 in HepG2 cells. The translation initiation codon is at 469 
nucleotides downstream of the transcriptional start site296.
GPR39 is expressed in many organs and various tissues, especially 
in stomach, white adipose tissue, and hypothalamus297,298,299. 
The colocalization of immunoreactive obestatin and its receptor 
GPR39 in the gastric mucosa and intestinal tissues implies 
its involvement in energy homeostasis300. Of interest, GPR39 
expression in white adipose tissues of rats was up-regulated 
during fasting whereas GPR39 levels were decreased in cultured 
mouse embryonic fibroblast cell lines during adipogenesis301. In 
human adipose tissue, decreased GPR39 expression was found in 
patients with obesity-associated type 2 diabetes mellitus302.
Beside the canonical form of GPR39 (named GPR39-1a), a splice 
variant GPR39-1b has been identified, which is encoded by the 
first exon and thus truncated after the fifth transmembrane helix, 
but at the present there is no references of functionality303,304,305.
Obestatin and its controversial bioactivity through 
gpr39 receptor
The relationship of obestatin and GPR39 was later challenged 
stating that obestatin did not bind GPR39 and induce any 
effects on GPR39-transfected cells306. This hypothesis was also 
296.  Egerod, K. L. et al. GPR39 splice variants versus antisense gene LYPD1: expression and 
regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Mol. 
Endocrinol. 2007; 21: 1685-98. 
297.  Jackson, V. R. et al. GPR39 receptor expression in the mouse brain. Neuroreport.  2006; 17: 813-6. 
298.  Zhao, C. M. et al. Characterization of obestatin- and ghrelin-producing cells in the gastroin-
testinal tract and pancreas of rats: an immunohistochemical and electron-microscopic study. 
Cell. Tissue Res. 2008; 331: 575-87. 
299.  Dun, S. L. et al. Distribution and biological activity of obestatin in the rat. J. Endocrinol. 
2006; 191: 481-9. 
300.  Zhang, J. V. et al. Obestatin receptor in energy homeostasis and obesity pathogenesis. 
Prog. Mol. Biol. Transl. Sci. 2013; 114: 89-107.
301.  Egerod, K. L. et al. GPR39 splice variants versus antisense gene LYPD1: expression and 
regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Mol. 
Endocrinol. 2007; 21: 1685-8.
302.  Catalán, V. et al. The obestatin receptor (GPR39) is expressed in human adipose tissue 
and is down-regulated in obesity-associated type 2 diabetes mellitus. Clin. Endocrinol. 2007; 
66: 598-601.
303.  Popovics, P. et al. GPR39: a Zn(2+)-activated G protein-coupled receptor that regulates pan-
creatic, gastrointestinal and neuronal functions. Cell. Mol. Life Sci.  2011; 68: 85-95. 
304.  Zhang, J. V. et al. Obestatin receptor in energy homeostasis and obesity pathogenesis. 
Prog. Mol. Biol. Transl. Sci. 2013; 114: 89-107.
305.  Sheng-Qiu, T. et al. Obestatin- Its physicochemical characteristics and physiological func-
tions. Peptides. 2008; 29: 639-645.
306.  Chartrel, N. et al. Comment on “Obestatin, a peptide encoded by the ghrelin gene, oppo-
ses ghrelin’s effects on food intake”. Science. 2007; 315: 766 [author reply 766]. 
previously reinforced by two groups that claimed that zinc 
ion (Zn2+) is a physiologically relevant agonist of GPR39307,308. 
Both groups emphasized that obestatin did neither bind 
to GPR39-expressing cells nor display any effect such as 
cAMP production. In response, Zhang and colleagues found 
out that the interaction of obestatin and GPR39 could not 
be reproduced due to the instable bioactivity of iodinated 
obestatin309. Just followed up their response about the 
bioactivity of obestatin, Zhang and colleagues found out that 
mono-iodinated obestatin can bind to GPR39, but not over-
iodinated obestatin. They also demonstrated in the same work 
that that c-fos expression, a transcription factor as a marker 
of activity in gastrointestinal, was induced by obestatin in 
wild-type mice but not in GPR39 null mice, suggesting that 
activities of obestatin depended on GPR39, and in cultured 
3T3-L1 cells, treatment with obestatin induced c-fos expression 
and activated the MAPK pathway, providing a cell model by 
which to study obestatin-signalling mechanisms310. Previously 
other group constructed GPR39-knockout mice and partially 
confirmed the in vivo effects of obestatin depending on 
GPR39311. The differences in energy homeostasis included: 
accelerated gastric emptying, increased gastric secretion, 
higher mature body weights and body fat compositions, 
reduced hyperphagia after fasting, and increased cholesterol 
levels. Despite the initial enthusiasm about the potential of 
this molecule as a physiological opponent of ghrelin, several 
observations related to this point have set its effectiveness 
into question. Consequently, the state-of-knowledge on 
obestatin suffers from serious gaps, especially for the lack of 
reproducibility of its central activities312, 313,314, 315,316 and the 
307.  Lauwers, E. et al. Obestatin does not activate orphan G protein-coupled receptor GPR39. 
Biochem. Biophys. Res. Commun. 2006;  351: 21-5. 
308.  Holst, B. et al. GPR39 signalling is stimulated by zinc ions but not by obestatin.  Endocri-
nology. 2007; 148: 13-20.
309.  Zhang, J. V.  et al. Response to comment on “Obestatin, a peptide encoded by the ghrelin 
gene, opposes ghrelin’s effects on food intake”. Science. 2007; 315: 766. 
310.  Zhang, J. V. et al. Obestatin induction of early-response gene expression in gastrointestinal 
and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol. Endo-
crinol. 2008; 22: 1464-75.
311.  Moechars, D. et al. Altered gastrointestinal and metabolic function in the GPR39-obestatin 
receptor-knockout mouse. Gastroenterology. 2006; 131: 1131-41. 
312.  Seoane, L. M. et al. Central obestatin administration does not modify either spontaneous 
or ghrelin-induced food intake in rats. J. Endocrinol. Invest. 2006; 29:  RC13-RC15.
313.  Chartrel, N. et al Comment on “Obestatin, a peptide encoded by the ghrelin gene, opposes 
ghrelin’s effects on food intake”. Science. 2007; 315: 766.
314.  Nogueiras, R. et al. Effects of obestatin on energy balance and growth hormone secretion 
in rodents. Endocrinology. 2007; 148: 21-26.
315.  Gourcerol, G, et al. Lack of interaction between peripheral injection of CCK and obestatin 
in the regulation of gastric satiety signalling in rodents. Peptides. 2006; 27: 2811-19.
316.  Tremblay, F, et al. Normal food intake and body weight in mice lacking the G protein-cou-
pled receptor GPR39. Endocrinology. 2006; 148: 501-6.
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exactly receptor that triggers out the obestatin bioactivity is still 
unknown317. 
Obestatin bioactivity
Keeping aside its controversial anorexigenic activity, 
accumulating publications have confirmed the initial role of 
obestatin in regulating energy homeostasis and its association 
with obesity, among many other physiological functions. Studies 
demonstrated that intraperitoneal injection (IP) of obestatin 
suppressed basal or ghrelin-stimulated food intake in mice318,319 
and rats320. Further studies explained that obestatin was involved 
in other different activities as, inhibiting thirst321 decreasing 
anxiety and improving memory322, regulating sleep323, increasing 
vasopressin secretion324, activating cortical neurons325. Obestatin 
also reduced adipocyte apoptosis and inflammation in metabolic 
tissues, as well as reduces insulin resistance326. Other studies 
on bone metabolism327
 
and term pregnancy328
 
have shown the 
correlation of expression levels of obestatin and GPR39.
Obestatin is also considered for its mitogenic effect, described 
in pancreatic β cells329; in 3T3-L1 preadipocytes330, bounding to 
GPR39 is reported to stimulate the phosphorylation of ERK1/2 
and potentially Akt, the downstream signalling partners331. In pri-
317.  Zhang, J. V. et al. Obestatin receptor in energy homeostasis and obesity pathogenesis. 
Prog. Mol. Biol. Transl. Sci. 2013; 114: 89-107.
318.  Green, B. D. et al. Direct and indirect effects of obestatin peptides on food intake and the 
regulation of glucose homeostasis and insulin secretion in mice. Peptides. 2007; 28: 981-7.
319.  Zizzari, P. et al. Obestatin partially affects ghrelin stimulation of food intake and GH secre-
tion in rodents. Endocrinology. 2007; 148: 1648-53.
320.  Bresciani, E. et al. Obestatin inhibits feeding but does not modulate GH and corticosterone 
secretion in the rat. J. Endocrinol. Invest. 2006; 29: RC16-RC18.
321.  Samson, W. K. et al. Obestatin acts in brain to inhibit thirst. Am. J. Physiol. Regul. Inte-
gr.  Comp. Physiol. 2007; 292 (1): R637-643. 
322.  Carlini, V. P. et al. Obestatin improves memory performance and causes anxiolytic effects 
in rats. Biochem. Biophys. Res. Commun. 2007; 352: 907-12. 
323.  Szentirmai, E. et al. Obestatin alters sleep in rats. Neurosci. Lett. 2006; 404: 222-6. 
324.  Samson, W. K. et al. Obestatin inhibits vasopressin secretion: evidence for a physiological 
role in the control of fluid homeostasis. J. Endocrinol. 2008; 196: 559-64.
325.  Dun, S. L. et al. Distribution and biological activity of obestatin in the rat. J. Endocrinol. 
2006; 191: 481-9. 
326.  Green, B. D. et al. Direct and indirect effects of obestatin peptides on food intake and the 
regulation of glucose homeostasis and insulin secretion in mice. Peptides.  2007; 28 (5): 981-7. 
327.  Pacheco-Pantoja, E. L. et al. Receptors and effects of gut hormones in three osteoblastic 
cell lines. BMC Physiol. 2011; 11:12-52.. 
328.  Fontenot, E. et al. Obestatin and ghrelin in obese and in pregnant women. Peptides. 2007; 
28: 1937-44.
329.  Granata, R. et al. Obestatin promotes survival of pancreatic β-cells and human islets and 
induces expression of genes involved in the regulation of β-cell mass and function. Diabetes. 
2008; 57: 967-79.
330.  Zhang, J. V. et al. Obestatin induction of early-response gene expression in gastrointestinal 
and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol. Endo-
crinol. 2008; 22: 1464-75.
331.  Granata, R. et al. Obestatin  promotes survival of pancreatic beta-cells and human islets 
mary cultures of human retinal pigmented epithelial cells (hRPEs), 
the results showed that this peptide induced cell proliferation in 
a dose-dependent manner with MEK/ERK 1/2 phosphorylation, 
the obestatin transmembrane signalling pathway involved the 
consecutive activation of Gi, PI3K, novel PKC (probably PKCε), and 
Src for ERK 1/2 activation332. This mitogenic mechanism was also 
supported in long-white piglet liver and adipose cells. Obesta-
tin-stimulated the mechanisms signalling pathway during ERK 
1/2 activation in cells, activates a PI3K through a PTX-sensitive 
G-protein. The activation of PI3K results in the phosphorylation of 
PKCε, which would activate Src. The latter would activate Raf-de-
pendent ERK 1/2 activation via Ras or by a direct activation of Raf. 
After activation, ERK 1/2 are translocated to the nucleus, where 
they phosphorylate and activate transcription factors that lead to 
the mitogenic activity333.
The same mitogenic result trough ERK signalling pathway was 
discovered in human gastric carcinoma, KATOIII 334. Lately, the 
same group, discovered a transmembrane signalling pathway 
responsible for obestatin induced-Akt activation in human gastric 
carcinoma cells, KATOIII and AGS (SCHEME-16). The results show 
that Akt activation requires the phosphorylation of T308 in the 
A-loop by the phosphoinositide-dependent kinase 1 (PDK1) 
and S473 within the HM by the mammalian target of rapamycin 
(mTOR) kinase complex 2 (mTORC2: Rictor, mLST8, mSin1, mTOR 
kinase) with participation neither of G
i/o
-protein nor G
β 
dimers. 
Obestatin induces the association of GPR39/beta-arrestin 1/Src 
signalling complex resulting in the transactivation of the epider-
mal growth factor receptor (EGFR) and downstream Akt signal-
ling. Upon administration of obestatin, phosphorylation of mTOR 
(S2448) and p70S6K1 (T389) rise with a time course that parallels 
that of Akt activation. Based on the experimental data obtained, a 
signalling pathway involving a beta-arrestin 1 scaffolding com-
plex and EGFR to activate Akt signalling is proposed335.
and induces expression of genes involved in the regulation of beta-cell mass and function. Dia-
betes. 2008; 57: 967-79. 
332.  Camiña, J. P. et al. Obestatin-mediated proliferation of human retinal pigment epithelial 
cells: regulatory mechanisms. J. Cell. Physiol. 2007; 211 (1): 1-9. 
333. Dong, X. Y. Ghrelin and its biological effects on pigs. Peptides. 2009; 30 (6): 1203-11. 
334.  Pazos, Y. et al. Stimulation of extracellular signal-regulated kinases and proliferation in the 
human gastric cancer cells KATO-III by obestatin. Growth Factors. 2007; 25: 373-81.
335.  Alvarez, C. J. et al. Obestatin stimulates Akt signalling in gastric cancer cells through β-ar-
restin-mediated epidermal growth factor receptor transactivation. Endocr. Relat. Cancer. 2009; 
16: 599-611.
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SCHEME-16. proposed model of signalling pathway for Akt and ErK1/2 
activation in response to obestatin in KATO-III and AgS cells. Translocation 
of β-arrestins 1 to obestatin receptor (GPR39) allows its association with Src. 
β-arrestin 1 activates Src (phosphorylation at Y416) that initiates the transac-
tivation of EGFR and subsequent downstream Akt signalling (Figure extracted 
from Endocr. Relat. Cancer. 2009; 16: 599-611).
Obestatin/gpr39 structure-bioactivity relationship
A structure-activity relationship for obestatin has been derived by 
employing this peptide and several analogues as ligands for the 
seven-transmembrane receptor GPR39 (SCHEME-17). The analysis 
of the data suggested that amidation at the C-terminus of human 
obestatin was essential for this molecule to adopt an α-helix 
structure. This α-helix exists between Ser20 and Leu23 and from 
Gly8 to Lys11. The presence of this structure correlated with the 
stabilization of the GPR39 conformations that were necessary 
for the full range of receptor activities, e.g., G protein-depend-
ent and β-arrestin-dependent signalling. Indeed, the change of 
this α-helix to a 3
10
 helix or the loss of this α-helical pattern was 
correlated with the absence of complete activation, as observed 
for non-amidated obestatin. Additionally, GPR39 showed to 
adopt multiple active conformations, which were related to the 
activation of specific signalling mechanisms. In particular, human 
(11–23)-obestatin wass able to induce selective coupling to a 
portion of the downstream signalling pathways, e.g., β-arres-
tin-dependent signalling. This observation supported the idea 
that human (11–23)-obestatin stabilizes a receptor conformation 
different from that induced by human obestatin. Most likely, this 
activity was related to the presence of the α-helix segment from 
Tyr16 to Leu23. Because this peptide is present in the stomach, 
it was proposed as the first example of an endogenous biased 
ligand for GPR39. Aditionally, mouse and human obestatin exhib-
ited clear conformational differences beyond their differences in 
primary structure. The mouse analogue adopts a distinct three-di-
mensional structure, which could not activate human GPR39. This 
evidence supported the existence of a species-specific activity336.
SCHEME-17. Superimposition of the 20 best representative structures of 
peptides 1 to 6, which possessed the lowest total energies, as calculated 
from the NMr data for the peptides in SDS micelles. (A) Human obestatin 
(1), (B) human non-amidated obestatin (2), (C) human (6–23)-obestatin (3), (D) 
human (11–23)- obestatin (4), (E) human (16–23)-obestatin (5) and (F) mouse 
obestatin (6). The Tyr16 side chain is shown in blue. (Figure extracted from 
PLoS One. 2012; 7(10):e45434.)
Identification of other hypothetical receptors that 
mediated obestatin effects
It was recently proposed that obestatin action might be 
meadiated at least partly by the glucagon-like peptide-1 (GLP-1) 
receptor (GLP-1R) in pancreatic β cells, which would explain to 
336.  Alén, B.O. et al. The NMR structure of human obestatin in membrane-like environments: 
insights into the structure-bioactivity relationship of obestatin. PLoS One. 2012; 7 (10): E45434.
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some extent its insulinotropic and survival effects337,338. The cDNA 
of GLP-1R was first isolated from a pancreatic islet cDNA library 
from rats, and its function as a receptor for GLP-1 was confirmed 
by binding experiments with radiolabeled GLP-1339. The cDNA of 
human GLP-1R was isolated by several groups in 1993340,341. At 
the same time, two exogenous ligands were identified: exendin-4 
(Ex-4) and exendin-(9–39)342. The interaction between GLP-1R to 
obestatin was proposed based on binding displacement assays 
of radiolabeled GLP-1 by obestatin343. However, these results 
were rapidly questionated based on results obtained from INS-1 
β and HEK cells overexpressing GLP-1R in which obestatin did 
not displace radiolabeled GLP-1 binding344.  Thus, the possible 
implication of GLP-1R still needs to be clarified . 
337.  Granata, R. et al. Obestatin promotes survival of pancreatic beta-cells and human islets 
and induces expression of genes involved in the regulation of beta-cell mass and function. Di-
abetes. 2008; 57: 967-97.
338.  Favaro, E. et al. The ghrelin gene products and exendin-4 promote survival of human 
pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-ki-
nase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signal-
ling pathways. Diabetologia. 2012; 55 (4): 1058-70.
339.  Thorens, B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin 
hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA.  1992; 89: 8641-5. 
340.  Dillon, J. S. et al. Cloning and functional expression of the human glucagon-like peptide-1 
(GLP-1) receptor. Endocrinology. 1993; 133: 1907-10. 
341.  Graziano, M. P. et al. Cloning and functional expression of a human glucagon-like pepti-
de-1 receptor. Biochem. Biophys. Res. Commun. 1993; 196: 141-6. 
342.  Thorens, B, et al. Cloning and functional expression of the human islet GLP-1 receptor. 
Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. 
Diabetes. 1993; 42: 1678-82. 
343. Granata, R. et al. Obestatin promotes survival of pancreatic beta-cells and human islets and 
induces expression of genes involved in the regulation of beta-cell mass and function. Diabe-
tes. 2008; 57: 967-97.
344.  Unniappan, S. et al. Metabolic effects of chronic obestatin infusion in rats. Peptides. 2008; 
29: 1354-61. 
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MATErIALS
peptides
Rat/mouse obestatin was obtained from California Peptide 
Research (CA, USA). Mouse ghrelin and des-acyl ghrelin were pur-
chased from Global Peptides (Co, USA). Insulin was obtained from 
NovoNordisk (Bagsvaerd, Dk). 
Antibodies
ANTIBODY USE DILU-TION SUppLIEr rEF
Actin WB 1:5000 Abcam ab1801
Akt WB 1:1000 Cell Signalling 4685
Alexa Fluor 594 IF 1:500 Invitrogen A11012
Alexa Fluor 647 IF 1:1000 Abcam ab150115
Anti-mouse Hrp WB 1:10000 Jackson 115-035-003
Anti-rabbit Hrp WB 1:10000 Jackson 111-035-003
C/EBpα WB 1:500 Santa CruzBiotechnology Inc. sc-61
C/EBpβ WB 1:500 Santa CruzBiotechnology Inc. sc-150
C/EBpσ WB 1:500 Santa CruzBiotechnology Inc. sc-151
Col1a2 WB 1:5000 Abcam ab34710
Cyclin D1 WB 1:1000 Cell Signalling 2978
eMHC IHF 1:20 Hibridoma Bank F1652
ErK 1/2 WB 1:1000 Cell Signalling 9102
FAT/CD36 WB 1:500 Santa CruzBiotechnology Inc. sc-9154
FATp1 WB 1:500 Santa CruzBiotechnology Inc. sc-25670
FATp4 WB 1:500 Santa CruzBiotechnology Inc. sc-31954
FITC-488 IF 1:1000 Abcam ab150089
FoxO1 WB 1:1000 Cell Signalling 9454
gADpH WB 1:5000 Abcam ab9485
gHSr1a WB 1:500 Santa CruzBiotechnology Inc. sc-20748
gLUT1 WB 1:500 Santa CruzBiotechnology Inc. sc7903
gLUT4 IHF 1:100 Cell signalling 2299
gLUT4 WB 1:1000 Cell Signalling 2299
gpr39 IHC 1:100 Abcam ab39227
gpr39 IHF 1:250 Abcam ab39227
gpr39 WB 1:1000 Abcam ab39227
IgF-r WB 1:1000 Cell Signalling 3027
IrS1 WB 1:500 Santa CruzBiotechnology Inc. sc-560
ANTIBODY USE DILU-TION SUppLIEr rEF
Isolectin IHF 2µg/mL Invitrogen 132450
Laminin IHF 1:2000 Abcam ab14055
MBOAT4 IHC 1:100 Santa CruzBiotechnology Inc. sc87999
MBOAT4 WB 1:500 Santa CruzBiotechnology Inc. sc87999
Miostatin WB 1:100 Abcam ab98337
Myf5 FC (1 µg/10
6 
cells)
Invitrogen SAP 4501943
Myf5 WB 1:500 Santa CruzBiotechnology Inc. sc-302
Myf6 WB 1:500 Santa CruzBiotechnology Inc. sc-301
MyoD IHC 1:100 Santa CruzBiotechnology Inc. Sc-304
MyoD WB 1:1000 Santa CruzBiotechnology Inc. Sc-304
Myogenin IHC 1:100 Santa CruzBiotechnology Inc. sc-576
Myogenin WB 1:1000 Hibridoma Bank F5D
MHC IHF 1:20 Hibridoma Bank MF20
MHC WB 1:500 Hibridoma Bank MF20
Obestatin IHC 1:100 ADI GPR391-A
Obestatin IHF 1:50 Abcam 41704
Obestatin
Neu-
trali-
zation 
assay
5µg/mL Abcam 41704
Obestatin WB 1:500 Abcam 41704
p21-waf FC 0,6µg/ml Abcam ab7960
p21-waf WB 1:1000 Abcam ab7960
p-38 WB 1:500 Santa CruzBiotechnology Inc. sc-535
p-ACC(S79) WB 1:1000 Cell Signalling 3661
p-Akt (S473) WB 1:1000 Cell Signalling 9271
p-AMpKα(T172) WB 1:1000 Cell Signalling 2535
p-AS160(T642) WB 1:1000 Cell Signalling 4288
pax7 IHF 1:20 Hibridoma Bank Pax7
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ANTIBODY USE DILU-TION SUppLIEr rEF
pax7 WB 1:500 Hibridoma Bank Pax7
pax7-FITC FC (1 µg/10
6 
cells)
Hibridoma Bank Pax7-FITC
pC 1/3 IHC 1:100 Santa CruzBiotechnology Inc. sc-15922
pC 1/3 WB 1:500 Santa CruzBiotechnology Inc. sc-15922
p-cJun(S63) WB 1:1000 Cell Signalling 3270
p-CamKII (T286) WB 1:1000 Cell Signalling 3361
pE IF 1:1000 Abcam ab7004
pEDF WB 1:500 Santa CruzBiotechnology Inc. sc-25594
p-ErK 1/2 (T202/
Y204) WB 1:1000 Cell Signalling 9101
p-FoxO1/FoxO3a WB 1:1000 Cell Signalling 9464
p-gSK3α/β(S21/9) WB 1:1000 Cell Signalling 9331
p-IgF-r WB 1:1000 Cell Signalling 6113
p-IrS1 WB 1:1000 Cell Signalling 2388
p-mTOr(S2448) WB 1:1000 Cell Signalling 2971
p-p38 (T180/Y182) WB 1:1000 Cell Signalling 9211
ppArγ WB 1:500 Santa CruzBiotechnology Inc. sc-7196
preproghrelin IHC 1:100 Santa CruzBiotechnology Inc. sc-10368
preproghrelin IHF 1:100 Santa CruzBiotechnology Inc. sc-10368
preproghrelin WB 1:200 Santa CruzBiotechnology Inc. sc-10368
pS6K1(S371) WB 1:1000 Cell Signalling 9205
S6K1 WB 1:1000 Cell Signalling 2217
Six-1 WB 1:500 Santa CruzBiotechnology Inc. sc-9127
Tubulin WB 1:5000 Cell Signalling T9026
VEgF WB 1:500 Santa CruzBiotechnology Inc. sc-152
VEgF-r2 WB 1:500 Santa CruzBiotechnology Inc. sc-504
Ki67 FC 1:100 Abcam ab15580
Ki67 WB 1:500 Abcam ab15580
ANIMALS
This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory 
Animals of the Faculty Animal Committee at the University of 
Santiago de Compostela (Santiago de Compostela, Spain) and 
Spienza-Università di Roma (Roma, Italy).  Experiments were 
performed in agreement with the Rules of Laboratory Animal 
Care and International Law on Animal Experimentation and all 
efforts were made to minimize suffering.
Subcutaneous mini-pump implantation animal 
model
Adult male Sprague–Dawley rats (250 g) were housed in 12 h 
light/12 h darkness cycles with free access to standard rat chow 
diet and water. Alzet® mini-pumps (model 1003D, CA, USA) were 
subcutaneous (SC) implanted. Animals were assigned to one of 
four-matched experimental groups (n=10/group): 1) 24 h mini-
pump SC implanted group [containing obestatin (300 nmol/
kg body weight/24 h)]; 2) 24 h mini-pumps SC control group 
(containing saline); 3) 72 h mini-pump SC implanted group 
[containing obestatin (300 nmol/kg body weight/24 h)]; and 4) 
72 h mini-pumps SC control group (containing saline). These 
mini-pumps hold 100 μL volume and deliver 1 µL/h. After 24 or 
72 h, rats were euthanatized to obtain omental, subcutaneous, 
gonadal adipose tissues, and gastrocnemius and soleus muscles. 
All tissues were washed with ice-cold Krebs–Ringer–HEPES 
buffer [KREBS buffer: HEPES (pH 7,4), 25 mM; NaCl, 125 mM; KCl, 
5 mM; MgSO
4
, 1,2 mM; CaCl
2
, 2 mM; KH
2
PO
4
, 2 mM; glucose, 6 
mM].  Immediately adipose tissue samples were snap-frozen in 
liquid nitrogen for its posterior use. Muscles tissue samples for 
histologic analysis, were mounted in tissue freezing medium 
(tragacanth paste) and frozen in isopentane. For western blot 
(WB) analysis, muscles were snap-frozen in liquid nitrogen. 
High-fat diet (HFD) mice model
Adult Swiss male mice (30 g, 8 weeks old) were housed in 12 h 
light/12 h darkness cycle. Animals were assigned to one of two-
matched experimental groups (n=10/group): 1) fed with standard 
diet (SD, control) or 2) high-fat diet (HFD) for 12 weeks (D12451, 
Research Diets, Inc., New Brunswick, NJ, USA). Food intake and 
body weight were measured weekly during the experimental 
phase. Animals were sacrificed when they were 20 weeks old. 
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Excised WAT, omental and subcutaneous, were washed with ice-
cold KREBS buffer and immediately tissue samples were snap-fro-
zen in liquid nitrogen for its posterior use.
Cardiotoxin-induced muscle injury in rat 
Adult male Sprague–Dawley rats (250 g) were housed in 12 h 
light/12 h darkness cycles with free access to standard rat chow 
diet and water. Gastrocnemius muscles from rats were impaired, 
along their entire length, with four intramuscular injections per 
muscle with cardiotoxin (CTX) purchased from Sigma-Aldrich 
(Missouri, USA) (10 μM CTX; 2 μl/g body weight) or equal volume 
of PBS to ensure equal distribution throughout the muscle1. 
At different times after injury (6, 24, 48, and 72 h; n=5 per time 
point), rats were sacrificed, and gastrocnemius muscles were 
dissected and divided for histological and WB analyses. For 
histologic analysis, muscle tissue samples were mounted in tissue 
freezing medium (tragacanth paste) and frozen in isopentane. For 
WB analysis, muscles were snap-frozen in liquid nitrogen. 
Freeze-induced muscle injury in mice 
Adult female Swiss mice (30 g) were housed in 12 h light/12 h 
dark cycles with free access to standard mice chow diet and 
water. Under anesthesia, mice hind limbs were shaved and both 
tibialis anterior (TA) muscles were exposed via a 1-cm-long inci-
sion in aseptically prepared skin overlying the muscle. Traumatic 
freeze injury was induced by applying directly a 120-mm-di-
ameter steel probe, pre-chilled on dry ice, to the belly of the TA 
muscle for 5 s2. During the regeneration time, mice were injected 
into the TA muscle with obestatin (300nmol/Kg body weight/24 h; 
20 µL; treated group) or equal volume of PBS (control group) each 
24 h during 5 days. The muscles were harvested at different time 
points after injury (12, 24, 48, 72, 96, 168 and 240 h; n=5 per time 
point). Muscle tissue samples were divided for WB, histological 
and flow cytometry (FC) analysis. For WB analysis, muscles were 
snap-frozen in liquid nitrogen. For histologic analysis, muscle 
tissue samples were mounted in tissue freezing medium (traga-
canth paste) and frozen in isopentane. For FC analysis samples 
were transported in PBS, as intact as possible, and then digested 
enzymatically. 
1.  Toschi, A. et al. Skeletal muscle regeneration in mice is stimulated by local overexpression of 
V1a-vasopressin receptor. Mol. Endocrinol. 2011; 25: 1661-73. 
2.  Melissa, W. et al. Early life nutrition modulates muscle stem cell number: implications for 
muscle mass and repair. Stem Cells. Dev. 2011; 20 (10): 1763-9.
Electroporation and muscle injury regeneration 
Adult female Swiss mice (30 g) were housed in 12h light/12 h 
dark cycles with free access to standard mice chow diet and wa-
ter. After anesthesia, TA were injected with specific cDNA as indi-
cated: for in vivo electroporation, 20 µg of plasmid DNA [mouse 
preproghrelin and GPR39 cDNAs were obtained from Origene 
(MD, USA)] or pCMV6 (Origene; MD, USA) combined with 5 µg 
of pCDNA 3.1-SNAP-GFP, marker of transfection efficacy, (kindly 
provided by Prof. Pozzan, University of Ferrara-Italy) diluted in 
20 μL of Dulbecco’s phosphate buffer solution [PBS: KCl, 0.2 g/L; 
KH
2
PO
4
, 0.2 g/L; NaCl, 8.0 g/L; Na
2
HPO
4
, 1.2 g/L (pH 7,2)]. All the 
plasmids were amplified in XL1-Blu competent cells purchased 
from Life Technologies, Invitrogen (NY, USA), and purified using 
the Plasmid Maxi Kit (Qiagen, Crawley, UK). The electric pulses 
were delivered using 3 × 5 mm GenePaddle electrodes (BTX, 
CA, USA) placed on either side of the muscle. Electroporations 
were performed 10 days before muscle injury, by delivering six 
electric pulses of 20 V each (three with the anode placed on 
the front of the injured TA, followed by three pulses with the 
polarity inverted). This protocol of gene delivery by electropora-
tion guarantees stable DNA expression for more than 4 months3. 
Mice were sacrificed at 96 h (n=5 per group: control, preprogh-
relin; GPR39 and preproghrelin+GPR39) and 7 days (n=5 per 
group) after injury. 
CELLS
Cell culture and differentiation induction of 3T3-L1 
mouse pre-adipocytes 
3T3-L1 cells were cultured as described by the supplier (European 
Collection of Cell Cultures, Wiltshire, UK). Briefly, 3T3-L1 cells 
were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% FBS (v/v), both purchased from Lonza (Basel, 
Switzerland), 100 U/mL penicillin and 100 U/mL streptomycin 
both purchased from Biowest (Nuaille, France). For routine 
differentiation, 80% confluent cells were treated with 0.5 mM 
IBMX, 25 μM DEX both from purchased from Sigma-Aldrich 
(Missouri, USA) and 861 nM (5 μg/mL) insulin for 3 days and 
maintained in DMEM containing 10% FBS, 100 U/mL penicillin, 
3.  Moresi, V. et al. Modulation of caspase activity regulates skeletal muscle regeneration and 
function in response to vasopressin and tumor necrosis factor.  PLoS ONE. 2009; 4 (5): E5570.
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100 U/mL streptomycin and supplemented with 172 nM (1 μg/
mL) insulin for 7 days after the beginning of differentiation unless 
otherwise stated. Before each experiment, 3T3-L1 pre-adipocytes 
or adipocyte cells were serum-starved 12 h in DMEM.
Cell Culture and differentiation induction of L6E9 
rat myoblasts 
L6E9 were cultured as described by the supplier (European 
Collection of Cell Cultures, Wiltshire, UK). L6E9 myoblasts 
were maintained in growth medium (GM) containing DMEM 
supplemented with 10% FBS, 100 U/mL penicillin, and 100 U/mL 
streptomycin. For routine differentiation, cells were grown to 80% 
confluence, and GM was replaced with differentiation medium 
(DM), DMEM supplemented with 2% FBS, 100 U/mL penicillin, and 
100 U/mL streptomycin for 7 days unless otherwise stated.
Cell Culture and differentiation induction of C2C12 
mouse myoblasts 
C2C12 were cultured as described by the supplier (European 
Collection of Cell Cultures, Wiltshire, UK). C2C12 myoblasts were 
maintained in GM containing DMEM supplemented with 10% 
FBS, 100 U/mL penicillin, and 100 U/mL streptomycin. For routine 
differentiation, cells were grown to 80% confluence, and GM was 
replaced with DM for 7 days unless otherwise stated.
Fibers mice isolation 
For fiber isolation, the plastic and glass material is necessary 
to coat all with 5% FBS in PBS. Gastrocnemius and TA muscles 
were dissected carefully, cutting tendons trying to keep the 
muscle as much intact as possible, avoiding muscle stretching. 
Muscles were washed with PBS and transfer them immediately 
to 1mL of collagenase type I enzymatic solution purchased from 
Worthington (NJ, USA) in DMEM(400 U/mL) incubating tubes 
for 1h at 37°C in a cell incubator. After, muscles were rocked for 
30 min at 37°C . After digestion, the medium was enriched with 
10% FBS, to block enzymatic action. Finally, all the solution was 
discarded in a pre-coated 100 mm cell dish, and with a pre-
coated pasteur pippete medium was blown against the muscle to 
release the single fibers4.
4.  Rosenblatt, J. D. et al. Culturing satellite cells from living single muscle fibre explants. In Vitro 
Cell. Dev. Biol. 1995, 31: 773–779.
Measurement of SCs division in fibers 
Isolated fibers were plated in a pre-coated dishes with growth 
factor–reduced Matrigel purchased from Life Technologies, 
Invitrogen (NY, USA) and DMEM with 10% FBS in a cell incubator 
(30 miofibers per well in 6 multiwell). Fibers were stimulated with 
obestatin 5 nM and cultured for 24 h. After incubation time, fibers 
were treated for immunofluorescence (IF) as explained below5.
rEAL TIME QUANTITATIVE rEVErSE 
TrANSCrIpTION pCr (QrT-pCr) 
For qRT-PCR, total RNA was isolated with Trizol purchased from 
Life Technologies, Invitrogen (NY, USA) and DNA-free kit (Applied 
Biosystems/Ambion, TX, USA) to generate first-strand cDNA 
synthesis performed with High-capacity cDNA Reverse Tran-
scription kit (Applied Biosystems/Ambion, TX, USA). qRT-PCR 
was performed using an ABI PRISM 7300 HT Sequence Detection 
System (Applied Biosystems/Ambion, TX, USA). For the analysis 
of the preproghrelin gene, ACTB was used as housekeeping gene 
(TaqMan: Applied Biosystems/Ambion, TX, USA). The fold change 
in gene expression was calculated using the 2-ΔΔCt relative 
quantitation method according to the manufacturer’s guidelines 
(Applied Biosystems/Ambion, TX, USA).
IMMUNOBLOT ANALYSIS
Immunoblot analysis of proteins 
Tissue samples or cells were directly lysed in ice-cold 
radioimmune precipitation buffer [Tris-HCl (pH 7.2), 50 mM; 
NaCl, 150mM; EDTA, 1mM; Nonidet P-40, 1% (v/v); sodium 
deoxycholate, 0.25% (w/v); protease inhibitor mixture and 
phosphatase inhibitor mixture, both inhibitors from purchased 
from Sigma-Aldrich (Missouri, USA)]. Lysates were clarified 
by centrifugation (14.000 rpm for 15 min at 4 °C), and the 
protein concentration was quantified using the QuantiProTM 
BCA assay kit purchased from Sigma-Aldrich (Missouri, 
USA). For immunoblotting, equal amounts of protein were 
fractionated by SDS-PAGE and transferred onto nitrocellulose 
5.  Kuang, S. et al. Asymmetric self-renewal and commitment of satellite stem cells in muscle. 
Cell. 2007; 129; 999-1010.
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membranes. Immunoreactive bands were detected by enhanced 
chemiluminescence ECL Western blotting Substrate; purchased 
from Thermo Fisher Scientific-Pierce (Massachusetts, USA). 
Immunoblot analysis of gLUT1, gLUT4, FAT/CD36, 
FATp1 and FATp4 in plasma membrane 
Treated cells were harvested by scraping. After centrifugation, 
pellets were resuspended in homogenization buffer [HEPES (pH 
7.4), 20 mM; sucrose, 255 mM; EDTA, 2 mM; protease and phos-
phatase inhibitor cocktail].  Homogenized with eight strokes, and 
then centrifuged at 1200 rpm for 5 min at 4°C to remove nuclei and 
unbroken cells. The supernatant was then centrifuged at 195,000 x 
g for 60 min at 4°C to obtain total membranes. The final pellet was 
resuspended in homogenization buffer and used for WB analysis6.
SMALL INTErFErINg rNA ASSAYS 
Small interfering rNA assays in 3T3-L1 cells 
Chemically synthesized double-stranded small interfering RNA 
(siRNA) duplexes (Santa Cruz Biothecnology, CA, USA) were for 
mouse preproghrelin: 3’-CAGAGAAAGGAAUCCAAGA-5’, 3’-CCU-
UCGAUGUUGGCAUCAA-5’ and 3’-CUCUCCUACCACUUUAAGA-5’.  
Mouse GPR39 targeted siRNAs (siRNA sequence numbers s89441, 
s89442, s89443) were selected from Silencer® Pre-designed 
sequences from Applied Biosystems/Ambion (TX, USA). Cells 
were transfected with Lipofectamine 2000 purchased from Life 
Technologies, Invitrogen (NY, USA).
sirNA assays in L6E9 cells 
Chemically synthesized double-stranded siRNA duplexes target-
ing either preproghrelin or GPR39 were selected from ON-TAR-
GETplus SMARTpool siRNA from Thermo Fisher-Dharmacon (Mas-
sachusetts, USA), (preproghrelin, CCAAGAAGCCACCA-GCUAA, 
CUGCUGACUUACAAAUAAA, CAGAGGAGGAG- CUGGAAAU, and 
UCAAAGAGGCGCCAGCUAA; GPR39, ACAAGGGACUCAACUGUAA, 
UUACGCAGGUAUUGCA- GAA, CCUGCAAGCUCCACACACGUU, and 
AGUUUGGCU- UGUUCAGAUA). An ON-TARGETplus non-targeting 
siRNA was used as a control for all siRNA experiments. All experi-
6.  Nishiumi, S. et al. Rapid preparation of a plasma membrane fraction from adipocytes and 
muscle cells: application to detection of translocated glucose transporter 4 on the plasma 
membrane. Biosci. Biotechnol. Biochem. 2007;71(9):2343-6.
ments were transfected with Lipofectamine 2000 purchased from 
Life Technologies, Invitrogen (NY, USA).
IMMUNOCHEMISTrY AND HISTOCHEMISTrY 
Immunochemistry 
Cells (preadipocytes, adipocytes, myoblasts and myotubes) were 
fixed on cover slips in 96% ethanol. WAT samples were fixed by 
immersion in 4% (w/v) buffered paraformaldehyde (PFA)-PBS 
for 24 h, dehydrated and embedded in paraffin by a standard 
procedure. Muscle samples were mounted in tissue freezing 
medium (tragacanth paste) and snap-frozen in nitrogen-cooled 
isopentane. Sections, 8 μm thick, were mounted on Histobond 
Adhesion Microslides (Marienfeld, Lauda-Königshofen, Germany), 
dewaxed and rehydrated. Slides were consecutively incubated 
with: 1) anti-obestatin, anti-GPR39, anti-preproghrelin, anti-
MBOAT4, anti-PC1/3, anti-MyoD and anti-myogenin in Dako 
ChemMate antibody diluent (Dako, Glostrup, Denmark); 2) 
EnVision peroxidase rabbit (Dako, CA, USA) used as the detection 
system and 3) 3,3’-diaminobenzidine-tetrahydrochloride (Dako 
liquid DAB + substrate-chromogen system). Cell and tissue 
sections were faintly counterstained with Harris’ hematoxylin. 
Immunochemistry (IC) controls were performed applying the 
primary antibody plus control antigen peptide (10 nmol/mL) to 
positive samples. 
Quantification of myofiber cross-section area 
Serial muscle cryostat sections were stained with hematoxylin/
eosin, and five randomly chosen microscopic fields from five 
different sections in each tissue block were examined using 
ImageJ64 analysis software.
Heidenhain´s AZAN trichrome stain 
Serial muscle cryostat sections were stained with azocarmine G 
for 15min at 60°C. Cryosections were sequentially washed with 
water, aniline alcohol, acetate alcohol, phosphotungstic acid and 
water. Cryosections were counter-stained with aniline, orange 
G and acetic acid for 30 min. Samples were finally dehydrated 
with alcohol and xilol before mounting. Five randomly chosen 
microscopic fields from three different sections in each 
cryosection were examined using ImageJ64 analysis software.
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IMMUNOFLUOrESCENCE ANALYSIS
Immunofluorescence analysis of gLUT translocation in 
3T3-L1 adipocytes 
Cells were cultured on cover slips and differentiated into adipo-
cytes. Serum-starved cells were treated with obestatin (100 nM) 
or insulin (172 nM) for 30 min. Intact cells were fixed with 4% 
(w/v) PFA-PBS for 15 min, washed, permeabilized and blocked 
with PBS-Triton X-100 (PBT) [PBT: Triton X-100, 1% (v/v); Tween-20, 
1% (v/v); heat inactivated normal goat serum, 5% (v/v); BSA, 0.2% 
(w/v) in PBS] for 30 min, and then incubated with anti-GLUT4 
in PBT overnight at 4°C. After three washes with PBS, cells were 
incubated with the secondary antibody in PBT for 45 min at 37°C. 
IF images were captured with a Leica TCS SP 2 (Leica Microsys-
tems, Heidelberg, Germany) confocal laser scanning micro-scope 
mounted on an Leica DM IRBE inverted microscope (Leica Mi-
crosystems, Heidelberg, Germany).
Analysis of differentiation and fusion indexes in L6E9 
cells 
L6E9 were cultured on coverslips and differentiated into 
myotubes under DM supplemented with obestatin (5 nM) 
for 6 days. Intact cells were fixed with 4% PFA-PBS for 15 min, 
washed, permeabilized, and blocked with PBT for 30 min and 
then incubated with anti-MHC diluted in PBT overnight at 4 
°C. After three washes with PBS, cells were incubated with the 
secondary antibody in PBT for 45 min at 37 °C. DAPI was used to 
counter-stain the cell nuclei purchased from Life Technologies, 
Invitrogen (NY, USA). Digital images of cell cultures were acquired 
with a Leica TCS-SP2 spectral confocal microscope (Leica Mi-
crosystems, Heidelberg, Germany). Five fields from three inde-
pendent experiments were randomly taken for each treatment. 
The differentiation grade was evaluated based on the number of 
MHC-positive cells above the total number of nuclei. The number 
of nuclei within individual myotubes (≥2 nuclei) was counted for 
20–50 myotubes. Myotubes were grouped into two categories, 
those with 2–3 nuclei and those with 4 or more nuclei, and the 
percentage of myotubes in each category was calculated relative 
to untreated cells7. 
7.  Horsley, V. et al. Regulation of the growth of multinucleated muscle cells by an NFATC2-de-
pendent pathway. J. Cell. Biol. 2001; 153: 329-38. 
Analysis to differentiate between hypertrophic 
growth and myoblast fusion in C2C12 cells 
C2C12 were cultured on coverslips and differentiated into 
myotubes in different groups: 1) differentiating cells under DM 
supplemented with obestatin (5 nM) for 7 days; 2) differentiating 
cells under DM supplemented with obestatin (5 nM) the first 
three days of differentiation; 3) differentiating cells under DM sup-
plemented with obestatin (5 nM) the last four days of differentia-
tion; 4) differentiating cells under DM supplemented with obesta-
tin (5 nM) the first three days of differentiation and addition of 
arabinofuranosyl cytidine (AraC, 50μM) purchased from Pfizer (NY, 
USA), a DNA synthesis suppressor, the second day of differenti-
ation, and, 5)  differentiating cells under DM supplemented the 
last four days of differentiation with obestatin (5 nM) and AraC 
(50μM) the second day of differentiation8,9. Intact cells were fixed 
with 4% buffered PFA-PBS for 15 min, washed, permeabilized, 
blocked with PBT for 30 min, and then incubated with anti-MHC 
diluted in PBT overnight at 4 °C. After three washes with PBS, cells 
were incubated with the secondary antibody in PBT for 45 min 
at 37 °C. DAPI was used to counterstain the cell nuclei purchased 
from Life Technologies, Invitrogen (NY, USA). Digital images of cell 
cultures were acquired with a Leica TCS-SP2 spectral confocal mi-
croscope (Leica Microsystems, Heidelberg, Germany). Five fields 
from three independent experiments were randomly taken for 
each treatment. The differentiation grade was evaluated based on 
the number of MHC-positive cells and the total number of nuclei 
as indicated . The number of nuclei within individual myotubes 
(≥2 nuclei) was counted for 20–50 myotubes. Myotubes were 
grouped into two categories, those with 2–3 nuclei and those 
with 4 or more nuclei, and the percentage of myotubes in each 
category was calculated relative to untreated cells10. 
IF in TA cross sections 
Muscle samples were mounted in tissue freezing medium (tra-
gacanth paste) and snap frozen in nitrogen-cooled isopentane. 
Sections, 8 µm thick, were mounted on Histobond Adhesion 
Microslides (Marienfeld, Lauda-Königshofen, DE). Muscle sections 
8.  Von Maltzahn, J. et al. Wnt7a–Fzd7 signalling directly activates the Akt/mTOR anabolic grow-
th pathway in skeletal muscle. Nat Cell Biol. 2012; 14  (2): 186-92.
9.  Crescenzi, M. J. et al. Transformation by myc prevents fusion but not biochemical differentia-
tion of C2C12 myoblasts: mechanisms of phenotypic correction in mixed culture with normal 
cells. Cell. Biol. 1994; 125 (5): 1137-45.
10.  Horsley, V. et al. Regulation of the growth of multinucleated muscle cells by an NFATC2-de-
pendent pathway. J. Cell. Biol. 2001; 153: 329-38. 
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were permeabilized and blocked with PBT for 30 min, and incu-
bated with primary antibodies [anti-Pax7, anti-embrional myosin, 
anti-GPR39, anti-preproghrelin and anti-isolectin diluted in PBT 
overnight at 4 °C], washed with PBS and then incubated with the 
appropriate secondary antibody for 45 min at 37 °C. DAPI was used 
to counterstain the cell nuclei purchased from Life Technologies, In-
vitrogen (NY, USA). Quantification of SCs was performed by count-
ing Pax7+ cells in a whole section using ImageJ64 analysis software. 
At least 4 sections from each muscle were analysed and the mean 
results of sections from each muscle were further calculated as 
mean value of muscles. For vessel counting, the total number of 
isolectin+ vessels and the total number of laminin myofibers were 
measured for each cross-section. Five fields from three independ-
ent experiments were randomly taken for each treatment. 
IF of SCs in fibers  
The IF analysis was developed based on the protocol described 
elsewhere11. Fibers were collected on pre-coated glass tubes. 
After centrifugation for 7 min at 1000 rpm, fibers were treat-
ed with 4% PFA for 10 min and then with a solution of  2N HCl 
supplemented with 0,5% (v/v) Triton X-100 for 30 min at room 
temperature (RT). Tubes were centrifuged and washed three 
times at 1000 rpm during 7 min with PBS. Fibers were treated 
with blocking buffer (BF) for 30 min [BF: goat serum, 10 % (v/v); 
and, FBS, 10 % (v/v) in PBS], and incubated with primary antibod-
ies [anti-Pax7 and anti-laminin diluted in BF overnight overnight 
at 4 °C], washed with PBS and then incubated with the appropri-
ate secondary antibody for 1 h. DAPI was used to counterstain the 
cell nuclei. Fibers were finally washed with PBS, and transferred 
to microscope slides and mounted with Mowioll reagent (Calbio-
chem-Millipore; CA, USA). For SCs counting, the total number of 
Pax7+ cells per length were measured for each fiber using Im-
ageJ64 analysis software. 
FLOW CYTOMETrY ANALYSIS
TA muscles samples from injured mice were transported freshly 
to the laboratory. SCs isolation method is described in detail 
elsewhere12. Briefly, the plastic and glass material was coated with 
11.  Rosenblant, J. D. Culturing satellite cells from living single muscle fiber explants. In Vitro Cell. 
Dev. Biol. 1995, 31: 773-9.
12.  Pasut, A. et al. Isolation of muscle stem cells by fluorescence activated cell sorting cytome-
try. Methods Mol. Biol. 2012; 798: 53-64.
5% FBS in PBS. TAs were minced and the enzymatic digestion was 
done by treatment with a solution of collagenase-dispase [2.5 U/
mL; Roche (Basel, Switzerland)] in DMEM for 1 h at 37 °C in a water 
bath rocking. After tissue digestion, FBS 10% (v/v) was added to 
inactivate the enzymes.  Minced muscles were resuspended with 
a pipette to obtain an homogeneous solution to assure enzyme 
inactivation. The solution was filtered (74 μm), washed twice with 
PBS and centrifuged at 1500 rpm for 7 min. Cells were fixed with 
1% PFA-PBS for 10 min and  permeabilized  with 70% (v/v) freeze 
ethanol and stored overnight at -20 °C. The day after samples 
were blocked for 15 min with PBS plus 5% BSA (w/v), and then  
incubated with the corresponding primary conjugated anti-
bodies [Pax7-FITC and Myf5-Alexa Fluor 647] for 1 h. After three 
washes with PBS plus 5% BSA (1500 rpm for 7 min), cells were 
incubated with propidium iodide (PI) (40 µg/mL final concentra-
tion)  purchased from Sigma-Aldrich (Missouri, USA) for 20 min. 
Events were acquired on a FACS Calibur four colours cytometer 
(B. Dickinson, Belgium) and analysed using Cell-Quest software. 
Gates were set to include only cells with DNA (PI positive), thus 
gating out cellular debris commonly observed in isolating cells 
from solid tissues.
MIgrATION/INVATION ASSAY 
In vitro migration assay in L6E9 cells 
Cells were seeded on 6-well plates, grown to 100% confluence 
in GM, and then wounded with a sterile pipette tip to remove 
cells by linear scratches. The cells were washed and maintained 
in GM or GM +5 nM obestatin. The progress of migration was 
photographed immediately after injury and at 8 and 24 h after 
wounding, near the crossing point. The wound was calculated 
by tracing along the border of the scratch using the ImageJ64 
analysis software and using the following equation: percentage 
of wound closure = ((wound area (0 h) - wound area (x h))/wound 
area (0 h)) x 10013.
Ex vivo migration assays in TA mice muscles 
Minced fresh mice gastrocnemius were inverted harvested in 
8 μm pore size transwell purchased from Corning (NY, USA) 
13.  Goetsch, K. P. et al. Optimization of the scratch assay for in vitro skeletal muscle wound 
healing analysis. Anal. Biochem. 2011; 411: 158-60. 
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and were allowed to migrate and invade into growth factor–
reduced matrigel using  obestatin (25 nM) as a chemoattractant. 
After 7 days, transwells were stained with 4 mmol/L calcein-
acetoxymethyl ester purchased from Life Technologies, 
Invitrogen (NY, USA), and visualized by confocal microscopy 
(Leica TCS SP2 confocal microscope) using a 10x objective. 
Optical sections were scanned at 5 µm intervals moving up 
from the underside of the membrane into the matrigel. The 
fluorescence from each optical section was quantified with LCS 
Lite software (Leica Microsystems)14.
QUANTIFICATION AND STAININg OF LIpIDS WITH 
OIL rED O
Treated cells were fixed for 1 h with 4% buffered paraformalde-
hyde-PBS. Each dish was rinsed three times with Milli-Q water 
and then with 60% iso-propanol (5 min at RT). Lipid droplets were 
stained for 10 min at room temperature with a working solution 
of 60% Oil Red O. For quantification, cells were washed exten-
sively with water to remove unbound dye, and iso-propanol was 
added to the stained culture plates and then analyzed by spectro-
photometry at 520 nm.
gLUCOSE UpTAKE ASSAYS 
In vitro assays in 3T3-L1 and L6E9 cells 
Cells were cultured in six-well culture plates. Serum-starved cells 
(12 h) were washed with PBS buffer and then cells were either un-
stimulated or stimulated with obestatin or insulin at the indicated 
concentrations for 30 min. Glucose transport was determined by 
addition of 2-[3H]deoxyglucose (0.5 μCi/mL) from GE-Amersham 
(Buckinghamshire, UK). The uptake was stopped after 5 min by 
aspiration, and cells were washed three times with ice-cold PBS. 
Cells were lysed in 1% SDS, and deoxyglucose uptake was deter-
mined by scintillation counting in triplicate. Non-specific uptake 
was measured in the presence of 20 μM cytochalasin B (cyB) 
purchased from Sigma-Aldrich (Missouri, USA).
14.  Muinelo-Romay, L. et al. High-Risk Endometrial Carcinoma Profiling Identifies TGF-b1 as a 
Key Factor in the Initiation of Tumor Invasion. Mol. Cancer. 2011; 10 (8): 1357-66.
DOgU ex vivo in gastrocnemius rat muscle 
Gastrocnemius were removed from hind limbs and cleaned from 
all adipose tissue and vessels. After washing muscles twice with 
PBS, gastrocnemius were placed on six-well culture plates for 30 
min in DMEM for stabilization in a culture incubator.  After that, 
muscles were either unstimulated or stimulated with obestatin 
or insulin at the indicated concentrations for 30 min. Glucose 
transport was determined by addition of 2-[3H]deoxyglucose (0.5 
μCi/mL) from GE-Amersham (Buckinghamshire, UK). The uptake 
was stopped after 5 min by aspiration, and muscles were washed 
three times with ice-cold PBS. Cells were lysed in 1% SDS, and 
deoxyglucose uptake was determined by scintillation counting in 
triplicate. 
DATA ANALYSIS
All values are presented as mean ± standard error of the mean 
(s.e.). Student t test were performed to assess the statistical 
significance of 2-way analysis. For multiple comparisons, ANOVA 
was employed. P< 0.05 was considered as statistically significant 
(*,#,##).

RESULTS

CHAPTER 1
OBESTATIN AS A REGULATOR OF ADIPOCYTE 
METABOLISM AND ADIPOGENESIS
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Obestatin activates Akt phosphorylation and 
AMpK dephosphorylation in 3T3-L1 adipocyte cells
First, the dose dependence of Akt activation by obestatin 
was examined in 3T3-L1 adipocytes. Akt phosphorylation at 
C-terminal hydrophobic motif (S473) [HM(S473); p-Akt(S473)] 
was observed using 10 nM obestatin, and the level of p-Akt(S473) 
plateaued at 100–200 nM (data not shown). Next, we examined 
the kinetic of Akt activation in response to obestatin. Significant 
p-Akt(S473) augment was observed 10 min after addition 
of obestatin (100 nM), being sustained by 60 min (Fig. 1.1A). 
Parallel to Akt activation, obestatin (100 nM) triggered the 
phosphorylation of a broad range of Akt downstream substrates: 
GSK3 α/β (S21/9), AS160 (T642) mTOR(S2448) and S6K1(T384) 
(Fig. 1.1B and C). Importantly, dephosphorylation of p-AMPKα 
(T172) and its downstream substrate ACC (S79) was observed in 
response to obestatin (100 nM) (Fig. 1.1C).
Fig. 1.1 Time-course of the effect of obestatin (100 nM) 3T3-L1 adipo-
cytes: (A) p-Akt(S473) and p-AMPKα (T172); (B) p-GSK3 α/β (S21/9) and 
p-AS160(T642) and (C) p-mTOR(S2448), p-S6K1(T384) and p-ACC(S79). Phos-
phorylation was expressed as a percentage of the maximal phosphorylation 
obtained for each residue (n=3; mean± S.E.). 
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Obestatin activates Akt phosphorylation and 
AMpK dephosphorylation in WAT
For in vivo obestatin administration, osmotic mini pumps were 
selected based on the short half-life of this peptide (~22 min)1. 
Male rats received a 24 h continuous subcutaneous (sc) infusion 
of obestatin (300 nmol/kg body weight/24 h) and dissected WATs 
were processed for WB analysis. Obestatin significantly activated 
Akt, measured as p-Akt (S473), in subcutaneous, gonadal and 
omental WAT (Fig. 1.2A). p-AMPKα (T172) was decreased by 
20% to basal phosphorylation in omental WAT with no effect in 
subcutaneous and gonadal WAT (Fig. 1.2A). A 72 h continuous sc 
infusion of obestatin (300 nmol/kg body weight/24 h) increased 
p-Akt (S473) and decreased p-AMPKα (T172) in subcutaneous, 
gonadal and omental WAT (Fig. 1.2B). The divergence between 
24 and 72 h might be explained by the stress generated by mini- 
pump implantation. 
1.  Zizzari, P. et al. Obestatin partially affects ghrelin stimulation of food intake and growth hor-
mone secretion in rodents. Endocrinology. 2007; 148: 1648-53.
Fig. 1.2 Obestatin activates Akt phosphorylation and AMpK dephospho-
rylation in WAT. (A) Effect of 24 h continuous sc infusion of obestatin (300 
nmol/kg body weight/24 h; n=10) on p-Akt(S473) and p-AMPKα (T172) from 
subcutaneous, gonadal and omental WAT obtained from male rats. (B) Effect 
of 72 h continuous sc infusion of obestatin (300 nmol/kg body weight/24 h; 
n=10) on p-Akt(S473) and p-AMPKα (T172) from subcutaneous, gonadal and 
omental WAT obtained from male rats. Phosphorylation was expressed as a 
percentage of control obtained from 24 h or 72 h mini pump sc implanted 
saline group (n=10; mean± S.E.). Asterisk (*) denotes P< 0.05 when comparing 
obestatin-treated group with untreated control group (saline).
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Obestatin increases gLUT4 levels in plasma 
membranes and glucose uptake in 3T3-L1 
adipocyte cells
The amplitude of Akt activation was evaluated on the basis of 
GLUT1 and GLUT4 translocation to plasma membrane in 3T3-
L1 adipocyte cells. Acute treatment with obestatin (100 nM, 30 
min) resulted in an increase in GLUT4 translocation to the plasma 
membrane by ~1.9-fold (Fig. 1.3A). Intriguingly, a modest GLUT1 
redistribution was observed in response to 100 nM obestatin 
(30 min) in 3T3-L1 adipocyte cells (~1.3-fold; Fig. 1.3A). Insulin 
(172 nM, 30 min) caused a higher increase of GLUT4 levels at 
the plasma membrane than obestatin in 3T3-L1 adipocyte cells 
(~2.8-fold) with no significant effect on GLUT1 translocation (Fig. 
1.3A). The effect of obestatin in the translocation of GLUT4 to the 
plasma membrane was confirmed by specific immunofluores-
cence staining (Fig. 1.3B). In quiescent 3T3-L1 adipocyte cells, the 
fluorescence was distributed throughout the cytoplasm. After 
exposure to obestatin (100 nM, 30 min), the fluorescence almost 
completely disappeared from the cytoplasm to be redistributed 
in the plasma membrane. The effect of obestatin on DOGU was 
examined in 3T3-L1 adipocyte cells. Cells were incubated with 
different concentrations of obestatin (0.001–200 nM) for 30 min, 
resulting in a dose- dependent increase in DOGU with a maximal 
effect at 100 nM obestatin (~2.0-fold; Fig. 1.3C). Insulin treatment 
(172 nM) caused an increase of DOGU by ~2.8-fold in adipocyte 
cells (Fig. 1.3C).
Fig. 1.3 Effect of obestatin in glucose up-take. (A) WB analysis of GLUT4 
and GLUT1 expression in membrane from 3T3-L1 adipocyte cells treated 
with obestatin (100 nM) or insulin (172 nM) for 30 min. GLUT expression was 
expressed as a percentage of basal expression obtained in control cells (n=3; 
mean± S.E.). (B) Immunofluorescence analysis of obestatin-induced GLUT4 
translocation in 3T3-L1 adipocyte cells. Serum-starved cells were stimulated 
with obestatin (100 nM, 30 min) and the amount of GLUT4 was determined 
by labeling with anti-GLUT4 antibody in combination with Alexa 594-con-
jugate goat anti- rabbit antibody in permeabilized cells. (C) Obestatin dose 
dependently stimulated 2-[3H]deoxyglucose uptake in 3T3-L1 adipocyte cells 
(n=3; mean± S.E.). Non-specific uptake was measured in the presence of 20 
μM cytochalasin B (CyB).
Obestatin shows no effect on FATp1, FATp4 and 
FAT/CD36 translocation to plasma membrane in 
3T3-L1 adipocyte cells
The levels of long chain fatty acid transport proteins 1 and 4 
(FATP1 and FATP4) and fatty acid translocase (FAT/CD36) at 
plasma membrane were examined by subcellular fractionation. 
As shown in Fig. 1.4, obestatin (100 nM, 30 min) did not modify 
FATP1, FATP4 and FAT/CD36 levels at the plasma membrane in 
3T3-L1 adipocyte cells. Remarkably, FATP1 and FATP4 redistribu-
tion was significantly affected in response to insulin (172 nM, 30 
min) in ~2.3- and 2.6-fold, respectively. In contrast to the FATP 
observation, FAT/CD36 redistribution was unaffected in response 
to insulin (172 nM, 30 min; Fig. 1.4).
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Fig. 1.4. Effect of obestatin on fatty acid transporters. WB analysis of FATP1, 
FATP4 and FAT/CD36 expression in membrane from 3T3-L1 adipocyte cells 
treated with 100 nM obestatin or with 172 nM insulin for 30 min. FATP1, FATP4 
and FAT/CD36 expression were expressed as a percentage of basal expression 
obtained in control cells (n=3; mean± S.E.). Expression of GHSR1a was deter-
mined to ensure equal membrane protein loading. Blots are representative of 
three independent experiments. Asterisk (*) denotes P<0.05 when comparing 
obestatin-treated group with untreated control group.
Obestatin promotes adipogenesis in vitro
To initiate the 3T3-L1 adipocyte differentiation process, IBMX, DEX 
and insulin are used. Among these three compounds, only insulin 
is capable of activating Akt system through IGF-1 receptor playing 
a pivotal role in adipogenesis2. Consistent with the effect on 3T3-
L1 adipocytes (Fig.1.1A), obestatin (100 nM) induced significant 
Akt(S473) phosphorylation, which was parallel to AMPK dephos-
phorylation at T172 in 3T3-L1 preadipocyte cells. To ascertain the 
effect of obestatin on adipogenesis, we first analyzed the effect 
of obestatin on Akt activation in 3T3-L1 preadipocytes (Fig 1.5A). 
The effect of acute GPR39 deficiency was determined by means 
of siRNA in 3T3-L1 preadipocyte cells. Under these conditions, the 
constructs decreased GPR39 expression by 50±10% (Fig. 1.5B). In 
the presence of a non-targeting control siRNA. Silencing of GPR39 
in preadipocyte cells decreased subsequent p-Akt(S473) with 
2.  Xu, J. et al. Protein kinase B/Akt 1 plays a pivotal role in insulin-like growth factor- 1 receptor 
signalling induced 3T3-L1 adipocyte differentiation. J. Biol. Chem.  2004; 279: 35914-22.
respect to siRNA control (47±2% under treatment with obestatin 
(100 nM) for 5 min; Fig. 1.5B). 
Fig.1.5 Effect of obestatin on preadipocytes trough gpr39. (A) Time-
course of the effect of obestatin (100 nM) on p-Akt(S473) and p-AMPKα(T172) 
in 3T3-L1 preadipocyte cells. Phosphorylation was expressed as a percentage 
of the maximal phosphorylation obtained for each residue (n=3; mean± S.E.). 
(B) Effect of siRNA depletion of GPR39 on obestatin-activated p-Akt(S473) 
(100 nM, 5 min) in 3T3-L1 preadipocyte cells. Expression of p-Akt(S473) and 
GPR39 was expressed as fold of their levels in control siRNA-transfected cells 
(n=3; mean± S.E.). 
Next, we examined the role of obestatin as promoter of terminal 
adipocyte differentiation working with 3T3-L1 preadipocyte cells 
maintained in DMEM containing 10% FBS with obestatin (0.001–
200 nM), ghrelin (0.001–200 nM) or insulin (172 nM) for 7 days after 
induction of differentiation under combination of 0.5 mM IBMX, 25 
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μM DEX and 861 nM insulin for 3 days. Oil red O staining revealed 
that the accumulation of lipid droplets was dose-dependent for 
obestatin or ghrelin treatments being maximal at 10 nM for both 
peptides (~3.6-fold; Fig. 1.6A). Insulin (172 nM) treatment increased 
the formation of lipid droplets (~7.8-fold; Fig. 1.6A). Co-treatment 
with obestatin or ghrelin (1 or 10 nM) and a half-dose of insulin (86 
nM) further stimulated adipocyte differentiation compared to the 
treatments with obestatin or ghrelin alone (Fig. 1.6A). 
The capability of obestatin as initiator of adipocyte differentiation 
was explored by the combination of IBMX, DEX and obestatin (1.96 
μM obestatin for 3 days and then maintained in DMEM containing 
10% FBS with 392 nM obestatin for 7 days; Fig. 1.6B). Obesta-
tin-stimulated adipocyte differentiation was detected at 10 nM, 
but maximal effects were observed at pharmacological levels for 
in vitro assays (≥1 μM). Obestatin treatment (1.96 μM) for 3 days 
(Group 2, Fig. 1.6B) induced more lipid droplets (~1.6-fold) than 
insulin treatment (Group 1, Fig. 1.6B). The accumulation was higher 
in cells maintained in DMEM/10% FBS with obestatin (392 nM) for 7 
days after induction of differentiation (Group 3, Fig. 1.6B), but fewer 
than that observed in full dose insulin-treated cells (172 nM) for 7 
days (Group 4, Fig. 1.6B). 
Fig.1.6. Effect of obestatin as a promoter or initiator of adipogenesis: 
(A) 3T3-L1 cells display an obestatin-dependent increase in adipogenesis. 
3T3-L1 preadipocyte cells were maintained in DMEM containing 10% FBS 
with different concentrations of obestatin, ghrelin or insulin (172 nM) for 7 
days after induction of differentiation by combination of 0.5 mM IBMX/25 μM 
DEX/861 nM insulin for 3 days. Lipid droplet accumulation was analyzed by 
spectrophotometry at 520 nm by Oil red O staining. Results are expressed as 
a fold of lipid accumulation over differentiation control (cells maintained in 
DMEM/10% FBS/172 nM insulin for 7 days after induction of differentiation 
under treatment with 0.5 mM IBMX/25 μM DEX/861 nM insulin for 3 days; 
n=3; mean± S.E.). Representative microscope fields of view (right) are shown 
at the same magnification. (B) Effect of obestatin as initiator of adipogenesis. 
3T3-L1 preadipocyte cells were maintained in DMEM containing 10% FBS with 
obestatin (392 nM) or insulin (172 nM) for 7 days after induction of differenti-
ation by treatment with 0.5 mM IBMX, 25 μM DEX, 861 nM insulin or 1.96 μM 
obestatin for 3 days. Lipid droplet accumulation was analyzed by spectropho-
tometry at 520 nm by Oil red O staining. Results are expressed as fold of lipid 
accumulation over differentiation control (cells maintained in DMEM/10% 
FBS/172 nM insulin for 7 days after induction of differentiation by treatment 
with 0.5 mM IBMX/25 μM DEX/861 nM insulin for 3 days; n=3; mean± S.E.). 
Asterisk (*) denotes P<0.05.
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Supporting this scenario, in obestatin-treated 3T3-L1 differenti-
ating adipocytes, C/EBPβ protein expression markedly increased 
at 24 h for p32 and p35 isoforms, respectively (Fig. 1.7A). Fur-
thermore, C/EBPδ protein expression peaked around 6 h after 
obestatin treatment (Fig. 1.7B). Consistently, obestatin treatment 
strongly increased the expression of PPARγ proteins peaking at 
48 and 144 h of differentiation for PPARγ1 and PPARγ2 isoforms, 
respectively (Fig. 1.7C). In addition, this treatment also increased 
the expression of C/EBPα proteins peaking at 24 and 72 h for p30 
and p42 isoforms, respectively (Fig. 1.7D).
Fig. 1.7 Obestatin regulation of transcription factors during adipogene-
sis: (A) C/EBPβ, (B) C/EBPδ , (C) PPARγ and (D) C/EBPα. 3T3-L1 preadipocyte 
cells were maintained in DMEM containing 10% FBS, obestatin (392 nM) or 
insulin (172 nM) for 7 days after induction of differentiation by treatment with 
0.5 mM IBMX, 25 μM DEX, 10% FBS, 861 nM insulin or 1.96 μM obestatin for 
3 days [in (D), asterisk (*) denotes unspecific band]. Data were expressed as 
percentage of control expression (n=3; mean± S.E.). Blots are representative of 
three independent experiments.
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preproghrelin expression increases throughout 
adipogenesis
We first examine obestatin expression in 3T3-L1 preadipocyte and 
adipocyte cells at protein level, utilizing immunocytochemistry. 
3T3-L1 adipocyte cells showed a stronger obestatin expression (Fig. 
1.8B) compared to that observed in 3T3-L1 preadipocyte cells (Fig. 
1.8A). No immunostaining was found with obestatin antibody pre-
adsorption control in 3T3-L1 adipocyte cells (Fig. 1.8C). This result 
leads us to focus on preproghrelin expression along adipogenesis 
as source of obestatin. Preproghrelin expression was examined at 
mRNA and protein level, by RT-PCR and immunoblot, respectively, 
in 3T3-L1 preadipocyte cells. The cells were maintained in DMEM 
containing 10% FBS with insulin (172 nM) for 7 days after induction 
for 3 days (0.5 mM IBMX, 25 μM DEX and 861 nM insulin). The 
amount of preproghrelin mRNA showed a biphasic pattern of 
expression. A rapid augment was observed at 6 h (~1.7-fold; Fig. 
1.8D), to reach values bellow basal by 24 h after the induction of 
differentiation. Preproghrelin mRNA expression increased from 
48 h, becoming maximal 72 h after induction to be sustained 
throughout terminal differentiation. As Fig. 1.8E shows, there is 
a rapid augment of preproghrelin protein expression at the time 
of differentiation into adipocytes (~4.0-fold, 6 h after induction) 
reaching a maximum 24 h after induction of differentiation 
(~5.8-fold) concomitant with the minimum of preproghrelin 
mRNA expression (Fig. 1.8D). Intriguingly, preproghrelin protein 
expression decreased 48 h after induction of differentiation to 
be sustained along terminal differentiation being higher than 
that in preadipocyte cells (~2.4-fold at 240 h). Furthermore, 
GPR39 protein expression decreased in terminal differentiation 
compared to undifferentiated 3T3-L1 cells (~40% reduction, 240 h 
after induction; Fig. 1.8F), showing two maximal expression levels 
concomitant with the maximum of preproghrelin expression (Fig. 
1.8D). 
Fig.1.8 Obestatin expression along adipogenesis. Immunocytochemical 
detection of obestatin in 3T3-L1 preadipocyte (A) and adipocyte cells (B) (ob-
jective magnification 40x). Obestatin immunostaining was mainly localized in 
the cytoplasm of 3T3-L1 adipocytes while it was faint in 3T3-L1preadipocyte 
cells. (C) Pre-adsorption control with mouse obestatin (10 nmol/mL) showed 
no positive immunostaining. (D) Preproghrelin mRNA levels in the course 
of adipogenesis. WB analysis of preproghrelin (E) and GPR39 (F) expression 
in the course of adipogenesis. Preproghrelin expression at mRNA or protein 
levels, were examined in 3T3-L1 preadipocyte cells maintained in DMEM con-
taining 10% FBS with insulin (172 nM) for 7 days after induction for 3 days (0.5 
mM IBMX, 25 μM DEX and 861 nM insulin). Protein expression was expressed 
as a fold over control cells (n=3; mean± S.E.). mRNA was quantified by RT-PCR 
and expressed as arbitrary units (n=5; mean± S.E.). Asterisk (*) denotes P<0.05 
when comparing obestatin-treated group with untreated control group.
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Consistent with the results from cultured cells, immunohis-
tochemical analysis confirmed the expression of obestatin in 
subcutaneous, gonadal and omental WAT obtained from male ad 
libitum rats (Fig 1.9 A–C, respectively).
 Fig.1.9 Immunohistochemical detection of obestatin in WAT : subcutane-
ous (A), gonadal (B) and omental (C) WAT (objective magnification 20x). 
Autocrine/paracrine role of obestatin on 
adipogenesis
The autocrine/paracrine role of obestatin on adipogenesis was 
tested in vitro performed with a neutralizing obestatin antibody 
(anti-obestatin Ab). As shown in the Fig. 1.10 (left panel) neutraliza-
tion of obestatin (100 nM) by pre-incubation with anti-obestatin Ab 
(1.3 μg/mL) reduced by ~70±3% the level of p-Akt (S473) in 3T3-L1 
preadipocyte cells. By contrast, insulin-induced Akt activity was not 
affected by pre-incubation with anti-obestatin Ab. The autocrine/
paracrine role on adipogenesis was then tested by combination of 
24 and 48 h serum-free conditioned medium (CM) of 3T3-L1 adipo-
cyte cells with neutralizing obestatin antibody (5 μg/mL), Fig. 1.10 
(right panel). 3T3-L1 preadipocyte cells were maintained in DMEM 
containing 0.1% BSA with obestatin (392 nM; Group 2), anti- obesta-
tin Ab, (Group 3), obestatin (392 nM)+anti-obestatin Ab (Group 4), 
CM-24h (Group 5), CM-24h+anti-obestatin Ab (Group 6), CM-48h 
(Group 7) or CM-48h+anti-obestatin Ab (Group 8) for 7 days after 
induction of differentiation under treatment with 0.5 mM IBMX, 25 
μM DEX and 861 nM insulin for 3 days. Oil Red O staining revealed 
that incubation with neutralizing obestatin Ab reduced by 35±3% 
accumulation of lipid droplets compared to 3T3-L1 preadipocyte 
cells maintained in DMEM/0.1% BSA/392 nM obestatin (Fig. 1.10, 
Group 3 versus Group 2). Neutralization of obestatin (392 nM) by 
pre-incubation with anti-obestatin Ab reduced by 35±8% accumu-
lation of lipid droplets compared to 3T3-L1 preadipocyte cells main-
tained in DMEM/0.1% BSA/392 nM obestatin (Group 4 versus Group 
2; Fig. 1.10). Serum-free conditioned medium, CM-24h or CM-48h, 
also activated accumulation of lipid droplets (~2.0- and ~2.5-fold, 
respectively; Groups 5 and 7 versus Group 1; Fig. 1.10). Pre-incu-
bation of the CM-24h or CM-48h with anti-obestatin Ab reduced 
accumulation of lipid droplets by 21±4% and 20±6%, respectively 
(Groups 6 versus Groups 5, and Group 8 versus Group 7, Fig. 1.10). 
Fig. 1.10 Autocrine/paracrine role of obestatin on adipogenesis. (Left 
panel) Anti-obestatin antibody specificity. Effect of anti- obestatin antibody 
(1.3 μg/mL), obestatin (100 nM), insulin (100 nM), anti-obestatin antibody+ 
obestatin and anti-obestatin antibody+ insulin on p-Akt(S473) in 3T3-L1 
preadipocytes. (right panel) 3T3-L1 preadipocyte cells were maintained in 
DMEM containing 0.1% BSA with obestatin (392 nM; Group 2), anti-obestatin 
antibody (5 μg/mL; anti-obestatin Ab; Group 3), obestatin (392 nM)+an-
ti-obestatin Ab (5 μg/mL; Group 4), CM-24h (Group 5), CM-24h+anti-obestatin 
Ab (5 μg/mL; Group 6), CM-48h (Group 7) or CM-48h+anti-obestatin Ab (5 μg/
mL; Group 8) for 7 days after induction of differentiation by treatment with 0.5 
mM IBMX, 25 μM DEX and 861 nM insulin for 3 days. Lipid droplet accumu-
lation was analyzed by spectrophotometry (520 nm) by Oil red O staining. 
Results are expressed as fold of lipid accumulation over differentiation control 
(Group 1; cells maintained in DMEM/0.1% BSA for 7 days after induction of 
differentiation by treatment with 0.5 mM IBMX/25 μM DEX/861 nM insulin for 
3 days; mean± S.E. of three independent experiments). Asterisk (*) denotes 
P<0.05 when comparing treated groups with control group; daggers (#, 
##) denote P < 0.05 when comparing treated groups with antibody-treated 
groups. Phosphorylation was expressed as fold of control (n=3; mean± S.E.). 
Blot is representative of three independent experiments. Asterisk (*) denotes 
P<0.05 when comparing obestatin-treated group with anti-obestatin ab+ 
obestatin group. 
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The effect of acute obestatin deficiency was determined by 
knock-down of preproghrelin by means of siRNA prior to induc-
tion of adipocyte differentiation. Under these conditions, the 
constructs decreased preproghrelin expression by 58±6% (Fig. 
1.11, left panel). Silencing of preproghrelin in preadipocyte cells 
decreased subsequent adipocyte differentiation with respect to 
siRNA control [43±5% and 48±4% for 3T3-L1 preadipocyte cells 
under treatment with 0.5 mM IBMX, 25 μM DEX, and insulin (861 
nM) for 3 days and then maintained in DMEM containing 10% FBS 
or insulin (172 nM) for 7 days, respectively (Fig. 1.11, right panel)].
Fig.11 Effect of sirNA depletion of preproghrelin on adipogenesis. (Left 
panel) 3T3-L1 cells transfected with preproghrelin siRNA prior to induction 
of adipocyte differentiation (DMEM/10% FBS with insulin (172 nM) for 7 days 
after induction for 3 days under 0.5 mM IBMX, 25 μM DEX and 861 nM insulin). 
Equal amounts of protein in each sample were used to assess the expression 
of preproghrelin by WB. Expression of preproghrelin was expressed as fold 
of the level of preproghrelin in control siRNA-transfected cells (mean± S.E.). 
(right panel) Lipid droplet accumulation was analyzed by spectrophotom-
etry at 520 nm by Oil red O staining. Results are expressed as fold of lipid 
accumulation over differentiation control. Asterisk (*) denotes P<0.05 when 
comparing treated control siRNA group with control siRNA group; dagger (#) 
denotes P<0.05 when comparing preproghrelin siRNA group with control 
siRNA group.
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results Preproghrelin expression is a key target for insulin action on adipogenesis
Expression of preproghrelin, pC1/3, and MBOAT4 
throughout adipogenesis in 3T3-L1 cells
Preproghrelin, PC1/3, and MBOAT4 proteins were found to 
predominate in 3T3-L1 adipocyte cells compared to preadipocyte 
cells as indicated in Fig. 2.1. To ascertain whether insulin 
determines this pattern of expression, mRNA and protein 
expression of preproghrelin, PC1/3, and MBOAT4 were analyzed in 
insulin-induced adipogenesis and compared to that with no insulin 
treatment (group A: DEX, IBMX and group B: insulin, DEX and IBMX) 
(Fig. 2.2). In Fig. 2.2A we showed that meanwhile the preproghrelin 
mRNA showed a maximum at 144 h in group A, insulin-stimulated 
group showed two peaks of expression at 6 and 144 h being ∼1.7- 
and 1.5-fold higher compared with the former. The PC1/3 mRNA 
levels significantly augmented for all times tested in the group A, 
although this pattern of expression was clearly regulated under 
insulin treatment in group B with a maximal display at 144 h (∼3.5-
fold). The MBOAT4 mRNA levels increased 24 h after treatment 
to return to near basal levels over 144h in group A (Fig. 2.2A). By 
contrast, insulin treatment inhibited MBOAT4 mRNA throughout 
adipogenesis to return to basal levels in terminal differentiation 
(Fig. 2.2A). Results of WB analysis (Fig. 2.2B) showed that the 
preproghrelin protein level markedly increased at 6 h (∼4.5-fold)
which was sustained along terminal differentiation in group B. A 
similar temporal profile was observed for PC1/3 protein showing 
two maximal expression levels concomitant with the maximum 
of preproghrelin expression (∼2.5- and 2.0-fold at 6 and 144 h 
respectively), whereas MBOAT4 protein was apparent within 24 h 
and increased in abundance throughout adipogenesis reaching 
maximal values in terminal differentiation (∼3.0-fold at 240 h). In 
marked contrast, the amount of preproghrelin, PC1/3, and MBOAT4 
protein was not significantly affected in the absence of insulin 
treatment (group A). 
Fig. 2.1 Immunohistochemical detection of preproghrelin derived 
enzymes. Preproghrelin, PC1/3, and MBOAT4 in 3T3-L1 preadipocyte and 
adipocyte cells (objective magnification 40x).
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Fig. 2.2 Quantitative analysis of mrNA and protein levels of preproghre-
lin and its derived enzymes during differentiation (A) Preproghrelin, PC1/3, 
and MBOAT4 mRNA levels in the course of adipogenesis. Data were normal-
ized to levels of ACTB and expressed as mean± S.E.M. (n=6). (B) WB analysis of 
preproghrelin, PC1/3, and MBOAT4 in adipogenesis. mRNA or protein levels 
were examined in group A (3T3-L1 preadipocyte cells maintained in DMEM 
containing 10% FBS for 7 days after treatment for 3 days with 0.5 mM IBMX, 25 
mM DEX) and group B (3T3-L1 preadipocyte cells maintained in DMEM con-
taining 10% FBS, insulin (172 nM) for 7 days after induction for 3 days (0.5 mM 
IBMX, 25 mM DEX, and 861 nM insulin)). For B data are expressed as mean± 
S.E.M. (n=3). For all experiments *P<0.05 versus control values.
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mTOr/56K1 pathway is involved in preproghrelin 
derived peptides regulation
To further explore the mechanism involved in the control of 
protein translation, the effect of rapamycin treatment (25 nM) was 
examined 2 h prior to insulin-induced adipocyte differentiation. 
Inhibition of mTORC1/S6K1 pathway significantly reduced the 
preproghrelin, MBOAT4, and PC1/3 protein expression at 72 h af-
ter insulin-activated adipogenesis (Fig. 2.3). Rapamycin treatment 
did not significantly alter the expression of analyzed proteins in 
3T3-L1 preadipocyte-treated controls.
Fig. 2.3 preproghrelin, and its derived enzymes, protein expression in 
absence or presence of rapamycin. After pretreatment with rapamycin 
(25 nM, 2 h), 3T3-L1 preadipocyte cells were maintained for 72 h in DMEM 
containing 10% FBS, 0.5 mM IBMX, 25 mM DEX, 861 nM insulin (differentiation 
medium, DM), or DMEM containing 10% FBS (standard medium, SM). Data are 
expressed as mean± S.E.M. (n=3). *P<0.05 versus control values.
Auto/paracrine role of preproghrelin-derived 
peptides in adipogenesis in 3T3-L1 cells
To define the auto/paracrine role of preproghrelin-derived 
peptides in adipogenesis, the effect of preproghrelin siRNA was 
first examined. Transfection of 3T3-L1 preadipocytes prior to 
induction of adipogenesis with siRNA designed against preprogh-
relin reduced target protein expression by 51±2% (Fig. 2.4). The 
effect of preproghrelin deficiency decreased MBOAT4 and PC1/3 
with respect to siRNA control (49±3 and 61±3% respectively; Fig. 
2.4, above panel). Oil Red O staining revealed that preproghrelin 
knock-down significantly reduced insulin-mediated adipogenesis 
by at least 30±1 and 50±5% for 3T3-L1 preadipocyte cells under 
treatment with IBMX, DEX, and insulin for 3 days and then main-
tained in DMEM containing 10% FBS or insulin for 7 days respec-
tively (Fig. 2.4, below panel). 
Fig. 2.4. Effect of sirNA depletion of preproghrelin on adipogenesis. 
(Above panel) 3T3-L1 cells transfected with preproghrelin siRNA prior to in-
duction of adipocyte differentiation (DMEM/10% FBS or DMEM/10% FBS with 
insulin (172 nM) for 7 days after induction for 3 days under 0.5 mM IBMX, 25 
mM DEX, and 861 nM insulin). Equal amounts of protein in each sample were 
used to assess the expression of MBOAT 4, PC1/3, and preproghrelin by WB. 
(Bellow panel) Lipid droplet accumulation was analyzed by spectrophotome-
try at 520 nm by Oil red O staining. Data are mean± S.E.M. of three independ-
ent experiments (*,P<0.05 versus control values).
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Similar results were obtained by neutralization of endogenous 
obestatin or UAG/AG using anti-obestatin (5 μg/mL) or anti-
ghrelin (5 μg/mL; antibody raised against a peptide mapping 
within an internal region of ghrelin) antibodies (Ab; Fig. 2.5A ). The 
differentiation-associated lipid accumulation was significantly 
reduced by anti-obestatin Ab (25±4%). A larger effect was 
observed with anti-ghrelin Ab (39±2%). These effects were 
reverted neutralizing the primary antibody with its respective 
antigen peptide (obestatin, AG or UAG, 5 μg/mL). The expression 
pattern of GHSR1a and GPR39 was further analyzed in Fig. 2.5B. 
The GHSR1a protein levels were concomitant with the maximum 
of preproghrelin expression (Fig. 2.2B)(∼1.7- and 1.4-fold at 6 h 
and 144 h respectively; Fig. 2.5B). The GPR39 levels showed a 
more sustained expression throughout adipogenesis with two 
maximal levels (∼2.3- and 2.2-fold at 48 h and 144 h respectively; 
Fig. 2.5B).
Fig. 2.5 Autocrine/paracrine role of obestatin and ghrelin/O-acyl ghrelin on 
adipogenesis. (A) 3T3-L1 preadipocyte cells were maintained in DMEM containing 
10% FBS (group 1), 10% FBS+ insulin (172 nM; group 2), 10% FBS+ insulin (172 
nM)+anti-obestatin Ab (5 μg/mL; group 3), 10% FBS+ insulin (172 nM)+anti-
obestatin Ab (5 μg/mL)+obestatin (5 μg/mL; group 4), 10% FBS+ insulin (172 
nM)+anti-ghrelin Ab (5 μg/mL; group 5), 10% FBS+ insulin (172 nM)+anti-ghrelin 
Ab (5 μg/mL)+AG (5 μg/mL; group 6) or 10% FBS+ insulin (172 nM)+anti-ghrelin 
Ab (5 μg/mL)+UAG (5 μg/mL; group 7) for 7 days after induction of differentiation 
by treatment with 0.5 mM IBMX, 25 mM DEX, and 861 nM insulin for 3 days. (B) WB 
analysis of GHSR1a and GPR39 along adipogenesis. Data are mean± S.E.M. of three 
independent experiments (*P<0.05 versus control values).
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preproghrelin, pC1/3, and MBOAT4 expression in 
WAT
Preproghrelin, PC1/3, and MBOAT4 were detected immunohis-
tochemically in omental and subcutaneous WAT obtained from 
mice under normal chow (control; Fig. 2.7A). WB analysis com-
paring WAT obtained from mice under normal chow and HFD 
showed that preproghrelin expression was enhanced in subcu-
Fig. 2.7. Detection of preproghrelin and its derived enzymes in WAT 
(A) Immunohistochemical analysis of preproghrelin, PC1/3, and MBOAT4 
in omental and subcutaneous WAT obtained from control mice (objective 
magnification 20x). (B) WB analysis of preproghrelin, PC1/3, and MBOAT4 in 
omental and subcutaneous WAT obtained from control and HFD mice (n=10 
per group). Data are mean± S.E.M. *P<0.05 versus control values. 
taneous WAT of HFD mice relative to WAT of control mice (∼0.5-
fold), although its expression was not altered in omental WAT of 
HFD mice (Fig. 2.7B). PC1/3 levels were enhanced in both omental 
and subcutaneous WAT of HFD mice (∼1.5- and 0.6-fold respec-
tively). MBOAT4 levels were also augmented in both omental and 
subcutaneous WAT of HFD mice (∼0.8- and 0.4-fold respectively; 
Fig. 2.7B).
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The Obestatin/gpr39 system is expressed in adult 
skeletal muscle
The expression of the obestatin/ GPR39 system was detected in 
adult gastrocnemius skeletal muscle from male ad libitum rats by 
IHC (Fig. 3.1.1 and 3.1.4, respectively). No immunostaining was 
found when obestatin or GPR39 antibodies were preadsorbed 
with homologous peptides (Fig. 3.1.2 and 3.1.5, respectively). 
In contrast, immunostaining was observed when obestatin 
antibody was preadsorbed with ghrelin peptide (Fig. 3.1.3). A 
comparative study with WB analysis demonstrated moderate 
obestatin expression in the gastrocnemius when compared with 
the stomach (∼0.4-fold; Fig. 3.1, right panel). In contrast, higher 
GPR39 expression in the gastrocnemius than in the stomach was 
detected (∼1.4-fold).
Fig. 3.1 Expression of obestatin and gpr39 in muscle and stomach. (Left 
panel) Immunohistochemical detection of obestatin (1.1) and GPR39 (1.4) in 
gastrocnemius muscle (objective magnification 20x). Preadsorption controls were 
performed, applying the primary antibody plus obestatin (1.2), ghrelin (1.3), or 
GPR39 control peptide (1.5) (10 nmol/mL per control peptide) to positive samples. 
Immunohistochemistry was also performed in the absence of primary antibody 
(1.6). (right panel) WB analysis of obestatin and GPR39 of extracts from stomach 
and gastrocnemius muscle of control rats (n=5). Results were expressed as a -fold 
of protein levels in the stomach. 
Obestatin/gpr39 system is up-regulated in skeletal 
muscle upon CTX injury
To examine the obestatin/GPR39 regulation in a model of skeletal 
muscle injury and regeneration, CTX solution (10 μM CTX; 2 
μl/g body weight)1 or an equal volume of PBS was injected into 
the gastrocnemius muscle. Tissues were analyzed at 6, 24, 48, 
and 72 h after treatment (n=5 at each time point). As shown 
in Fig. 3.2A WB analysis revealed that the maximal expression 
of preproghrelin (∼4.5- fold), obestatin (∼1.7-fold), and GPR39 
(∼2.1-fold) occurred at 24 h after CTX treatment. Maximal protein 
expression of the myogenic nuclear factors MyoD (∼2.9-fold) 
and myogenin (∼2.4-fold) paralleled with the expression of 
preproghrelin, obestatin, and GPR39 at the 24 h time point (Fig. 
3.2A, left panel). Immunohistochemical analysis of obestatin, 
GPR39, MyoD, and myogenin was also performed at the 24 h time 
point (Fig. 3.2B.3–3.2B.6). The strongest signal for both obestatin 
(Fig. 3.2.3) and GPR39 (Fig. 3.2.4) occurred in damaged myofibers 
(Fig. 3.2.5 and 3.2.6).
1.  Zeng, L. et al. Insulin-like 6 is induced by muscle injury and functions as a regenerative factor. 
J. Biol. Chem. 3010; 285: 36060-9. 
Results Chapter 3
90
Fig.3.2 (A) Left panel: Relative protein expression of preproghrelin, obestatin, 
GPR39, MyoD, and myogenin in CTX- or PBS-injected gastrocnemius muscle 
was assessed at the indicated time points by WB (n = 5 per group and time 
point). Protein expression was expressed as a -fold over PBS control muscle. 
Right panel: Representative WB images of gastrocnemius muscle sections 24 h 
after PBS or CTX injection. (B). Representative images of gastrocnemius mus-
cle sections 24 h after PBS or CTX injection: hematoxylin/eosin (2.1, control, 
and 2.2, +CTX); immunohistochemical detection of obestatin, GPR39, MyoD, 
and myogenin after CTX injection (2.3, 2.4, 2.5, and 2.6, respectively; objective 
magnification 20x). WB are representative of three independent experiments. 
Data were expressed as the mean ±S.E. *, P <0.05 versus control values.
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Obestatin is up-regulated during myogenic 
differentiation in vitro
To elucidate the role of this system in myogenesis, an in vitro 
cell culture model that closely recapitulates the formation and 
maintenance of skeletal muscle was utilized: the rat skeletal muscle 
L6 myoblasts (subclone E9, L6E9 cells)2. Upon reaching confluence, 
serum was withdrawn to induce the differentiation of L6E9 cells from 
proliferative myoblasts into terminally differentiated myotubes to 
permit fusion and form multinucleated cells that express markers of 
differentiated skeletal muscle. As shown in Fig.3.3, L6E9 myotubes, 
obtained during a 6-day differentiation period, showed a stronger 
obestatin expression when compared with that observed in L6E9 
myoblast cells (Fig. 3.3.3 when compared with Fig. 3.3.1). In contrast, 
GPR39 was detected in L6E9 in both myoblast and myotube cells 
(Fig. 3.3.2 and 3.3.4, respectively). 
Fig.3.3 Immunocytochemical detection of obestatin and gpr39 in myo-
blast and myotube L6E9 cells (objective magnification 40x)
These results led us to focus on preproghrelin expression during 
myogenesis as a source of obestatin. Preproghrelin expression 
was examined at the mRNA and protein levels by real-time PCR 
and WB, respectively, from samples taken at the proliferative 
state and throughout differentiation. Within 6 h of differentiation, 
the preproghrelin mRNA levels experienced a rapid increase 
(∼1.6-fold; Fig. 3.4A), which subsequently returned to basal level 
values by 48 h of induction. Transcript expression increased 
again from 72 h, reaching maximal levels at 144 h after induction 
of differentiation (∼2.3-fold). As shown in Fig. 3.4B, WB analysis 
2.  Nadal-Ginard, B. Commitment, fusion, and biochemical differentiation of a myogenic cell line 
in the absence of DNA synthesis. Cell. 1978; 15: 855-64. 
confirmed the dynamic regulation of preproghrelin expression 
at the time of differentiation into myotubes, with a rapid 
increase at the 6 h time point, reaching a maximum at 24 h after 
induction of differentiation (∼4.4- fold) concomitant with the rise 
of preproghrelin mRNA expression. Intriguingly, preproghrelin 
protein expression began to decrease 48 h after induction 
of differentiation (∼2.1-fold at 144 h), remaining at sustained 
but reduced levels during terminal differentiation; however, 
the levels remained higher than in myoblast cells (Fig. 3.4B). 
Obestatin peptide expression closely paralleled the expression of 
preproghrelin (∼4.5- and 3.0-fold at 24 and 144 h, respectively). 
GPR39 protein expression showed maximal expression levels at 
two time points: 6 and 144 h (∼2.9- and 2.6-fold, respectively), 
concomitant with maximum expression levels of the myogenic 
transcription factor myogenin (Fig. 3.4B). The expression of MHC 
reached maximal levels 72 h after induction, which marked the 
progression of terminal differentiation (Fig. 3.4B).
Fig.3.4  Analysis of mrNA and protein 
levels along differentiation. (A) Rela-
tive mRNA transcripts of preproghrelin 
in the course of L6E9 myogenesis. mRNA 
was quantified by real-time PCR and 
expressed as arbitrary units (n =3). (B) 
WB analysis of preproghrelin, obestatin, 
GPR39, myogenin, and MHC expression 
in the course of L6E9 myogenesis. Pro-
tein level was expressed as a -fold over 
control cells in growth conditions (n = 3). 
Immunoblots are representative of three 
independent experiments. Data were 
expressed as the mean ±S.E.*, P <0.05 
versus control values.
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Autocrine/paracrine role of obestatin on myogenesis in 
vitro
The effect of acute obestatin deficiency was first determined by 
preproghrelin knock-down by means of siRNA prior to induction of 
myogenic differentiation. Under these conditions, the constructs 
decreased preproghrelin level by 57±2% relative to siRNA control 
(si-control; Fig. 3.5A) during a 96 h differentiation period. Silencing 
of preproghrelin (si-preproghrelin) decreased myogenin and MHC 
expression levels with respect to si-control (46±6 and 33±7%, 
respectively; Fig. 3.5A). Correspondingly, the cell cycle arrest protein 
p21 expression was decreased in the presence of si-preproghrelin 
(26 ± 2%; Fig. 3.5A). The individual autocrine role of obestatin was 
tested using a neutralizing obestatin antibody (Ab)3. L6E9 cells 
were maintained in GM and DM, anti-obestatin Ab (5 μg/mL) in 
DM, obestatin + anti- obestatin Ab (1:1, w/w) in DM, or pre-immune 
IgG (5 μg/mL) in DM during a 6 day differentiation period in 
which DM plus reactive were replaced every 24 h. As shown in Fig. 
3.5B, anti- obestatin Ab reduced myogenin and MHC expression 
levels with respect to standard differentiation conditions (40±3 
% and 89±2%, respectively), whereas obestatin + anti-obestatin 
Ab or pre-immune IgG treatments, used as Ab controls, did not 
affect the differentiation marker levels. Simultaneously, Akt 
phosphorylation at the C-terminal hydrophobic motif (Ser- 473) 
(HM(S-473); p-Akt(S-473)) and p38 phosphorylation at T-182 
(p-p38(T-182)) showed significant decrease in the presence of the 
obestatin neutralizing Ab (60±2 and 30±3%, respectively; Fig. 3.5B). 
Furthermore, the presence of the anti- obestatin Ab reduced p21 
expression (32±1%; Fig. 3.5B).
Fig 3.5. Effect of sirNA depletion of preproghrelin on myogenesis. (A) 
L6E9 cells were transfected with preproghrelin siRNA prior to induction of 
myogenesis for 96 h. Expression of myogenin, MHC, p21, and preproghrelin 
was denoted as a -fold of the respective levels in control siRNA-transfected 
cells (n=3). (B) Differentiating L6E9 cells were maintained in DM, DM 
supplemented with anti-obestatin antibody (5 μg/mL; anti-obestatin Ab), 
obestatin + anti-obestatin Ab (1:1, w/w), or pre-immune IgG (5 μg/mL) for 6 
days. Expression of p-p38(T-182), p-Akt(S-473), or p21 is expressed as a -fold of 
respective expressions in DM control (n = 6). Data were expressed as the mean 
± S.E. *, p < 0.05 versus control values.
3
3.  Gurriarán-Rodríguez, U. et al. Obestatin as a regulator of adipocyte metabolism and adipo-
genesis. J. Cell. Mol. Med. 2011; 15: 1927–40.
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gpr39 regulates myogenesis in vitro
First, the effect of acute GPR39 deficiency on obestatin signalling 
was determined by treatment of L6E9 myoblast cells with siRNA 
(si-GPR39). Under these conditions, the constructs decreased 
GPR39 expression by 69±2% (Fig. 3.6A). In the presence of 
si-control, obestatin-activated Akt(S-473) and p38(T-182) phos-
phorylation was identical to levels observed with un-transfected 
cells. Silencing of GPR39 decreased subsequent p-Akt(S-473) and 
p-p38(T-182) with respect to si-control by 61±2 % and 52±1% 
with treatment of obestatin (5 nM, 10 min; Fig. 3.6A), respective-
ly. Second, the effect of acute GPR39 deficiency on myogenesis 
was further evaluated on myogenic differentiation. Under these 
conditions, the constructs decreased GPR39 expression by 50±3% 
(Fig. 3.6B) during a 96 h differentiation period. The GPR39 knock-
down decreased the expression levels of myogenin and MHC by 
40±5 % and 41±4% with respect to si-control, respectively (Fig. 
3.6B).
Fig. 3.6 Effect of gpr39 knock-down by sirNA (A) On obestatin-activated 
p-Akt(S-473) and p-p38(T-182) in L6E9 myoblast cells (5 nM, 5 min). GPR39 
was expressed as a -fold of its level to control siRNA-transfected cells (n =3). 
Activation of Akt and p38 was expressed relative to control siRNA-transfected 
cells. (B) Effect of siRNA depletion of GPR39 on myogenesis. L6E9 cells were 
transfected with GPR39 siRNA prior to induction of myogenesis for 96 h. 
Expression of myogenin and MHC was expressed as a -fold of the respective 
levels to control siRNA-transfected cells (n= 3). Immunoblots are representa-
tive of three independent experiments. Data were expressed as the mean ± 
S.E. *, p < 0.05 versus control values.
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Obestatin enhances myogenic proliferation in vitro
To ascertain the influence of obestatin on myogenesis, the effect 
of obestatin (0.001–100 nM) on intracellular targets leading to 
either proliferation (ERK1/2) or differentiation (p38 and Akt) was 
first assayed in L6E9 myoblasts. P-Akt (S-473), p-p38 (T-182), and 
p-ERK1/2 (W-202/T-204) were observed using different concen-
trations of obestatin (0.001–100 nM), and the level of phospho-
rylation peaked at 5 nM in L6E9 myoblasts (data not shown). 
Fig. 3.7A shows that myoblast treatment with obestatin (5 nM) 
elicited a time-dependent increase in p-Akt(S-473), p-ERK1/2 
(W-202/T-204), and p-p38 (T-182) protein levels, which reached 
a maximum at 10 min. Mitogenic action was then explored by 
dose-effect experiments performed on myoblasts treated with a 
range of obestatin concentrations (0.01– 100 nM) in GM (prolifer-
ating conditions; Fig. 3.7B). Maximal effect in the cell number was 
observed at 5 nM obestatin (∼2.2- fold). This mitogenic effect was 
compared with that induced by ghrelin, under the same range 
of concentrations (0.01–100 nM) in GM. As shown in Fig. 3.7C, 
ghrelin showed proliferative capability in L6E9 myoblast cells, 
although its effect was lower than that of obestatin for all doses 
tested.
Obestatin enhances migration/invasion  in vitro
We performed invasion/migration assays on L6E9 myoblast cells 
supplemented with obestatin (5 nM). Confluent monolayers 
of cells were physically wounded with a scratch and allowed 
to migrate to heal for 8 and 24 h, eliminating the possibility of 
proliferation accounting for the wound closure. As shown in Fig. 
3.8, at 8 h after initial scratch, obestatin-treated cells exhibited 
an ∼53% increase in the invasion/migration capability when 
compared with the control. At 24 h after scratch, the increase was 
∼21% for obestatin-treated cells when compared with control.
Fig. 3.7 (A) Time course of the effect of obestatin (5 nM) in L6E9 myoblast 
cells on p-Akt(S-473), p-ERK1/2(W-202/T-204), p-AMPK(W-172), and p-p38(T- 
182) (n = 3). AMPK, AMP-activated protein kinase. (B) Dose-response effect of 
obestatin (0.01–100 nM) on L6E9 myoblast cell proliferation (48 h, n = 5). (C) 
Dose-response effect of obestatin/ghrelin (0.01–100 nM) on L6E9 myoblast 
cell proliferation (48 h, n = 5). Co: cells initially seeded. Control: cells main-
tained 48 h in GM. Immunoblots are representative of three independent 
experiments.
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Fig.3.8 Evaluation of invasion/migration obestatin role: (Left panel) L6E9 
myoblast cells at 100% confluence were wounded with a sterile pipette tip to 
remove cells. Photographs were taken (objective magnification 10x) at 0, 8, 
and 24 h after injury. (right panel) wound closure was evaluated using the 
equation described in the chapter of “Material and Methods.” For these panels, 
data were expressed as the mean± S.E. 
Obestatin enhances myogenic differentiation in 
vitro
To assess the activity of obestatin as a promoter of the differen-
tiation process, L6E9 cells were switched to DM supplemented 
with obestatin at a range of concentrations (0.001–100nM) for 7 
days. As shown in Fig. 3.9A, the protein levels of myogenin and 
MHC, as detected by immunoblot, were dose-dependent and 
up-regulated with the maximal effect at 5 nM for both differen-
tiation markers (∼1.7- and 1.6-fold, respectively). The possibility 
that obestatin accelerates differentiation was also investigated 
(DM + 5 nM obestatin for 7 days). WB analyses revealed normal 
kinetics with enhanced protein level of both myogenin and MHC 
when compared with control cells (DM for 7 days; supplemental 
Fig. 3.9B). To confirm the observation that obestatin activates 
the differentiation program, the ability of this peptide to activate 
the differentiation program under GM (GM + 5 nM obestatin) 
was evaluated in L6E9 myoblast cells for 7 days. The protein 
levels of myogenin and MHC, as detected by immunoblot, were 
significantly increased when compared with control cells in GM 
(∼4.2- and 14-fold, respectively; Fig. 3.9C). The expression for both 
differentiation markers was induced to similar levels upon 7 days 
of treatment with ghrelin (5 nM; supplemental Fig. 3.9C).
Fig.3.9 Obestatin as a enhancer of  myogenesis.(A) Dose-response effect of 
obestatin (0.01–100 nM) on differentiating L6E9 cells for 7 days (n=6). Levels 
of myogenin and MHC were represented as a -fold of respective expression 
in GM. (B) Time course along differentiation adding obestatin 5nM on 
differentiating L6E9 cells for 7 days (n=6). Levels of myogenin and MHC were 
represented as a -fold of respective expression in GM. (C) Effect of obestatin 
on myogenic differentiation in GM conditions on L6E9 cells for 7 days (n=6). 
Levels of myogenin and MHC were represented as a -fold of respective 
expression in GM without obestatin.
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These results were confirmed by quantifying the differentiation 
grade by immuno- fluorescence. After 7 days, obestatin-treated 
cells (DM + 5 nM obestatin) increased by ∼250% in myotube num-
ber when compared with control cells (DM; Fig. 3.10A). Moreover, 
myotubes were grouped into two categories, those with 2–3 
nuclei and those with 4 or more nuclei4. As shown in Fig. 3.10B, 
∼22% of control myotubes contained ≥4 nuclei, versus ∼67% of 
obestatin-treated cells (DM +5 nM obestatin). This effect repre-
sents an increase of ∼3.4-fold respect to control cells (DM).
Obestatin regulates myogenic and angiogenic 
markers in vivo with an hypertrophic effect
Based on the short half-life of this peptide (∼22 min), osmotic mi-
ni-pumps were selected for in vivo obestatin administration5. Male 
rats received a 72 h continuous subcutaneous infusion of obesta-
tin (300 nmol/kg of body weight/24 h), and dissected gastrocne-
mius and soleus tissues were processed for WB analysis. Levels of 
Pax7, Myf5, MyoD, myogenin, Myf6, and MHC were up-regulated 
in gastrocnemius and soleus muscle tissues from obestatin-treat-
ed rats when compared with control tissues (Fig. 3.11A, left panel). 
Pax7 increased expression was demonstrated also by IF, showing 
a pronounced enhanced expression after obestatin infusion (Fig. 
3.11A, right panel). Moreover, obestatin treatment resulted in a 
significant up-regulation of the VEGF and VEGF-R2 (VEGF recep-
tor) expression in both gastrocnemius and soleus muscle when 
compared with controls (Fig. 3.11B). Conversely, the plateled 
endothelial growth factor (PEDF) expression level was significant-
ly down-regulated in gastrocnemius and soleus muscle under 
obestatin treatment (Fig. 3.11B).
It is noteworthy that after 72 h of infusion, a significant increase in 
myofiber diameters was observed in gastrocnemius muscle (Fig. 
3.12). A minor effect was observed in the soleus myofiber area 
(Fig. 3.12). 
4.  Horsley, V. et al. Regulation of the growth of multinucleated muscle cells by an NFATC2-de-
pendent pathway. J. Cell Biol. 2001; 153: 329-38.
5.  Zizzari, P. et al. Obestatin partially affects ghrelin stimulation of food intake and growth 
hormone secretion in rodents. Endocrinology. 2007; 148: 1648-53.
Fig. 3.10 IF analysis of obestatin as a myogenic enhancer: (A) Left panel 
immunofluorescence detection of MHC and DAPI (objective magnification 
20x) in L6E9 myotube cells under DM (control) or DM + obestatin (5 nM) at 
the 7-day point after stimulation. Right panel, the differentiation grade was 
evaluated based on the number of MHC-positive cells above total nuclei and 
expressed as a -fold of control. (B) Representative images used to determined 
the number of nuclei within individual myotubes (at least two nuclei) in L6E9 
myotube cells under DM (control) or DM + obestatin (5 nM) at the 6-day 
point after stimulation (left panel, objective magnification 20x). Myotubes 
were grouped into two categories, and the percentage of myotubes in each 
category was determined (right panel). Data were expressed as the mean ± 
S.E. as described under “Experimental Procedures.” *, p < 0.05 versus control 
values.
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Fig. 3.11 Effect of 72-h continuous subcutaneous 
infusion of obestatin (300 nmol/kg of body 
weight/24 in vivo. (A) Left panel: WB of myogenic 
markers (MyoD, Myf5, Pax7, myogenin, Myf6, 
and MHC)of gastrocnemius  and soleus muscles 
after 72h of continuous obestatin infusion. Right 
panel: IF of Pax7 of gastrocnemius sections after 
72h of continuous obestatin infusion.   (B) WB 
of angiogenic markers VEGF, VEGFR2, and PEDF 
expression. Protein levels were expressed as a 
-fold of control obtained from a 72-h mini-pump 
subcutaneously implanted in saline group (n 
=10 per group). Immunoblots are representative 
of mean values from each rat group. Data were 
expressed as the mean± S.E. *, p < 0.05 versus 
control values.
Fig.3.12  Hematoxylin/eosin-stained my-
ofiber cross-section area of gastrocnemi-
us and soleus. Sections are representative 
of the mean value of total cross-section 
area. Data were expressed as the mean± 
S.E. *, p < 0.05 versus control values.
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Obestatin activates Akt downstream targets 
and inactivates AMpK in L6E9 myotube cells and 
skeletal muscle tissue
As previously described in L6E9 myoblast cells (Fig.3.7) the kinetic 
of Akt activation in response to obestatin (5 nM) in L6E9 myotube 
cells showed significant pAkt(S473) augment at 10 min post-treat-
ment reaching a maximum at 30min being sustained by 60 min 
(Fig. 4.1A). Parallel to Akt activation, obestatin triggered the phos-
phorylation of a broad range of Akt downstream substrates: GSK3 
α/β (S21/9), AS160 (T642) and S6K1(T384) (Fig. 4.1B and D). Im-
portantly, dephosphorylation of p-AMPKα (T172)  (Fig. 4.1A) and 
its downstream substrate ACC (S79) was observed in response to 
obestatin (Fig. 4.1C).
Fig. 4.1 Time-course of the effect of obestatin L6E9 myotubes: (A) p-Ak-
t(S473) and p-AMPKα (T172); (B) p-GSK3 α/β (S21/9) and p-AS160(T642); (C) 
and p-ACC(S79) and (D) p-S6K1(T384) Phosphorylation was expressed as a 
percentage of the maximal phosphorylation obtained for each residue (n=3; 
mean± S.E.). 
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For in vivo obestatin administration, osmotic mini pumps were 
selected based on the short half-life of this peptide (~22 min)1.
Male rats received a 24 h continuous sc infusion of obestatin (300 
nmol/kg body weight/24 h) and dissected muscles were pro-
cessed for WB analysis. Obestatin significantly activated at 24 h 
Akt, measured as p-Akt (S473), by 60% to basal phosphorylation 
in soleus and gastrocnemius muscles (Fig. 4.2A). p-AMPKα (T172) 
was decreased by 20% to basal phosphorylation in soleus with no 
1.  Zizzari, P. et al. Obestatin partially affects ghrelin stimulation of food intake and growth hor-
mone secretion in rodents. Endocrinology. 2007; 148: 1648-53.
effect in gastrocnemius (Fig. 4.2A). At 72 h continuous sc infusion 
of obestatin (300 nmol/kg body weight/24 h) increased p-Akt 
(S473) by 50% in soleus and more than 400% in gastrocnemius 
muscles over basal phosphorylation and decreased p-AMPKα 
(T172) by 50% in soleus and in gastrocnemius decreased almost 
to control levels(Fig. 4.2B). The divergence between 24 and 72 
h might be explained by the stress generated by mini-pump 
implantation.
Fig. 4.2 Obestatin activates Akt phosphorylation and AMpK dephospho-
rylation in muscle. (A) Effect of 24 h continuous sc infusion of obestatin (300 
nmol/kg body weight/24 h; n=10) on p-Akt(S473) and p-AMPKα (T172) from 
soleus and gastrocnemius muscles obtained from male rats. (B) Effect of 72 
h continuous sc infusion of obestatin (300 nmol/kg body weight/24 h; n=10) 
on p-Akt(S473) and p-AMPKα (T172) from soleus and gastrocnemius muscles 
obtained from male rats. Phosphorylation was expressed as a percentage 
of control obtained from 24 h or 72 h mini pump sc implanted saline group 
(n=10; mean± S.E.). Asterisk (*) denotes P< 0.05 when comparing obesta-
tin-treated group with untreated control group (saline).
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Obestatin increases gLUT4 levels in plasma 
membranes and glucose uptake in vitro and ex vivo
The amplitude of Akt activation was evaluated on the basis of 
GLUT1 and GLUT4 translocation to plasma membrane in L6E9 
myotubes cells. Acute treatment with obestatin (5 nM, 30 min) re-
sulted in an increase in GLUT4 translocation to the plasma mem-
brane by ~1.9-fold, this increase in GLUT4 translocation was equal 
to the one produced for the positive control insulin (172 nM, 30 
min)  (Fig. 4.3A). Intriguingly, there is not GLUT1 redistribution in 
response to obestatin (30 min) neither to insulin (172 nM, 30 min) 
in L6E9 myotubes (Fig. 4.3A). The divergence between GLUT4 
and GLUT1 might be explained by the different roles on glucose 
uptake depending on the type of glucose transporter and the 
tissue expression. The effect of obestatin on DOGU was exam-
ined in vitro in L6E9 myotubes cells. Cells were incubated with 
different concentrations of obestatin (0.001–200 nM) for 30 min, 
resulting in a dose- dependent increase in DOGU with a maximal 
effect at 10 nM obestatin (~3.0-fold; Fig. 4.2C). Surprisingly insulin 
treatment (172 nM) caused an equal increase of DOGU in L6E9 
myotubes cells (Fig. 4.3C). Ex vivo DOGU experiments with soleus 
and gastrocnemius muscles, showed after treatment (obestatin 
172 nM and insulin 172nM both 30 min) an equal 50% increase 
in gastrocnemius muscle for both treatments over non-treated 
muscles. In the soleus case the increase with obestatin treatment 
was lower by a ~1.2-fold and with insulin was by ~1.5-fold. The di-
vergence between soleus and gastrocnemius might be explained 
by the different type of fibers depending on the muscle and its 
different glucose metabolism.
Fig. 4.3 Effect of obestatin in glucose up-take. (A) WB analysis of GLUT4 and 
GLUT1 expression in membrane from L6E9 myotube cells treated with obesta-
tin (5 nM) or insulin (172 nM) for 30 min. GLUT expression was expressed as a 
percentage of basal expression obtained in control cells (n=3; mean± S.E.). (B) 
Obestatin dose dependently stimulated 2-[3H]deoxyglucose uptake in L6E9 
myotube cells (n=3; mean± S.E.). (C) Obestatin stimulated 2-[3H]deoxyglucose 
uptake in gastrocnemius and soleus muscles (n=3; mean± S.E.).
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Overexpression of the preproghrelin/gpr39 
system in vivo enhances muscle regeneration 
To investigate the role of the obestatin/GPR39 system in muscle 
regeneration in vivo, preproghrelin, and thus obestatin, was 
overexpressed by electroporation of a CMV-preproghrelin 
expression plasmid into TA muscles of 8 week-old mice. 
Freeze muscle injury was chosen because of the significantly 
reduced inflammatory response relative to other methods 
such as CTX injection. Changes in protein expression were 
analysed at 96 h post-injury, corresponding to the acute phase 
of regeneration, and at 168-h post-injury when satellite cells 
have returned to a quiescent stage. Histological analysis of 
muscles electroporated with pCMV6 revealed no regeneration 
deficit as compared to saline electroporation (Fig. 5.1A). In 
addition, immunostaining of cryosections of TA muscles 168 
h following electroporation with the CMV plasmids exhibited 
overexpression levels of preproghrelin, GPR39 or both (left 
panels of Fig. 5.1B-D, respectively). TA muscles electroporated 
with CMV-preproghrelin exhibited an increase in protein 
expression of Pax7, MyoD, myogenin and eMHC (Fig. 5.1B) at 
96 and 168 h time points. At the same times, overexpression 
of CMV-GPR39 resulted in an increased of these myogenic 
markers(Fig. 5.1C). Notably, TA muscles electroporated with both 
CMV-preproghrelin and CMV-GPR39 revealed a larger increase 
of Pax7, MyoD, myogenin and  embryonic myosin heavy chain 
(eMHC) (Fig. 5.1D) at 96 and 168 h time points. Taken together, 
these results indicate that overexpression of preproghrelin and/
or GPR39 enhance muscle regeneration, as evidenced by the 
increase of the expression of myogenic markers. Nonetheless, 
the electroporation conditions used also result in an injury to 
the muscle, raising the question of whether active regeneration 
is a direct consequence of the obestatina/GPR39 response.
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Fig. 5.1.  Overexpression of preproghrelin/gpr39 in electroporated TA. 
(A) Representative H&E stained TA cross-sections at  96 h or168 h after freeze 
injury, comparing electroporated-TA with control CMV plasmid to TA under 
vehicle administration. (B) Left panel: immunostaining of cryosections of TA 
muscles 168 h following electroporation with the control or preproghrelin 
CMV plasmids demonstrating overexpression of preproghrelin at 168 h 
post-injury. Right panel: WB quantification  of Pax7, MyoD, myogenin and 
eMHC expression in TA muscles electroporated with CMV-preproghrelin at 
96 and 168 h post-injury. (C) Left panel: immunostaining of cryosections of 
TA muscles 168 h following electroporation with the control or GPR39 CMV 
plasmids demonstrating overexpression of GPR39 at 168 h post-injury. Right 
panel: WB quantification of Pax7, MyoD, myogenin and eMHC expression in 
TA muscles electroporated with CMV-GPR39 at 96 and 168 h post-injury. (D) 
Left panel: immunostaining of cryosections of TA muscles 168 h following 
electroporation with the control or preproghrelin and GPR39 CMV plasmids 
demonstrating overexpression of both preproghrelin and GPR39 at 168 h 
post-injury. Right panel: WB quantification  of Pax7, MyoD, myogenin and 
eMHC expression in TA muscles electroporated with both CMV-preproghrelin 
and CMV-GPR39 at 96 and 168 h post-injury. Data were expressed as mean± 
S.E. (n=10 per time point). Asterisk (*) denotes P< 0.05 when comparing mice 
electroporated with CMV plasmid to CMV-preproghrelin, -GPR39 or  
–preproghrelin plus-GPR39.
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Obestatin enhances muscle regeneration in vivo 
To address whether the exogenous administration of obestatin 
is capable of stimulating productive regeneration, obestatin 
(300 nmol/kg body-weight) or vehicle was directly injected into 
TA of 2-month-old mice (n=35/group). Histological analysis 
revealed (Fig. 5.2A). WB analysis showed a significant increase, 
as compared to control, in the protein expression of Pax7, MyoD, 
myogenin eMHC for the time tested (Fig. 5.2A-D). To confirm 
eMHC up-regulation during muscle regeneration, IF analyses 
were performed on cryosections of freeze-injured TA fixed 96 h 
post-injury (Fig. 5.2E). In control TA muscle, eMHC was expressed 
at detectable levels in regenerating fibers (Fig. 5.2E, left). By 
contrast eMHC was markedly up-regulated in obestatin-treated 
TA muscles (Fig. 5.2E, right). 
Fig. 5.2 Effect of intramuscular administration of obestatin in freeze-in-
jured TA. WB analysis of Pax7 (A), MyoD (B), myogenin (C) and eMHC (D) at 
different time points during the muscle regeneration under intramuscular 
administration of vehicle or obestatin (n=10 per time point corresponding 
to n=5 per group). (E) IF analysis of eMHC in freeze-injured TA at 96 h under 
obestatin or vehicle administration. The images are representative of five 
independent experiments. For A-D,  *denotes P< 0.05 when comparing 
control muscle (undamaged) versus treated-muscles (vehicle- or obesta-
tin-treated muscles). # denotes P<0.05 when comparing vehicle- and 
obestatin-treated muscle at each time point. 
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Obestatin enhances hypertrophy in vivo 
Histological analysis revealed that treated-to-control ratios of 
regenerating fibre cross-section areas were 62 and enhances 28% 
larger in obestatin-treated mice (324±29 and 755±42 µm2) than in 
control mice (199±22 and 588±88 µm2) at 96 and 168 h after injury, 
respectively (Fig. 5.3B). At 240 h post-injury, cross-section area 
analysis revealed a significant increases, as compared to control, in 
the % of myofibers of larger area (Fig. 5.3C): 24% vs. 3% of fibers in 
a range between 4-3x103 µm2, 56% vs. 39% between 2-1x103 µm2, 
and 18% vs. 56% between 1-0.5x103 µm2, respectively. Consistent 
with these results, the number of myonuclei per myofiber were 
significantly increased by 91% in obestatin-treated TA (481±19 cells 
per muscle section) compared to control TA muscles (251±17 cells 
per muscle section) 240 h after injury (Fig. 5.3D). Taken together, 
these data indicate that obestatin delivered by intramuscular 
injection markedly enhances muscle regeneration, as evidenced by 
up-regulation of the expression of specific myogenic factors and 
the significantly increased size of myofibers. 
Fig. 5.3 Effect of intramuscular administration of obestatin in freeze-
injured TA. (A) Time course analysis by H&E of muscles cryosection along 
the regeneration process under vehicle or obestatin treatment (n=10 per 
time point). (B) Measurement of regenerating myofibers as cross-sectional 
area (µm2) at 96 and 168 h post injury. (C) Analysis the percentage of fibers 
associated to different cross-sectional area groups at 240 h post injury under 
vehicle or obestatin treatment,. (D) Analysis by IF expression of myonuclei 
(DAPI) per 100 myofibers in cryosections at 240 h post-injury under vehicle 
or obestatin treatment. For A and D, the images are representative of five 
independent experiments. Data were expressed as the mean ± S.E. (n=5 per 
group; *, p < 0.05).
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Obestatin enhances satellite cell activation after 
muscle injury 
Based on the up-regulation of Pax7, an specific SCs marker, in 
obestatin-treated TA muscles, SCs  were quantified on muscle 
sections 96 h post-injury (Fig. 5.4A). The density of SCs in obesta-
tin-treated TA muscles harbored ~2.3-fold more Pax7+ cells per 
section (427±7 cells per muscle section) than control TA muscles 
(189±12 cells per muscle section) 96 h after injury. In addition, 
myofibers were isolated from obestatin-treated and control TA 
muscles 96 h after injury (Fig. 5.4B). The number of activated 
satellite cell (Pax7+) normalized to myofiber length was corre-
spondingly higher in myofibers obtained from obestatin-treat-
ed muscles than in control  (~2.2-fold; Fig. 5.4B). These results 
demonstrate that obestatin stimulates sc division and conse-
quently drive the expansion of SCs pool.
Fig. 5.4  Analysis of pax7 ex-
pression in obestatin-treated TA 
muscle or isolated-myofibers. (A) 
IF analysis of Pax7 in TA cryosections 
at 96h post-injury under vehicle or 
obestatin administration (left panel, 
objective magnification 20x; middle 
panel, magnification of a significative 
area). (B) IF expression of pax7 in TA 
isolated-myofibers at 96 h post-injury 
under vehicle or obestatin adminis-
tration. IF images are representative 
of five independent experiments. 
Data were expressed as the mean ± 
S.E. (*, p < 0.05).
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Obestatin enhances Ki67 and Cyclin D1 in early 
stages of muscle regeneration 
As previously indicated, obestatin treatment stimulates the 
expansion of SCs, which would then give rise to transient 
amplifying progenitors that undergo normal proliferation and 
differentiation. The elevated protein level of Ki67, 2.3-fold higher 
in obestatin-treated TA muscles than in control muscles (Fig. 
5.5A), implies enhanced proliferation 96 h after muscle injury. 
Added to this fact, the elevated protein expression of Cyclin 
D1, 2.2-fold higher in obestatin-treated TA muscles than in 
control muscles, demonstrated enhanced proliferation during 
regeneration (Fig. 5.5B). Together, these data demonstrate that 
obestatin enhances cell proliferation during early stages of 
muscle regeneration. 
Fig. 5.5 Expression of mitogenic markers in obestatin-treated TA at 96 h 
after freeze injury. WB analysis of Ki67 (A) or cyclin D1 (B) in TA under vehicle 
or obestatin administration. Immunoblots are representative of five inde-
pendent experiments (n=5 per group; mean± S.E.; *denotes P< 0.05).
Obestatin affects the essential network for 
regenerating muscle fibre growth 
Obestatin-treatment-to-control ratios of VEGF and VEGF-R2 
protein levels were 130 and 80% higher in obestatin-treated 
TA compared than in control TA muscles 96-h after injury, 
respectively (Fig. 5.6A). Vessel counting, evaluated as isolectin+ 
per myofiber, showed differences in capillary density in obestatin-
treated TA (1.5±0.06) compared to control TA muscles (0.5±0.01) 
96 h post-injury (Fig. 5.6B). These data indicated that obestatin 
contributed to the restoration of VEGF/VEGF-R2 tissue levels 
and to the subsequent dynamic process of capillary formation 
and muscle regeneration. Protein levels of myostatin, measured 
as precursor, latency-associated peptide (LAP) and dimer, were 
respectively 20, 30 and 60% lower in obestatin-treated TA 
than in control TA muscles 96-h after injury (Fig. 5.6C), which 
corroborated the obestatin role on muscle regeneration and 
growth. Of note, is that there was no significant elevation of 
collagen 1α2 (Col1α2) 96 and 240 h after injury (Fig. 5.7, right 
panel). This result was endorsed by Azan trichrome staining 
of muscle sections 240-h after injury (Fig. 5.7F, left panel).
This indicated that fibrosis in obestatin-treated muscles is not 
enhanced during regeneration and did not contribute to the 
increases size of regenerated muscle. 
Fig. 5.7  Expression of fibrogenic markers. WB analysis of collagen 1α-2 
isoforms at 96 h and 240 h after TA freeze injury (left panel). Analysis of fibrosis 
by Azan trichrome stain in vehicle- and obestatin–treated TA at 240 h after 
reeze injury (right panel). Immunoblots are representative of five independent 
experiments (n=5 per group; mean± S.E.).
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Fig. 5.6 Evaluation of microvascularization and miostatin expression in 
obestatin-treated TA after muscle damage (A) WB analysis of VEGF and 
VEGF-R2 expression in TA under vehicle or obestatin administration at 96 h 
after TA freeze injury. (B) IF analysis of isolectin+ cells in TA under vehicle or 
obestatin administration at 96 h after TA freeze injury (objective magnification 
20x). (C) WB analysis of myostatin isoforms (precursor, LAP and dimer) in TA 
under vehicle or obestatin administration at 96 h after TA freeze injury. For A 
and C, immunoblots are representative of five independent experiments (n=5 
per group; mean± S.E.). For B, IF images are representative of five independent 
experiments (n=5 per group; mean± S.E.). Asterisk (*) denotes P< 0.05 when 
comparing obestatin-treated with vehicle-treated groups.
Obestatin regulates mitogenesis and myogenesis 
during differentiattion 
The elevated protein levels of Ki67 and Cyclin D1 in TA muscle 
under obestatin treatment, implies an enhance proliferation 
during the early stage of regeneration. To ascertain this possibility, 
the mitogenic action was explored by dose-effect experiments 
performed on cultured C2C12 myoblasts treated with a range 
of obestatin concentrations (0.1–100 nM) in GM (proliferating 
conditions; Fig. 5.8A). Maximal effect in the cell number was 
observed at 5 nM obestatin (2.4-fold). During the differentiation 
process, immunoblot analysis of Ki67 and p21 revealed elevated 
protein expression when compared obestatin-treated cells 
(DM+5 nM obestatin) with control cells (DM; Fig. 5.8B). At 24 h, 
Ki67 showed maximal expression levels, followed by an increase 
in the expression of p21 that reached maximal levels at 48 h, 
reflecting growth arrest to promote cellular differentiation. In 
fact, the protein levels of myogenin and MHC were up-regulated, 
displaying maximal levels at 72 and 96 h respectively (Fig. 5.8B). 
It is noteworthy that, both proliferating and myogenic markers, 
displayed normal kinetics with enhanced protein levels when 
compared obestatin-treated with control cells, aiming that 
obestatin exerts a double mitogenic and myogenic effect.
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Fig.5.8 Effect of obestatin on mitogenesis and myogenesis. (A) Dose-re-
sponse effect of obestatin (0.01–100 nM) on C2C12 myoblast cell proliferation 
(48 h, n = 5).  (B) Time course on C2C12 of Ki67, p21, myogenin and MHC 
along differentiation.  Protein level was expressed as a -fold over control 
cells in growth conditions (n = 3). Immunoblots are representative of three 
independent experiments. Data were expressed as the mean ±S.E.*, P <0.05 
versus control values.
Hipertrophic effect triggered by obestatin is 
independent of mitogenic effect 
Exogenous administration of obestatin to TA during regeneration 
enhanced the area and the number of myonuclei per myofiber. 
To investigate whether obestatin was in fact stimulating 
hypertrophic growth of myofibres, C2C12 myoblasts were treated 
with obestatin (Fig. 5.9A). Myotube areas were 110% larger in 
obestatin-treated cells (DM+5 nM obestatin; 941±4 µm2) than 
in control cells (DM; 449±3 µm2) 168-h after differentiation. 
Moreover, myotubes were grouped into two categories, those 
with 2–3 nuclei and those with 4 or more nuclei. ~30% of control 
myotubes contained 4 nuclei, versus 73% of obestatin-treated 
cells. This effect represents an increase of ~2.43-fold respect to 
control cells (Fig. 5.9A). Having shown that obestatin increased 
myotube size with associated enhancement of nuclei number, 
we assessed whether hypertrophy was dependent on mitogenic 
effect. To reach this point, obestatin was administrated 3 days 
after differentiation when myoblasts withdrawal the cell cycle 
(Fig. 5.9 B). In this case, myotube areas were ~80% larger in 
obestatin-treated cells (DM for 72 h followed by DM+5 nM 
obestatin for 96 h; 736±7 µm2) than in control cells (DM; 409±6 
µm2) at 168 h after differentiation. Under this conditions, ~25% 
of control myotubes contained 4 nuclei versus 77% of obestatin-
treated cells.  Furthermore, myotubes were treated with obestatin 
after administration of cytosine arabinoside (AraC), an inhibitor 
of DNA replication1. Of note, is that obestatin-treated cells 
displayed ~92% larger in myotubes areas (DM for 72 h followed 
by DM+AraC+5 nM obestatin for 96 h; 853±3 µm2; Fig. 5.9C) than 
in control cells (DM; 444±4 µm2) at 168 h. Obestatin treatment 
led to a ~69% of myotubes contained 4 nuclei versus 11% of 
control cells.  Furthermore, immunoblot analyses revealed no 
differences in myogenin and MHC levels between both groups: 
DM+obestatin and DM+AraC+obestatin (Fig. 5.9D). Therefore, 
obestatin increases myoblast fusion and acts on established 
myotubes to induce hypertrophy independently of the mitogenic 
effect produced in the first three days of differentiation.
1.  Von Maltzahn, J. et al. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic grow-
th pathway in skeletal muscle. Nat. Cell. Biol. 2011; 14(2):186-91.
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Fig. 5.9 role of obestatin in myotube hypertrophic response. (A) 
Representative images used to determine the myotube area (µm2; left panel; 
objective magnification 20x) and the number of nuclei within individual 
myotubes (at leats two nuclei) in C2C12 myotube cells under DM (control) or 
DM + obestatin (5 nM) at the 7 day point after stimulation. (B) Representative 
images used to determine the myotube area (µm2; left panel; objective 
magnification 20x) and the number of nuclei within individual myotubes 
(at leats two nuclei) in C2C12 myotube cells under DM (control) or DM + 
obestatin (5 nM) three days after differentiation. (C) Representative images 
used to determine the myotube area (µm2; left panel; objective magnification 
20x) and the number of nuclei within individual myotubes (at leats two nuclei) 
in C2C12 myotube cells under DM (control) or DM + AraC (50 µM)+obestatin 
(5 nM) three days after differentiation (D) WB analysis of the expression of 
myogenin and MHC C2C12 myotube cells under DM (control) or DM + AraC 
(50 µM) + obestatin (5 nM) three days after differentiation. Immunoblots are 
representative of three independent experiments. Data were expressed as the 
mean ±S.E.*, P <0.05 versus control values.
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Obestatin controls myogenesis by regulating Akt, 
ErK1/2, p38 and CamkII activity
To establish the molecular events activated by obestatin to 
drive myogenic process, the activity of Akt/mTOR signalling 
was examined in differentiating C2C12 cells during 168 h (Fig. 
5.10A). Obestatin treatment (5 nM) resulted in markedly elevated 
levels of phosphorylated Akt [pAkt(S473)] and its downstream 
target S6K1 [pS6K1(S371)] during myogenesis. Despite the 
increased Akt activity under obestatin treatment, lower levels 
of pFoxO1(T24) and pFoxO3a(T32) were observed obestatin-
treated cells than control cells (DM). Obestatin increased ERK1/2 
activity [pERK1/2(T202/Y204)] in early steps of differentiation 
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program. Strikingly, obestatin markedly elevated levels of 
phosphorylated p38 [pp38(T180/Y182)] during differentiation. 
The phosphorylation levels of c-Jun [pc-Jun(S63)] showed no 
significant differences following obestatin treatment. By contrast, 
the phosphorylation pattern of CamkII [pCamkII(T286)] showed 
clear differences under obestatin treatment. Gradual increase of 
pCamkII (T286) was observed in control cells reaching maximal 
levels at 240 h. Under obestatin treatment, maximal levels 
were showed at early time points, 12-48 h, to decline to basal 
phosphorylation after 48 h. In regenerating TA muscle, obestatin 
treatment resulted in robust activation of Akt and S6K1 96 h 
Fig.5.10 Obestatin-activated intracellular signalling nodes in C2C12 and 
TA during the myogenesis and regeneration programs. (A) WB analysis 
of p-Akt (S473), p-ERK ½ (T202/Y204), p-p38 (T180/Y180), p-S6K1 (S371), 
p-FoxO1 (T24)/FoxO3a (T32), P-CamKII and p-cJun (S63), and its respective 
non phosphorilated forms, in obestatin-treated C2C12 cells (5 nM) along my-
ogenesis. (B) WB analysis of p-Akt (S473), p-ERK ½ (T202/Y204), p-p38 (T180/
after injury (Fig. 5.10B). None of the other components, ERK1/2, 
FoxO1, FoxO3a, p38, c-Jun and CamKII, showed to be significantly 
phosphorylated at this time. Together, the obestatin action is 
determined by a kinase hierarchy that coordinates myogenesis 
in a manner analogous to the myogenic transcription factors. 
Initially, obestatin appears to activate ERK1/2, CamkII and Akt 
to promote proliferation. Akt/mTOR and p38 activity drive 
differentiation, fusion and hypertrophy at later points. Finally, p38 
activity promotes the mid to late stages of differentiation. Based 
on these results, the central signalling node implicated in the 
regulation of myogenesis by obestatin appears to be Akt.
Y180), p-S6K1 (S371), p-FoxO1 (T24)/FoxO3a (T32), P-CamKII and p-cJun (S63), 
and its respective non phosphorilated forms, in mouse TA under treatment 
of obestatin (300 nmol/Kg) at 96 h after freeze injury. Immunoblots are 
representative of three independent experiments. Data were expressed as the 
mean ±S.E.*, P <0.05 versus control values.
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Obestatin regulates myogenesis by limiting IgFr/
IrS1 activity 
Obestatin signals to activate the Akt/mTOR pathway through 
cross-talk with tyrosine kinase receptors, i.e. EGFR. To investigate 
the possibility that obestatin was indirectly activating the Akt/
mTOR pathway through IGFR, activation of IGFR, measured as 
phosphorylated IGFR [p-IGFR(Y1316)], was examined in differen-
tiating C2C12 cells during 168 h (Fig. 5.11A). Obestatin showed to 
increase the level of p-IGFR (Y1316) at early time points (12-48 h). 
However, under these conditions there was a substantial increase 
of the IRS-1 phosphorylation at S636/639 [pIRS-1(S636/639)], sites 
shown to inhibit PI3K binding to IRS-1 and consequent activation 
of Akt-associated IGFR signalling (Fig. 5.11A). In regenerating TA 
muscle, obestatin treatment showed to enhance the levels of 
p-IGFR(Y1316) and p-IRS-1(S636/639) 96-h after injury (Fig. 5.11B). 
Therefore, obestatin action on Akt/mTOR pathway is independent 
of IGFR/IRS1 activity.
Fig. 5.11 Obestatin regulation of  IgFr and IrS1 (A) WB analysis of p-IGFR 
(Y1316) and p-IRS1 (S636/639) in C2C12 cells along differentiation. (B) WB 
analysis of p-IGFR (Y1316) and p-IRS1 (S636/639) in mice TA 96h after freeze 
injury. Immunoblots are representative of three independent experiments. 
Data were expressed as the mean ±S.E.*, P <0.05 versus control values.
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gpr39 is expressed in SCs on ex vivo myofibers
To elucidate the autocrine/paracrine role of obestatin/GPR39 
system on SCs activation, a culture model of ex vivo-isolated 
myofibers that closely recapitulates the SCs niche was utilized. 
IF analysis of myofibers fixed immediately following isolation 
from TA muscles revealed that SCs expressed detectable levels of 
GPR39 (Fig. 6.1A). In contrast, no immunostaining was found for 
obestatin (Fig. 6.1B). 
Fig. 6.1 Expression of obestatin and gpr39 in SCs muscle fibers. Immuno-
fluorescence detection of obestatin (A) and GPR39 (B) in Pax7+ SCs (objective 
magnification 20x). 
Obestatin enhances SCs apical-basal division 
versus planar division on ex vivo myofibers
The specific expression of GPR39 in SCs suggested that obestatin 
might be involved in regulating muscle stem cell function in a 
paracrine mode, due to the expression of obestatin in mature 
fibers. Differences in the behavior of daughter cells from 
planar versus vertical division have yielded evidences that the 
orientation of cell division with respect to the myofiber may 
indicate or convey asymmetry in the two daughter cells1,2. 
Therefore, we examined the ability of obestatin to alter the ratio 
between planar and apical-basal cell divisions of SCs in vitro. 
Myofibers were isolated from TA muscle and cultured under 
non-adherent conditions. In this culture system, quiescent 
SCs become activated following myofiber isolation. Thus, we 
first visualized the outcome of the first division by fixing and 
immunostaining the myofibers after 24 h of culture. When 
stimulated with obestatin (5 nM), we observed an increase of 
52% in the proportion of  total SCs divisions in obestatin treated 
fibers versus control fibers (Fig.6.2, left panel). Regarding the type 
1.  Sambasivan, R. et al. Skeletal muscle stem cell birth and properties. Semin. Cell. Dev. Biol. 
2007; 18: 870-82.
2.  Siegel, A. et al. Muscle satellite cell proliferation and association: new insights from myofiber 
time-lapse imaging. Skeletal Muscle. 2011; 1 (1):1-7.
of division, the percentage of planar division in control fibers was 
a 74% versus 41,9 % in the obesatin-treated fibers. In the case 
of apical-basal divisions it is noteworthy that obestatin-treated 
fibers had a percentage of 58,1% versus 25,5% showed in control 
fibers (n=5, n≥ x pairs; Fig. 6.2 right panel). These data reinforced 
the fact that obestatin favoured the commitment of SCs versus 
the stemness.
Fig. 6.2 Quantification of SCs divisions. (A) Immunofluorescence quan-
tification of total SCs divisions per myofiber length (µm). (B) Orientation of 
cell division within the SCs niche. Left panel: IF examples of dividing SCs in 
planar division and apical-basal obestatin division (objective magnification 
63x). Right panel:  Relative quantification of planar division versus apical-basal 
comparing control and obestatin-treated myofibers, respectively (objective 
magnification 63x).  Quantification is representative of seven independent 
experiments. Data were expressed as the mean ±S.E.*, P <0.05 versus control 
values.
Ex vivo migration of myoblasts is promoted by 
obestatin
To examine whether obestatin was capable of inducing myoblast 
migration in a 3-dimensional culture assay an inverted version 
of the classical Boyden chamber invasion assay was used. SC-de-
rived cells (myoblasts) from muscle were able to migrate through 
the membrane and to invade into the Matrigel as an extracellular 
matrix, when obestatin was applied on top of the Matrigel as a 
chemoattractant being ~8.0-fold higher compared to control cells 
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at 7 days (Fig. 6.3). These data demonstrated: (1) an anti-apoptotic 
effect; and, (2), more importantly, obestatin promoted migration 
of myoblasts, a critical step in muscle regeneration, reinforcing 
previous data.
Fig. 6.3 Effect of obestatin on  myoblast migration. Left panel:  
Representative images of calcein-satined myoblasts migrated into the upper 
chamber (objective magnification 20x) at 7 days. Right panel:  Quantification 
of the maximal myoblast calcein staining. Quantification is representative of 
five independent experiments. Data were expressed as the mean ±S.E.*, P 
<0.05 versus control values.
Obestatin enhanced different SC populations 
during in vivo muscle regeneration
SCs were initially considered to be a homogeneous population 
of committed muscle progenitors3. However, several studies 
have pointed to a heterogeneous population4,5. SCs cells (Myf5−) 
are capable of either symmetrical cell division to give rise to 
two Myf5− daughter cells, or asymmetric cell division to give rise 
to one Myf5− stem cell and one Myf5+ committed precursor6. 
Kuang S. et al described that the 82% of apical-basal oriented 
doublets contained a Pax7+/Myf5− cell against the basal surface 
and a Pax7+/ Myf5+ cell located on the apical side against 
the muscle fiber and 92% of planar divisions give rise to two 
symmetrical cells.7. To know the ratio between Pax7+/Myf5− and 
Pax7+/ Myf5+ cells, these populations were measured along the 
regeneration process by FC. To reach this aim, DNA synthesis 
was first examined by propidium iodide (PI) staining at different 
time points, 12-168 h, during the regeneration process in order 
to discard apoptotic cells and to evaluate the cell cycle. Within the 
3.  Bischoff, R. The satellite cell and muscle regeneration. In Myology. Ed. A.G. Engel and C. Fran-
zini-Armstrong,  McGraw-Hill. (New York,USA). 1994.
4.  Schultz, E. Satellite cell proliferative compartments in growing skeletal muscles. Dev. Biol. 
1996; 175: 84-94.
5.  Beauchamp, J. R. et al. Expression of CD34 and myf5 defines the majority of quiescent adult 
skeletal muscle satellite cells. J. Cell. Biol. 2000; 151: 1221-34.
6.  Cossu, G. et al. Oriented cell divisions and muscle satellite cell heterogeneity. Cell. 2007; 129 
(5): 859-61.
7.  Kuang, S. et al. Asymmetric self-renewal and commitment of satellite stem cells in muscle. 
Cell. 2007; 129: 999-1010.
early stage of regeneration, 12 h, of obestatin treatment (300 nmol/
kg body-weight) after muscle injury, ~60 % of cells exhibited PI 
staining related to uninjured muscle. Cells exposed to vehicle alone 
showed a ~90% PI staining (Fig. 6.4A). However, this difference was 
not kept along muscle regeneration in which obestatin treatment 
showed to increase PI staining related to control injured muscle. 
It is important to note that at the end of the regeneration process 
(168 h), corresponding to late stage of the regeneration program, 
~30 % of cells exhibited PI staining compared to ~58 % of cells 
exposed to vehicle alone (Fig. 6.4A and 6.4B).
Fig. 6.4 Evaluation of the effect of obestatin treatment on pI positive cells 
during muscle regeneration. (A)Time course of  PI staining comparing cells 
treated with obestatin or vehicle alone obtained from freeze injured TA. These 
PI staining was related to control injured TA. Data were expressed as the mean 
±S.E representative of five independent experiments. (B) Representative DNA 
histogram of the apoptosis at 168 h after freeze injuried TA comparing control 
(vehicle) versus obestatin treatment. 
An analysis of the cell cycle of living cells by FC demonstrated 
that within the early stage of regeneration, 12-48 h post-injury, 
obestatin treatment (300 nmol/kg body-weight) increased 
the percentage of cells in G
o
 phase related cells exposed to 
vehicle alone (~82% versus ~50% at 12 h, respectively; Fig. 6.5A). 
Furthermore, obestatin showed to enhance the percentage 
of cells in S phase during the late stages of regeneration, 
corresponding to 72-168 h (~85% for obestatin-treated cells 
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versus ~60% for vehicle-treated cells; Fig. 6.5B) correlating to the 
minimum of G
o
 phase at 72 h for obestatin-treated cells (Fig. 6.5A 
and Fig. 6.5D). No significant differences in the percentage of cells 
in G
1 
phase between the groups of obestatin- and vehicle-treated 
cells (Fig. 6.5C). The biggest divergence in cell cycle phases 
between treated and non-treated groups was produced at 72 h 
after freeze injury (Fig. 6.5D). 
Fig.6.5 Time course of cell cycle during the regeneration process of total 
mononuclear cells isolated from freeze- injuried TA under obestatin or 
vehicle administratioin. Quantification of cells in G
o 
(M1) phase (A) S phase 
(B) and  G
1 
(M2) phase (C). Data were expressed as the mean ±S.E representa-
tive of five independent experiments. (D) Representative DNA histograms of 
vehicle- (left panel) and obestatin-treated cells (right panel) showing the cell 
cycle phases at 72 h post-injury.
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Finally, SCs from injured mice TA were immunostained with Pax7, 
Myf5 and Pax7/Myf5 over gated PI whole cell lysates (Fig. 6.6A-
C). The population of Pax7+ and Myf5+ cells increased during 
regeneration showing maximal levels 96 h post-injury (~30% and 
~9% for obestatin versus 15% and 3% for vehicle-treated cells, 
respectively). Furthermore, the population of Pax7+/Myf5+ was 
also increased at the late stage of myogenic program being ~5 
fold higher in for obestatin treatment related to control at 168 h 
post-injury (Fig. 6.6C). This pattern expression was demostrated 
after FC analysis with IF using the same samples from FC, showing 
the different ratio of myogenic markers expression (Fig. 6.6E). 
Fig. 6.6 Time course of the cell population expressing Pax7 (Pax7+, A), Myf5 
(Myf 5+, B) and  Myf5/Pax7 (Myf 5+/ Pax7+, C). Cells, obtained from injured-TA 
treated with vehicle (control) or obestatin (300 nmol/kg body-weight) and 
analysed by FA as indicated in Method section. (D) Representative flow 
cytometry histograms of gated PI samples, comparing the Pax7+, Myf 5+ and 
Myf 5+/ Pax7+ in whole lysates of cells, obtained from injured-TA treated with 
vehicle (control) or obestatin (300 nmol/kg body-weight) at 96h post-freeze 
injury.  (E)  Immunofluorescence detection of Pax7, Myf5 and myonuclei 
(DAPI) myoblast-derived SCs obtained from injured TA treated with vehicle 
(control) or obestatin (300 nmol/kg body-weight) at 96 h post-injury.
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CHApTEr 1
We provided the first evidence that obestatin regulates adipocyte 
metabolism and adipogenesis. Preproghrelin expression, and thus 
obestatin, increased during adipogenesis being sustained through-
out terminal differentiation of 3T3-L1 cells. In vitro 3T3-L1 cells 
secreted obestatin whose effects on adipocyte differentiation were 
neutralized by an obestatin antibody. Preproghrelin knock-down 
experiments revealed that obestatin contributes to adipogenesis, a 
fact that is supported by the effect of exogenous obestatin on the 
expression of C/EBPβ, C/EBPδ, C/EBPα and PPARγ and, consequently, 
lipid accumulation. In 3T3-L1 adipocyte cells, obestatin activated Akt 
phosphorylation and its downstream targets, GSK3α/β, mTOR, S6K1 
and inhibited AMPK activity. This fact was confirmed in vivo in omen-
tal, subcutaneous and gonadal WAT obtained from male rats under 
continuous sc infusion of obestatin. The relevance of obestatin as 
regulator of preadipocyte/adipocyte metabolism was also supported 
by AS160 phosphorylation, GLUT4 translocation and augment of glu-
cose uptake in 3T3-L1 adipocyte cells. By contrast, obestatin failed to 
modify translocation of fatty acid transporters, FATP4 and FAT/CD36, 
to plasma membrane.
Exposure of 3T3-L1 cells, a well-characterized model for studying 
the differentiation of white adipocytes, to obestatin regulates Akt 
activity. This study also demonstrated that chronic in vivo obestatin 
administration in male rats enhanced Akt activity in omental, 
subcutaneous and gonadal fat. It is well known that Akt regulates 
mammalian cell cycle progression and cell survival1. Furthermore, 
there is strong evidence, including results obtained from genetic 
mouse models, supporting the concept that Akt is a key node for 
regulation of a multitude of metabolic events such as glucose 
uptake, glycogen synthesis, gluconeogenesis, lipid metabolism, 
protein synthesis and differentiation processes as adipogenesis2,3,4,5,6. 
One of the physiological functions of Akt is to stimulate glucose 
uptake by GLUT4 trafficking through GAP known as AS1607,8,9. Our 
1.  Manning, B. D. et al. Akt/PKB signalling: navigating downstream. Cell. 2007; 129: 1261-74.
2.  Xu, J. et al. Protein kinase B/Akt 1 plays a pivotal role in insulin-like growth factor- 1 receptor 
signalling induced 3T3-L1 adipocyte differentiation. J. Biol. Chem. 2004; 279: 35914-22.
3.  Chen, W. S. et al. Growth retardation and increased apoptosis in mice with homozygous 
disruption of the Akt1 gene. Genes Dev. 2001; 15: 2203-8.
4.  Cho, H. et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance 
of glucose homeostasis in mice. J. Biol. Chem. 2001; 276: 38349-52.
5.  Garofalo, R. S. et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth 
deficiency in mice lacking Akt2/PKB beta. J. Clin. Invest. 2003; 112: 197-208.
6.  Berggreen, C. et al. Protein kinase B activity is required for the effects of insulin on lipid meta-
bolism in adipocytes. Am. J. Physiol. Endocrinol. Metab. 2009; 296: E635-46
7.  Kane, S. et al. A method to identify serine kinase substrates. Akt phosphorylates a novel 
adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J. Biol. Chem. 2002; 277: 
22115-8.
8.  Eguez, L. et al. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating 
protein. Cell Metab. 2005; 2: 263-72.
9.  Larance, M. et al. Characterization of the role of the Rab GTPase-activating protein AS160 in 
results showed that obestatin increased AS160 phosphorylation 
on Thr 642, consistent with Akt mediating obestatin-induced 
phosphorylation. AS160 keeps a GAP domain that maintains its 
target Rab(s) in their inactive GDP-state. AS160 phosphorylation 
suppresses its GAP activity, shifting the equilibrium of its targets 
Rab(s) to an active GTP form, enabling it to mediate GLUT4 
trafficking10. Indeed, obestatin increased GLUT4 membrane 
translocation and glucose transport in 3T3-L1 adipocyte cells, 
although in smaller extension to that of insulin. Inside the cell, 
glucose is converted to glucose 6-phosphate that can be stored by 
conversion to glycogen or catabolized by glycolysis, both processes 
under the control of Akt signalling11. In this sense, obestatin 
inactivated GSK3α/β, an Akt substrate, through phosphorylation 
in 3T3-L1 adipocyte cells. This inactivation leads to a decrease 
in the phosphorylation of GS resulting in its activation, thereby 
stimulating glycogen synthesis. Consequently, Akt-directed 
signalling coordinates the obestatin-evoked glucose uptake and 
storage as glycogen in adipose tissue by regulation of AS160 and 
GSK3. In addition to glucose uptake, obestatin showed to regulate 
mTORC1/S6K1 signalling, a critical element integrating cellular 
metabolism with growth factor signalling12. mTORC1 controls 
many aspects of cellular metabolism including adipose tissue 
metabolism13. In particular, mTORC1/S6K1 plays an important 
role in adipogenesis and, thus, in lipid accumulation14. Loss of 
mTORC1/S6K1 activity correlates with a decrease in adipocytes 
accumulation, suggesting that the mTOR pathway is required for fat 
accumulation15. Furthermore, activation of mTORC1 signalling is a 
critical step in adipocyte differentiation16. The capacity of obestatin 
to modulate Akt activity in preadipocyte and adipocyte cells is not 
an isolated fact since this kinase is also activated by this peptide 
in pancreatic®-cell lines, human islets17 and gastric cell lines18. 
In gastric cell lines, a signalling pathway involving a β-arrestin 
1 scaffolding complex and EGFR to activate Akt signalling was 
insulin-regulated GLUT4 trafficking. J. Biol. Chem. 2005; 280: 37803-13.
10.  Zaid H, et al. Insulin action on glucose transporters through molecular switches, tracks and 
tethers. Biochem. J. 2008; 413: 201-15.
11.  Manning, B. D. et al. Akt/PKB signalling: navigating downstream. Cell. 2007; 129: 1261-74.
12.  Um, S. H.  et al. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, 
S6K1. Cell Metab. 2006; 3: 393-402. 
13.  Dann, S. G. et al. mTOR complex1-S6K1 signalling: at the cross- roads of obesity, diabetes 
and cancer. Trends Mol. Med. 2007; 13: 252-9. 
14.  Kim, J. E. et al. Regulation of peroxisome proliferator-activated receptor-gamma activity by 
mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004; 53: 2748-56. 
15.  Um, S. H. et al. Absence of S6K1 protects against age- and diet-induced obesity while en-
hancing insulin sensitivity. Nature. 2004; 431: 200-5.
16.  Zhang, H. H. et al. Insulin stimulates adipogenesis through the Akt- TSC2-mTORC1 pathway. 
PLoS One. 2009; 4: E6189.
17.  Granata, R. et al. Obestatin promotes survival of pancreatic beta-cells and human islets and 
induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes. 
2008; 57: 967-79.
18.  Pazos, Y. et al. Stimulation of extracellular signal-regulated kinases and proliferation in the 
human gastric cancer cells KATO-III by obestatin. Growth Factors. 2007; 25: 373-81.
127
Discussion Chapter 1
proposed, as previously described19. It will clearly be of interest to 
establish whether this also occurs in adipose cells.
Parallel to Akt activation, AMPK inactivation was triggered by obestatin 
in 3T3-L1 pre-adipocyte and adipocyte cells. Similarly, 72 h continuous 
sc infusion of obestatin in vivo resulted in decreased AMPK activity in 
WAT similar to that observed in vitro. Thus, a decline in AMPK phospho-
rylation would be expected to lead to a reduction in ACC phosphoryl-
ation, and thus an increase in the activity of this enzyme. Accordingly, 
we found that ACC phosphorylation was also decreased by obestatin 
in this study. Based on it, increased ACC activity consequently leads to 
increased malonyl Co-A levels, which mediate an inhibitory effect on 
CPT-1, preventing fatty acid transport into mitochondria and fatty acid 
oxidation, promoting fatty acid synthesis20. Thus, Akt activation and 
AMPK inactivation seem to be inversely correlated during obestatin 
stimulation. This fact was confirmed in vivo in omental, subcutane-
ous and gonadal WAT obtained from male rats under continuous sc 
infusion of obestatin. This enzymatic activity favors fat deposition with 
the consequent inhibition of breakdown plus burning stored fat and 
reduction of body weight. Furthermore, obestatin works in a rapid, 
hormone-like manner, being its effect insulin independent.
This study demonstrates a novel role for obestatin as an adipogenic 
molecule. Based on the promoter role exerted by obestatin on 
insulin-induced adipogenesis and the fact that obestatin expression 
increased in adipocytes compared to preadipocyte cells, we 
postulated that obestatin might exert an autocrine/paracrine effect 
on the differentiation process. The fact that preproghrelin expression 
increased in the course of differentiation process being sustained 
throughout terminal differentiation of 3T3-L1 cells supports our 
hypothesis. Furthermore, preproghrelin knock-down experiments 
revealed its contribution to adipogenesis, although it would involve 
both ghrelin and obestatin. The implication of obestatin seems to be 
confirmed by neutralization of obestatin with specific antibody in 
3T3-L1 cells that reduced their adipogenic potential. This is further 
supported by the effect of exogenous obestatin on the expression 
of master regulators of adipocyte fate, C/EBPβ, C/EBPδ, C/EBPα and 
PPARγ21. We can hypothesize that ghrelin and obestatin mutually 
contribute to adipogenesis as pro-adipogenic factors promoting 
lipogenesis. Indeed, it has been shown that ghrelin stimulates lipid 
19.  Alvarez, C. J. et al. Obestatin stimulates Akt signalling in gastric cancer cells through be-
ta-arrestin-mediated epidermal growth factor receptor transactivation. Endocr. Relat. Cancer. 
2009; 16: 599-611.
20.  Munday, M. R. Regulation of mammalian acetyl-CoA carboxylase. Biochem. Soc. Trans. 2002; 
30: 1059-64.
21.  Rosen, E. D.  et al. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006; 
7: 885-96.
accumulation in vitro22,23, and in vivo 24,25. Thus, the original concept 
that these two peptides derived from the same gene show opposite 
actions is not completely correct. Interestingly, ghrelin and obestatin 
knock-down by preproghrelin siRNA revealed a key contribution of 
both peptides to insulin-induced terminal adipogenesis suggesting 
that the insulin effect might be mediated by expression and secretion 
of both peptides on the late stage of adipogenesis.
The expression of GPR39 in 3T3-L1 cells and its expression changes 
during adipogenesis suggests its implication in adipocyte differentia-
tion. This fits well with the expression pattern of GPR39 in mouse em-
bryonic fibroblast cells during adipocyte differentiation26. This hypoth-
esis seems to be consistent with the up-regulation of preproghrelin 
expression and, in consequence, with the increase of the biosynthesis 
and secretion of obestatin by adipocytes, which exerts a paracrine 
control on pre-adipocyte via a GPR39-dependent mechanism. 
In summary, in this report we describe a novel role of obestatin in 
the autocrine/paracrine regulation of adipogenesis. The adipogenic 
role of obestatin is supported by: 1) the activation of Akt signalling, 
2) the regulation of adipocyte metabolism and, 3) the inhibition 
of adipogenesis by disruption of preproghrelin or neutralization 
of obestatin. Intriguingly, circulating obestatin and ghrelin levels 
do not increase in obese subjects, a fact shared with ghrelin27,28,29. 
Therefore, neither obestatin nor ghrelin appear to be determinant 
in maintaining obesity. Nonetheless this fact does not rule out a 
function for obestatin in the development of obesity. In this sense, 
it is remarkable that the magnification of WAT is related to the 
development of the metabolic disorders, and the identification 
of factors that participate to this phenomenon would provide 
new aspects for the understanding of adipogenesis as well as the 
pathogenesis of obesity and associated comorbidities.
22.  Kim, M. S. et al. The mitogenic and anti-apoptotic actions of ghrelin in 3T3-L1 adipocytes. 
Mol. Endocrinol. 2004; 18: 2291-301.
23.  Rodríguez, A. et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human 
visceral adipocytes. Int. J. Obes. 2009; 33: 541-52. 
24.  Davies, J. S. et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. 
Mol. Endocrinol. 2009; 23: 914-24. 
25.  Wells T. Ghrelin—defender of fat. Prog. Lipid. Res. 2009; 48: 257-74. 
26.  Egerod, K. L. et al. GPR39 splice variants versus antisense gene LYPD1: expression and re-
gulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Mol. En-
docrinol. 2007; 21: 1685-8.
27.  Vicennati, V. et al. Circulating obestatin levels and the ghrelin/obestatin ratio in obese wo-
men. Eur. J. Endocrinol. 2007; 157: 295-301. 
28.  Huda, M. S. et al. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, 
but do not change in response to a meal. Int. J. Obes. 2008; 32: 129-35.
29.  Zamrazilová, H. et al. Plasma obestatin levels in normal weight, obese and anorectic wom-
en. Physiol. Res. 2008; 57: S49-55.
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CHApTEr 2
In this chapter, we have demonstrated that preproghrelin plays a 
critical role in the process of adipogenesis. We have shown that 
insulin-induced adipocyte conversion is impaired in the absence of 
preproghrelin. Furthermore, neutralization of preproghrelin-derived 
peptides displays defective accumulation of lipid droplets. Thus, pre-
proghrelin is a key source of autocrine peptides involved in adipocyte 
differentiation. Furthermore, we have identified that preproghrelin 
and the enzymatic machinery associated to the processing of this 
peptide into UAG and AG are up-regulated during adipose conver-
sion. This enzymatic system includes PC1/3, which cleaves after Arg. 
28 of proghrelin leading to the production of the mature 28 amino 
acid peptide30 and MBOAT4, a polytopic membrane-bound enzyme 
that attaches the octanoyl residue to Ser 3 in AG31,32. The changes in 
mRNA and protein expression were further associated with insu-
lin action, although transcription and translation of these targets 
showed different regulatory systems. In addition, acute inhibition 
of mTORC1 activity in the presence of rapamycin led to decreased 
levels of these proteins. These data suggest the involvement of the 
mTORC1/S6K1 pathway in the regulation of preproghrelin, PC1/3, 
and MBOAT4 translation during the early steps of adipogenesis. This 
point disagree with the findings that inhibition of mTORC1 stimu-
lates gastric and pancreatic preproghrelin expression33,34. Indeed, it 
is likely that the mTORC1/S6K1 pathway and preproghrelin interact 
in a tissue-specific manner. In addition, the type of pharmacological 
treatment, chronic versus acute, might also explain this paradigm. In 
this sense, it is important to note that chronic rapamycin treatment 
can inhibit both mTORC1 and mTORC2 activities35,36.
The potential role of preproghrelin as source of auto/paracrine pep-
tides has remained unstudied in adipose tissue, possibly as a result 
of the perception that preproghrelin is not substantially expressed 
in this tissue. As reported here and elsewhere37,38, however, adipose 
tissue expresses relatively high levels of preproghrelin. This peptide 
30.  Zhu, X. et al. On the processing of proghrelin to ghrelin. J. Biol. Chem. 2006, 281: 38867-70.
31.  Gutierrez, J. A. et al. Ghrelin octanoylation mediated by an orphan lipid transferase. PNAS. 
2008; 105: 6320-5.
32.  Yang, J. et al. Identification of the acyltransferase that octanoylates ghrelin, an appetite-sti-
mulating peptide hormone. Cell. 2008; 132: 387-96.
33.  Xu, G. et al. Gastric mammalian target of rapamycin signalling regulates ghrelin production 
and food intake. Endocrinology. 2009; 150: 3637-44.
34.  An, W. et al. Modulation of ghrelin O-acyltransferase expression in pancreatic islets. Cell. 
Physiol. Biochem. 2010; 26: 707-16.
35.  Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/
PKB. Molecular Cell. 2006; 22: 159-68.
36.  Laplante, M. et al. mTOR signalling at a glance. J. Cell Sci. 2009; 122: 3589-94.
37.  Gnanapavan, S. et al. The tissue distribution of the mRNA of ghrelin and subtypes of its 
receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 2002; 87: 2988.
38.  Knerr, I. et al. Leptin and ghrelin expression in adipose tissues and serum levels in gastric 
banding patients. Eur. J. Clin. Invest. 2006; 36: 389-94. 
undergoes stepwise processing to produce UAG, AG, and obestatin39. 
AG is widely known for its role in adipogenesis and lipid storage in 
WAT in both rodents40 and humans41. By contrast, the role of UAG in 
adipogenesis is not clear, because there are reports showing that 
UAG suppressed adipogenesis and lipid accumulation42,43, whereas 
others showed that UAG increased adipogenesis and lipid accumu-
lation in both rodents44 and human adipocytes45. In this study, we 
found that the net effect of these secreted preproghrelin- derived 
peptides favors adipocyte conversion. This fact appears to be a 
consequence of the Akt activation by both AG and obestatin in adi-
pose tissue46,47. There is strong evidence, including results obtained 
from genetic mouse models, supporting the concept that Akt is a 
key node for regulation of the transcriptional program required for 
adipogenesis48,49,50,51,52,53 .Interestingly, knock-down experiments by 
preproghrelin siRNA displayed defective adipocyte differentiation. 
We propose that insulin activates preproghrelin expression and con-
sequent secretion of preproghrelin-derived peptides, which intensify 
insulin signalling to Akt in an autocrine manner in preadipocyte cells. 
The co-expression of GHSR1a and GPR39 supports this autocrine 
function. These peptides further determine the progressive expres-
sion of PC1/3 and MBOAT4 related to adipocyte differentiation de-
fining the secretion rate between AG and UAG. Through a paracrine 
action, preproghrelin-derived peptides impact on adipocytes leading 
to Akt signalling favoring regulation processes such as hypertrophy. 
Thus, it is likely that the insulin effect is mediated by expression and 
secretion of these peptides on the late stage of adipogenesis.
39.  Zhu, X. et al. On the processing of proghrelin to ghrelin. J. Biol. Chem. 2006; 281: 38867-70.
40.  Wells, T. Ghrelin - defender of fat. Prog. Lipid Res. 2009; 48: 257-74.
41.  Rodriguez, A. et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human 
visceral adipocytes. Int. J. Obes. 2009; 33(5): 541-52.
42.  Delhanty, P. J. et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signalling 
pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS ONE. 2010; 
5: E11749.
43.  Zhang, W. et al. Effect of des-acyl ghrelin on adiposity and glucose metabolism. Endocrino-
logy. 2008; 149: 4710-16.
44.  Thompson, N. M. et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly 
in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. 
Endocrinology. 2004; 145: 234-42.
45.  Rodriguez, A. et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human 
visceral adipocytes. Int. J. Obes. 2009; 33: 541-52.
46.   Gurriarán-Rodríguez, U. et al. Obestatin as a regulator of adipocyte metabolism and adipo-
genesis. J. Cell. Mol. Med. 2011; 15: 1927–40.
47.  Lodeiro, M. et al. c-Src regulates Akt signalling in response to ghrelin via beta-arrestin signa-
lling-independent and -dependent mechanisms. PLoS ONE. 2009; 4: E4686.
48.  Cho, H. et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance 
of glucose homeostasis in mice. J. Biol. Chem. 2001; 276: 38349-52.
49.  Garofalo, R. S. et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth 
deficiency in mice lacking Akt2/PKB beta. J.  Clin. Invest. 2003; 112: 197-208.
50.  Xu, J. et al. Protein kinase B/Akt1 plays a pivotal role in insulin-like growth factor-1 receptor 
signalling induced 3T3-LI adipocyte differentiation. J. Biol. Chem. 2004; 279: 35914-22.
51.  Manning, B. D. et al. Akt/PKB signalling: navigating downstream. Cell. 2007; 129: 1261-74.
52.  Zhang, H. H. et al. Insulin stimulates adipogenesis through the Akt-TSC2- mTORC1 pathway. 
PLoS ONE. 2009; 4: E6189.
53.  Berggreen, C. et al. Protein kinase B activity is required for the effects of insulin on lipid 
metabolism in adipocytes. Am. J. Physiol. Endocrinol. Metab. 2009; 296: E635-E646.
129
Discussion Chapter 2
In agreement with our data obtained in vitro, where the expression 
of preproghrelin, PC1/3, and MBOAT4 was increased during 
adipogenesis, we found that, in both omental and subcutaneous fat 
of mice fed on HFD, the expression of these factors is higher than in 
the WAT of mice fed on SD. The only exception was the expression 
of preproghrelin in omental fat that remained unchanged between 
SD and HFD mice, indicating that preproghrelin is regulated in a 
fat depot-specific manner. Overall, our findings showing higher 
levels of preproghrelin-related factors in the WAT of animals where 
adipogenesis is stimulated suggest that preproghrelin, PC1/3, and 
MBOAT4 might play an important role in the accumulation of lipids 
during diet- induced obesity.
In summary, we have shown that insulin triggers the expression of 
preproghrelin, and have demonstrated that preproghrelin is a critical 
target for insulin-induced adipogenesis. The mechanisms of regula-
tion of these targets by insulin await further investigation.
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CHApTEr 3
We have shown that healthy skeletal muscle expresses obestatin and 
GPR39, and this expression strikingly increased upon muscle injury. 
In vitro, obestatin was preferentially expressed by L6E9 myotubes, 
whereas GPR39 was equally expressed in both myoblast and myotube 
cells. Expression of both obestatin and GPR39 was coordinately 
up-regulated during the early stages of myogenesis, and their levels 
remained sustained throughout terminal differentiation of L6E9 cells. 
Functionally, blocking obestatin during myogenesis induced a decrease 
in myogenic-associated markers (myogenin, MHC). Silencing of 
preproghrelin or GPR39 expression produced similar results. Obestatin 
stimulation of undifferentiated L6E9 cells promoted migration function 
and mitogenic activity of myoblasts. Furthermore, this peptide 
promoted myogenic differentiation, increasing the expression of 
myogenic markers. Additionally, these results were supported by in 
vivo testing of the gastrocnemius and soleus muscle obtained from 
male rats under continuous subcutaneous infusion of obestatin. The 
testing of this peptide showed an up-regulation of a set of transcription 
factors regulating myogenesis: (i) markers associated with satellite 
cell activation: Pax7 and Myf5; (ii) markers associated with early 
differentiation: MyoD, myogenin, and Myf6; and (iii) a marker associated 
with late differentiation: MHC. Altogether, these observations 
demonstrated that the obestatin/GPR39 system is involved in 
myogenesis and that obestatin is expressed by differentiating 
myogenic precursors to function in an autocrine manner.
After injury, SCs are activated and enter the cell cycle to proliferate, 
and eventually, they fuse to replace degenerated muscle fibers, 
preserving muscle structure and function. Several signals, derived 
both from damaged fibers and from infiltrating cells, are involved in 
SCs activation54,55. From the data presented thus far, obestatin should 
be incorporated into the list of myogenic regulatory factors derived 
from damaged fibers. Based on its overexpression in muscle injury, its 
up-regulation during myogenesis, and its promoter role on myogenic 
differentiation and fusion of L6E9 cells, it is possible to speculate 
that obestatin exerts an autocrine effect on the skeletal myogenic 
process. The fact that preproghrelin expression increased in the 
course of differentiation and remained sustained throughout terminal 
differentiation of L6E9 cells supports this hypothesis. Furthermore, 
preproghrelin knock-down experiments uncovered its contribution to 
myogenesis, although it would implicate both ghrelin and obestatin. 
The myogenic role of obestatin is supported by neutralization of 
this peptide with a specific antibody in L6E9 cells, which reduced its 
54.  Chargé, S. B. et al. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 
2004; 84: 209-38. 
55.  Ten Broek, et al. Regulatory factors and cell populations involved in skeletal muscle regene-
ration. J. Cell. Physiol. 2010; 224: 7-16. 
myogenic potential through myogenin and MHC down-regulation. 
Further support for a myogenic role for obestatin is demonstrated 
by the effect on the activation and proliferation of myoblasts, with 
the resulting growth arrest by contact and initiation of myogenesis, 
e.g. myogenesis activation of proliferating myoblasts in GM. The 
increased expression of myogenic regulator factors, Pax7, Myf5, MyoD, 
myogenin, Myf6, and MHC56, associated with subcutaneous infusion of 
obestatin in rats reinforces this suggestion. Considering the myogenic 
characteristics of ghrelin and des-acyl ghrelin previously described57, 
we hypothesized that preproghrelin-derived peptides mutually 
contribute to myogenesis as pro-myogenic factors, as corroborated 
by the mitogenic and myogenic roles for ghrelin and obestatin 
described in the present work. Although the myogenic characteristics 
of ghrelin found in this study are in agreement with previous works58, 
the mitogenic action of ghrelin appears to be in contradiction with a 
previous study showing inhibition of C2C12 myoblast cells59. Even if 
the role of ghrelin and des-acyl ghrelin in mitogenesis remains unclear 
and varies depending on the nature of the study, the myogenic 
properties of preproghrelin-derived peptides reinforce our hypothesis.
Obestatin has multiple functional properties, and its capacity to 
stimulate myoblast migration, proliferation, and differentiation in 
vitro is particularly interesting. In L6E9 myoblasts, obestatin was 
shown to enhance ERK, Akt, and p38 activities. These pathways are 
activated by regeneration signals and demonstrate the ability of 
muscle progenitors to execute different stages of the regeneration 
program: (a) the ERK/MAPK pathway activates cell migration and 
proliferation60,61; (b) the Akt pathway promotes cell proliferation, 
survival, and differentiation62; and (c) the p38 pathway stimulates cell 
cycle arrest and terminal differentiation63. The convergence of these 
pathways at the chromatin level defines the mechanism for integration 
of mitogenic and myogenic signals to direct the transition from 
quiescence to terminal differentiation64. Thus, the range of obestatin 
functions, together with its expression in normal and regenerating 
56.  Braun,T. et al. Transcriptional mechanisms regulating skeletal muscle differentiation, grow-
th, and homeostasis. Nat. Rev. Mol. Cell Biol. 2011; 12:  349-61.
57.  Filigheddu, N. et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of 
C2C12 skeletal muscle cells. Mol. Biol. Cell. 2007; 18: 986-94. 
58.  Filigheddu, N. et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of 
C2C12 skeletal muscle cells. Mol. Biol. Cell. 2007; 18: 986-94. 
59.  Filigheddu, N. et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of 
C2C12 skeletal muscle cells. Mol. Biol. Cell. 2007; 18: 986-94. 
60.  Mourkioti, F. et al. IGF-I, inflammation, and stem cells: interactions during muscle regenera-
tion. Trends Immunol. 2005; 26: 535-42. 
61.  Leloup, L. et al. Involvement of the ERK/MAP kinase signalling pathway in milli-calpain acti-
vation and myogenic cell migration. Int. J. Biochem. Cell Biol. 2007; 39: 1177-89.
62.  Wu, M. et al. Akt/protein kinase B in skeletal muscle physiology and pathology. J. Cell Physiol. 
2011; 226: 29-36. 
63.  Lluís, F. et al. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell 
Biol. 2006; 16: 36-44.
64.  Serra, C. et al. Functional interdependence at the chromatin level between the MKK6/p38 
and IGF1/PI3K/Akt pathways during muscle differentiation. Mol. Cell. 2007; 28: 200-13.
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skeletal muscle, is consistent with a role in regulating myofiber 
formation and homeostasis. In this regard, obestatin shows functional 
similarity with IGF-I and IGF-II, because both factors have the capacity 
to promote both proliferation and differentiation of muscle cells65,66.
Silencing of GPR39 expression in L6E9 myoblast cells demonstrated 
that this G protein-coupled receptor is the extracellular target for 
obestatin action. Although there is ongoing controversy regarding 
GPR3967,68, our findings on L6E9 myoblasts are consistent with the role 
of this receptor on obestatin signalling in preadipocyte 3T3-L1 cells69,70 
and in gastrointestinal and adipose tissues71. The expression of GPR39 
in L6E9 cells and its changes during myogenesis further suggest a role 
for GPR39 in this process. Definitive evidence for the requirement of 
GPR39 in myogenesis came from the observation that its knock-down 
by siRNA significantly diminished the myogenic capacity of L6E9 cells. 
Furthermore, the preproghrelin expression up-regulation and, as a 
consequence, the increase of obestatin biosynthesis and secretion by 
myotubes, together with its faint expression in myoblasts, lead us to 
speculate that obestatin might exert a paracrine role on myoblasts via 
a GPR39-dependent mechanism. Similarly, the obestatin/GPR39 system 
exerts an autocrine/paracrine control on adipogenesis72. Combined, 
these all point to the role of obestatin/GPR39 signalling as a key com-
ponent for proper skeletal and adipose tissue development. In fact, our 
results underscored a key role for pre-proghrelin-derived peptides on 
adipogenesis through an autocrine/paracrine mechanism as well73.
Male rats under continuous subcutaneous infusion of obestatin 
showed a modified expression of transcription factors that regulate 
the progression through the myogenic lineage in soleus and 
gastrocnemius muscle tissue. Up-regulation of Pax7 expression 
might be indicative of a control on satellite cell activation to 
enhance myogenic specification and/or to induce self-renewal74 ,75. 
65.  Mourkioti, F. et al. IGF-I, inflammation, and stem cells: interactions during muscle regenera-
tion. Trends Immunol. 2005; 26: 535-42.
66.  Matheny, R. W. et al. Minireview: Mechano-growth factor: a putative product of IGF-I gene 
expression involved in tissue repair and regeneration. Endocrinology. 2010; 151: 865-75.
67.  Chartrel, N. et al. Comment on “Obestatin, a peptide encoded by the ghrelin gene, opposes 
ghrelin’s effects on food intake”. Science. 2007; 315: 766.
68.  Holst, B. et al. GPR39 signalling is stimulated by zinc ions but not by obestatin. Endocrino-
logy. 2007; 148: 13-20.
69.  Gurriarán-Rodríguez, U. et al. Obestatin as a regulator of adipocyte metabolism and adipo-
genesis. J. Cell. Mol. Med. 2011; 15: 1927–40.
70.  Gurriarán-Rodríguez, U. et al. Obestatin as a regulator of adipocyte metabolism and adipo-
genesis. J. Cell. Mol. Med. 2011; 15: 1927–40.
71.  Zhang, J. V. et al. Obestatin induction of early-response gene expression in gastrointestinal 
and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol. Endo-
crinol. 2008; 22: 1464-75.
72.  Gurriarán-Rodríguez, U. et al. Obestatin as a regulator of adipocyte metabolism and adipo-
genesis. J. Cell. Mol. Med. 2011; 15: 1927–40.
73. Gurriarán-Rodríguez, U. et al. Obestatin as a regulator of adipocyte metabolism and adipo-
genesis. J. Cell. Mol. Med. 2011; 15: 1927–40.
74.  Wang, Y. X. et al. Satellite cells, the engines of muscle repair. Nat. Rev. Mol. Cell Biol. 2012; 
13: 127-33.
75.  Olguin, H. C. et al. Pax7 up-regulation inhibits myogenesis and cell cycle progression in 
It is known that this transcription factor is maintained in satellite 
cells and proliferating myoblasts but is down-regulated before 
differentiation76,77. Furthermore, the expression of myogenic regulatory 
factors is coordinated by this factor. Indeed, up-regulation of MyoD 
and Myf5 was observed in obestatin-treated rats, denoting the 
conversion of satellite cells into myoblast78, although it is not possible 
to rule out a role for this peptide in the replenishment of the satellite 
cell pool. MyoD and Myf5 are required for the expression of myogenic 
precursors and act upstream of Myf6 and myogenin. Accordingly, Myf6 
and myogenin were up-regulated, denoting myoblast differentiation79. 
Moreover, MHC was observed to be up-regulated, as an indication 
of myogenic differentiation. Additionally, obestatin was shown to 
increase the expression of VEGF and VEGFR-2 in this tissue. Conversely, 
PEDF expression was down-regulated. The expression and role of 
VEGF as an autocrine myogenic factor in muscle was previously 
described. Furthermore, VEGFR2 was shown to be up-regulated 
during myogenic differentiation80. In addition to its myogenic action, 
it is important to note its known angiogenic role81. This latter effect is 
important in attracting distant vessels to the myoblast differentiation 
sites. This implies that VEGF, produced by differentiating myocytes, 
provides the needed vascularization of developing skeletal muscle. 
This is further supported by down-regulation of the anti-angiogenic 
factor PEDF82. All together, our data support the view that obestatin 
regulates the “hierarchy” of transcription factors involved in the control 
of the different stages of the myogenic program, including activation, 
proliferation, and differentiation, exerting a role in the expression of 
VEGF/ VEGFR2 for the potential regulation of the angiogenic process in 
skeletal muscle tissue.
In summary, we propose that the obestatin/GPR39 system signalling 
is involved in muscle regeneration, in which obestatin exerts an 
autocrine function to control the myogenic differentiation program, 
thereby implicating its potential for use as a therapeutic agent for 
the treatment of trauma-induced muscle injuries or skeletal muscle 
myopathies.
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In this study, we described that obestatin controls the signalling 
pathway associated to glucose uptake in skeletal muscle. In L6E9 
myotube cells, obestatin activated Akt phosphorylation and its 
downstream targets, GSK3α/β, S6K1 and inhibited AMPK activity. 
This fact was confirmed in vivo in gastrocnemius and soleus 
obtained from male rats under continuous sc infusion of obestatin. 
The significance of obestatin as regulator of myotubes metabolism 
was also supported by AS160 phosphorylation, GLUT4 translocation 
to plasma membrane and augment of glucose uptake in vitro in 
L6E9 myotube cells. This effect was further confirmed ex vivo in 
soleus and gastrocnemius muscles. 
There are two major signalling pathways that participate in glucose 
transport in skeletal muscle. One is the Akt signalling pathway, 
and the other is the AMPK signalling pathway83. Whether crosstalk 
exists between these two signalling pathways is still unclear. In 
this study, we showed that obestatin-stimulated glucose uptake 
appears to be dependent on Akt activation hence obestatin 
triggered AMPK inactivation through dephosphorylation at Thr 172 
from α subunit. Akt is known to stimulate glucose uptake by GLUT4 
trafficking through GAP known as AS16084. Our results showed 
that obestatin increased AS160 phosphorylation on Thr 642, 
consistent with Akt mediating obestatin-induced phosphorylation. 
AS160 phosphorylation suppresses its GAP activity, shifting the 
equilibrium of its targets Rab(s) to an active GTP form, enabling 
it to mediate GLUT4 trafficking85. Certainly, an increase in GLUT4 
membrane translocation and glucose transport was observed 
in L6E9 myotubes after obestatin treatment, although in smaller 
extension to that of insulin. By contrast, obestatin failed to regulate 
GLUT1 translocation in L6E9 myotubes, likely due to GLUT1 is 
more implicated in the control of glucose basal metabolism, and 
in overfeeding conditions is GLUT4 the transporter that mediates 
the glucose uptake86. Likewise, in the soleus and gastrocnemius 
muscles, there was an increased in muscle glucose uptake after 
obestatin treatment, the quantitative differences between both 
muscle types, may be due to the diverse type of fiber pattern, 
that is intimately correlated with the metabolism type87. In 
83.  Russell, R.R. et al. Translocation of myocardial GLUT-4 and increased glucose uptake through 
activation of AMPK by AICAR. Am. J. Physiol. 1999; 277(2): 643-9.
84.  Eguez, L. et al. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating 
protein. Cell Metab. 2005; 2: 263-72.
85.  Zaid H, et al. Insulin action on glucose transporters through molecular switches, tracks and 
tethers. Biochem. J. 2008; 413: 201-15.
86.  Joost, H, et al. The extended GLUT-family of sugar/polyol transport facilitators: nomencla-
ture, sequence characteristics, and potential function of its novel members. Mol. Membr. Biol. 
2001; 18 (4): 247-56. 
87.  Henriksen, E.J. et al. Glucose transporter protein content and glucose transport capacity in 
rat skeletal muscles. Am. J. Physiol. 1990; 259(4): 593-8.
addition, obestatin showed to regulate mTORC1/S6K1 signalling, 
a critical element integrating cellular metabolism with growth 
factor signalling88. mTORC1 controls many aspects of cellular 
metabolism including skeletal muscle tissue metabolism89. One 
of the consequence of the increased glucose uptake in skeletal 
muscle mass is the cell mass increase which leads to hypertrophy in 
skeletal muscle fibers90. It has been described that in vivo muscle-
specific overexpression of constitutively active Akt1 or Akt2 results 
in increased mTORC1/S61 activity, glycogen accumulation, and 
muscle fiber hypertrophy91, as well as the opposite effect was 
reached after double-knockout of Akt1 and Akt2; these mice 
display severe skeletal muscle atrophy (50% decrease in muscle 
mass), mainly due to markedly decreased individual muscle fiber 
size92.
In the cytoplasm, glucose is converted to glucose 6-phosphate 
that can be stored by conversion to glycogen or catabolized by 
glycolysis, both processes under the control of Akt signalling 93. In 
this sense, obestatin inactivated GSK3α/β, an Akt substrate, through 
phosphorylation in L6E9 myotube cells. This inactivation leads to 
inactivation of GS, leading to glycogen synthesis and storage94. 
After obestatin treatment, L6E9 myotubes enhanced GSK3α/β 
phosphorylation, thereby stimulating glycogen synthesis. Parallel 
to Akt activation, AMPK inactivation was triggered by obestatin in 
vivo and in vitro. The decline in AMPK activation would be expected 
to lead to an increase in ACC activity. Indeed, it was found that 
ACC phosphorylation was decreased by obestatin. Based on it, 
decreased AMPK activity and increased ACC activity consequently 
leads to switch on anabolic pathways that consume ATP, such 
as synthesis of glycogen and protein, and to switch off catabolic 
pathways that generate ATP, such as lipid oxidation and glucose 
88.  Um, S. H.  et al. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, 
S6K1. Cell Metab. 2006; 3: 393-402. 
89.  Zoncu, R. et al. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. 
Rev. Mol. Cell. Biol. 2011 ;12(1):21-35. 
90.  Miaozong, W. et al. Akt/Protein Kinase B in skeletal muscle physiology and pathology. J. Cell. 
Physiol. 2010; 226: 29-36.
91.  Cleasby, M. E. et al. Functional studies of Akt isoform specificity in skeletal muscle in vivo; 
maintained insulin sensitivity despite reduced insulin receptor substrate-1 expression. Mol. En-
docrinol. 2007; 21: 215-28.
92.  Peng, X. D. et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed 
bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003; 
17: 1352-65.
93.  Manning, B. D. et al. Akt/PKB signalling: navigating downstream. Cell. 2007; 129:  1261-74.
94.  Jørgen, F. P. et al. Invited Review: Effect of acute exercise on insulin signalling and action in 
humans. J. Appl. Physiol. 2002; 93: 384-92.
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oxidation95,96,97,98. Therefore, Akt activation and AMPK inactivation 
seem to be inversely correlated during obestatin stimulation.
In summary, we described that obestatin is implicated in the reg-
ulation of glucose uptake in skeletal muscle. This role is supported 
by the activation of Akt signalling and the regulation of membrane 
translocation of GLUT4. 
95.  Zhang, B.B. et al. AMPK: an emerging drug target for diabetes and the metabolic syndrome. 
Cell Metab. 2009; 9(5): 407-16.
96.  Long, Y.C. et al. AMP-activated protein kinase signalling in metabolic regulation. J.Clin. In-
vest. 2006;116(7):1776-83. 
97.  Hardie, D. G . et al. AMPK: a key regulator of energy balance in the single cell and the whole 
organism. Int. J. Obes. 2008; 32 (4): S7-12. 
98.  O´Neill, H. M. et al. AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: 
Implications for obesity. Mol. Cel. Endocrinology. 2013;  366: 135-51.
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The obestatin/GPR39 system has been demonstrated to regulate the 
myogenic program. Such function is result of its autocrine role in the 
regulation of transcription factors involved in the control of the dif-
ferent stages of myogenesis. In this study, we further demonstrated 
that obestatin augments regeneration by stimulating SCs expansion 
as well as myofiber hypertrophy after muscle injury.
In response to obestatin the hierarchy of transcription factors 
regulating progression through the myogenic lineage was clearly 
increase. This is endorsed by the increased expression of myogenic 
regulator factors, Pax7, MyoD, myogenin, and MHC, demonstrating 
the myogenic potential for this peptide when it is administrated 
into injured muscle. SCs number increased on muscle sections as 
well as in myofibers obtained from obestatin-treated muscles 96 h 
after injury. The increased SCs proliferation was concomitant with 
enhanced tissue expression of Ki67, a proliferating cell marker, 
and cyclin D1, a well-known effector of the G1 to S cell cycle phase 
transition, 96 h after injury. In addition, Pax7 coordinates the 
expression of myogenic regulatory factors. Indeed, up-regulation 
of MyoD was observed in obestatin-treated mice, indicating the 
conversion into myoblasts. Furthermore, MyoD determines the 
expression of myogenic precursors acting upstream of myogenin. 
Accordingly, myogenin was up-regulated, implying myoblast 
differentiation. MyoD and myogenin act together to drive 
differentiation99. In this process, the expression of embryonic/
developmental forms of MHC was observed to be enhanced 
denoting terminal myogenic differentiation. Further support was 
demonstrated by enhancement of the myogenic markers by in 
vivo overexpression of preproghrelin during muscle regeneration. 
However, it would implicate the mutual contribution of the known 
preproghrelin-derived peptides, ghrelin and obestatin100,101,102. 
Importantly, in vivo co-overexpression of GPR39 and preproghrelin 
during muscle regeneration resulted in an larger enhancement of 
the myogenic markers compared to that obtained from GPR39 or 
preproghrelin overexpression alone.
At the end of muscle regeneration, obestatin showed to increase the 
area of newly formed muscle fiber. However, muscle function is not 
only proportional to the muscle size but also depends on the myo-
nuclei density in each myofiber, which is determined by SCs differ-
99.  Yin, H. et al. Satellite cells and the muscle stem cell niche. Physiol. Rev. 2013; 93(1):23-67.
100.  Gurriarán-Rodríguez, U. et al. The obestatin/GPR39 system is up-regulated by muscle in-
jury and functions as an autocrine regenerative system. J. Biol. Chem. 2012; 287(45): 38379-89.
101.  Filigheddu, N. et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of 
C2C12 skeletal muscle cells. Mol. Biol. Cell. 2007; 18: 986–94.
102.  Porporato, P.E. et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in 
mice. J. Clin. Invest. 2013;123(2):611-22.
entiation and fusion. In this sense, obestatin also promoted augment 
the number of myonuclei in agreement with the regulation of satellite 
cell activity. This duality might be interpreted as a result of elevated 
proliferation of satellite cell proliferation would provide an elevated 
potential for transcription and ultimately greater protein translation 
with little alteration in the kinetics of protein synthesis, leading to 
muscle hypertrophy. However, the role of SCs in the hypertrophy 
response is unclear103. In various experimental models, hypertrophy 
response was observed with no SCs incorporation104,105. On the other 
hand, several studies demonstrated the contribution of satellite cells to 
hypertrophy response in adult muscles106,107. In our particular case, the 
data obtained from obestatin stimulation 3 days after C2C12 differ-
entiation or in AraC-treated cultures displayed similar enhancement 
of myofiber area and fusion. Furthermore, the protein expression of 
myogenin and MHC was not affect by AraC treatment. Therefore, the 
hypertrophic response to obestatin is not associated with and depend-
ent on the addition of new myonuclei via proliferation and further 
fusion. The degree of muscle hypertrophy is strongly associated with 
the degree of Akt/mTOR/S6K1 activation108,109, a pathway activated by 
obestatin during the distinct skeletal muscle regeneration processes 
or the differentiation program. This pathway controls mechanisms of 
protein synthesis at several stages (e.g., translation capacity, translation 
efficiency) through increases of translation of specific mRNAs, which 
terminate in myotube and fiber enlargement.  Thus, we show that 
obestatin controls distinct stages  from the myogenic program: pro-
liferation, differentiation, myoblast fusion and hypertrophy response. 
These roles suggest different mechanisms of action in the processes 
associated to the skeletal muscle regeneration. 
In addition to the myogenic action, obestatin showed to regulate the 
expression of factors that define the regenerative microenvironment 
responsible for stimulating and coordinating skeletal muscle 
repair. Obestatin showed to increase the expression of VEGF and its 
receptor isoform VEGF-R2 during muscle regeneration. In addition 
to its myogenic action110, VEGF showed to stimulate muscle healing 
103.  O’Connor, R. S. et al. Last word on point: counterpoint: satellite cell addition is/is not obli-
gatory for skeletal muscle hypertrophy J. Appl. Physiol. 2007;103:1107.
104.  McCarthy, J. J. et al. Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. 
Development. 2011; 138: 3657–66.
105.  Wang, Q. et al. Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell 
activation J. Physiol. 2012; 590: 2151–65.
106.  Guerci, A. et al. Srf-dependent paracrine signals produced by myofibers control satellite 
cell-mediated skeletal muscle hypertrophy. Cell Metab. 2012;15(1): 25-37.
107.  Serrano, A. L. et al. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal 
muscle hypertrophy. Cell Metab. 2008; 33-44.
108.  Lee, C.H. et al. mTOR pathway as a target in tissue hypertrophy. Annu. Rev. Pharmacol. 
Toxicol. 2007; 47:443-67. 
109.  Glass, D. J. Skeletal muscle hypertrophy and atrophy signalling pathways. Int. J. Biochem. 
Cell. Biol. 2005; 37(10): 1974-84.
110.  Bryan, B. A. et al. Coordinated vascular endothelial growth factor expression and signalling 
during skeletal myogenic differentiation. Mol. Biol. Cell. 2008; 19: 994 –1006.
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by promoting angiogenesis111,112,113. In particular, VEGF produced 
by differentiating myocytes, provides the needed vascularization 
of developing skeletal muscle. Our results further indicated that 
obestatin-treated injured muscles increased capillary density being 
indicative of enhanced microvascularization. These new developed 
capillaries, sprout out from peripheral surviving capillaries, would 
help to provide the injured area with oxygen and substrates aiding 
in the regenerative process. Added to vascularization, obestatin 
treatment did not increase collagen deposition in regenerating 
muscle ruling out a fibrotic response. Thus, the enhancement of 
vascularization through the expression of the VEGF/VEGFR2 system 
and a normal accumulation of fibrous connective tissue contribute to 
the regenerative role of obestatin. 
Obestatin reduced the expression of the endogenous muscle growth 
regulator myostatin. One mechanism by which myostatin regulates 
muscle growth appears to be direct inhibition of the proliferation and 
differentiation of SCs114,115,116. However, myostatin not only regulates 
the growth of myocytes but also directly regulates muscle fibrosis 
through stimulation of muscle fibroblasts and expression of extracel-
lular matrix protein such as collagen117. Therefore, it is reasonable to 
expect that, in addition to its own myogenic effect, obestatin has the 
potential to increase muscle regeneration through a regulatory role 
on myostatin expression.
One of the most remarkable observations from this study was 
that obestatin has multiple functional properties associated to 
skeletal muscle regeneration, and its capacity to stimulate myoblast 
proliferation, differentiation, myoblast fusion and hypertrophy 
response is under regulation of a kinase hierarchy. In C2C12 
differentiating myoblasts, obestatin showed to enhance ERK, Akt, 
CamkII and p38 activities. These pathways displayed the ability to 
execute different stages of the regeneration program. The ERK1/2 
belongs to a well-defined pathway, which is critical for cellular 
proliferation and migration118. In the context of obestatin-induced 
111. Patel-Hett, S. et al. Signal transduction in vasculogenesis and developmental angiogenesis. 
Int. J. Dev. Biol. 2011; 55: 353-63.
112.  Deasy, B.M. et al. Effect of VEGF on the regenerative capacity of muscle stem cells in dys-
trophic skeletal muscle. Mol. Ther. 2009 ;17(10):1788-98. 
113.  Messina, S. et al. VEGF overexpression via adeno-associated virus gene transfer pro-
motes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J. 
2007;21(13):3737-46. 
114.  McCroskery, S. et al. Myostatin negatively regulates satellite cell activation and self-re-
newal. J. Cell. Biol. 2003;162(6):1135-47. 
115. Wagner, K.R. et al. Muscle regeneration in the prolonged absence of myostatin. Proc. Natl. 
Acad. Sci. U S A. 2005; 102(7): 2519-24. 
116.  Schuelke, M. et al. Myostatin mutation associated with gross muscle hypertrophy in a 
child. N. Engl. J. Med. 2004; 350(26):2682-8.
117.  Bo Li, Z. et al.  Inhibition of myostatin reverses muscle fibrosis through apoptosis. J. Cell Sci. 
2012; 125(17): 3957-65. 
118.  Leloup, L. et al. Involvement of the ERK/MAP kinase signalling pathway in milli-calpain 
activation and myogenic cell migration. Int. J. Biochem. Cell Biol. 2007; 39: 1177–89.
activity, ERK does initially decrease with myoblast differentiation, 
which is necessary for differentiating myoblasts to overcome its 
inhibitory effect. In fact, ERK was showed to inhibit differentiation 
by preventing the nuclear accumulation of members of the 
myocyte enhancer factor-2 (MEF2)119, and the expression of certain 
myogenic factors, including MyoD120 and the CDK inhibitor p21121. 
CamkII signalling prevents formation of MEF2–HDAC complexes by 
phosphorylation of HDAC4/HDAC5, promoting nuclear export of 
these transcriptional repressors and rising MEF2 activity on muscle 
specific genes such as MyoD and myogenin122. In particular the faster 
activation of CamKII by obestatin (≥12 h), compared with that of 
control (≥144 h), is not consistent with an earlier expression response 
to obestatin of myogenin, compared with control. This reflects 
additional roles for CamKII in the obestatin-regulated signalling 
during differentiation. In this sense, it is possible to speculate about 
the role of this kinase in the regulation of cell cycle, and hence, 
controlling proliferative step during differentiation. This is based on 
role described on G2/M and the metaphase-anaphase transition123. 
The Akt pathway has emerged as a critical signalling node within 
myogenic program. Consequences of Akt activation include diverse 
responses, ranging from primarily metabolic functions such as 
glucose transport, glycolysis, glycogen synthesis and the suppression 
of gluconeogenesis to protein synthesis, increased cell size, cell-cycle 
progression and apoptosis suppression124. Obestatin showed to 
increase activated levels of Akt during myogenesis, from proliferating 
to differentiating cells. The wide range of cellular functions mediated 
by this kinase is related to the different Akt isoforms. Thus, Akt1 
was described essential early in differentiation leading to cell cycle 
progression125. By contrast, Akt2 triggers myoblast cell cycle exit and 
drives differentiation determining myotube maturation126. Following 
commitment to differentiation, the hypertrophic muscle growth 
induced by obestatin might be under regulation of the downstream 
effectors of the Akt pathway, FoxO1 and FoxO3a127. Indeed, obestatin 
119.  Winter, B. et al. Activated raf kinase inhibits muscle cell differentiation through a MEF2-de-
pendent mechanism. J. Cell. Sci. 2000;113 (23):4211-20.
120.  Gredinger, E. et al. Mitogen-activated protein kinase pathway is involved in the differentia-
tion of muscle cells. J. Biol. Chem. 1998; 273(17): 10436-44.
121.  Wu, Z. et al. p38 and extracellular signal-regulated kinases regulate the myogenic program 
at multiple steps. Mol. Cell Biol. 2000; 20(11): 3951-64.
122.  Scicchitano, B. M. et al. Vasopressin-dependent myogenic cell differentiation is mediated 
by both Ca2+/calmodulin-dependent kinase and calcineurin pathways. Mol. Biol. Cell. 2005; 
16(8): 3632-41.
123.  Skelding, K. A. et al. Controlling the cell cycle: the role of calcium/calmodulin-stimulated 
protein kinases I and II. Cell Cycle. 2011; 10(4): 631-9.
124.  Wu, M. et al. Akt/protein kinase B in skeletal muscle physiology and pathology. J. Cell Phy-
siol. 2007; 226: 29 –36.
125.  Rotwein, P. et al. Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation. J. Cell. 
Physiol. 2009; 219(2): 503-11.
126.  Héron-Milhavet, L. et al. Only Akt1 is required for proliferation, while Akt2 promotes cell 
cycle exit through p21 binding. Mol. Cell. Biol. 2006; 26(22): 8267-80.
127. Glass, D. J. et al. Skeletal muscle hypertrophy and atrophy signalling pathways. Int. J. Bio-
chem. Cell. Biol. 2005;37(10):1974-84.
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increased S6K1 activity, a key downstream signalling effector of Akt/
mTOR for regulation of muscle cytoplasmic volume128. Other effectors 
of the Akt/mTOR, such as FoxO transcription factors might contribute 
to control obestatin-induced growth. The obestatin-induced 
inactivation of FoxO1 and FoxO3a by phosphorylation could justify 
such a function129,130,131.The relative contribution of this pathway 
for the control of muscle cytoplasmic volume by obestatin remains 
lower than the contribution by S6K1. p38 kinase activity increased 
over the course of differentiation under obestatin treatment that fit 
well with the established role of this kinase in skeletal myogenesis. In 
fact, p38 stimulates cell cycle arrest and full myoblasts differentiation 
through the control of muscle-specific gene expression132,133 ,134,135 
. Our results further show that obestatin mediates cessation of the 
JNK/cJun proliferation-promoting pathway136, which is a prerequisite 
for the commencement of the differentiation program. Interestingly, 
decreased activation of the JNK/cJun pathway was concomitant 
to p38 activation in differentiation-promoting conditions under 
obestatin treatment. The convergence of these pathways at the 
chromatin level defines the mechanism for integration of mitogenic 
and myogenic signals to direct the transition from quiescence to 
terminal differentiation137. Therefore, obestatin action is a highly 
coordinated process in which various signalling pathways integrate 
to activate a specific gene expression program associated to each 
stage of myofiber formation process.
Once obestatin activates GPR39, two routes are triggered in parallel: 
1) a Gi-dependent, ERK1/2 activation; and ii) a β-arrestin 1-mediated 
signalling pathway causing Akt phosphorylation138,139. Akt activation 
is switched by cross-activation of receptor tyrosine kinases (RTKs), 
128.  Ohanna, M. et al. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors 
for cell cycle and size control. Nat. Cell Biol. 2005; 7(3): 286-94.
129.  Sandri, M. et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atro-
gin-1 and cause skeletal muscle atrophy. Cell. 2004; 117(3): 399-412.
130.  Stitt, T. N. et al.The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-indu-
ced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 2004; 14(3): 395-403.
131.  Glass, D. J. et al. Skeletal muscle hypertrophy and atrophy signalling pathways. Int. J. Bio-
chem. Cell. Biol. 2005; 37(10): 1974-84.
132.  Keren, A. et al. The p38 MAPK signalling pathway: a major regulator of skeletal muscle 
development. Mol.Cell. Endocrinol. 2006; 252(1-2): 224-30.
133.  Lluís, F. et al. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends 
Cell. Biol. 2006; 16(1): 36-44.
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135.  Perdiguero, E. et al. Genetic deficiency of p38alpha reveals its critical role in myoblast cell 
cycle exit: the p38alpha-JNK connection. Cell Cycle. 2007; 6(11):1298-303.
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cycle exit: the p38alpha-JNK connection. Cell Cycle. 2007; 6(11): 1298-303.
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and IGF1/PI3K/AKT pathways during muscle differentiation. Mol. Cell. 2007; 28: 200 –13.
138.  Alén, B. O. et al. The NMR structure of human obestatin in membrane-like environments: 
insights into the structure-bioactivity relationship of obestatin. PLoS One. 2012; 7 (10): E45434.
139.  Alvarez, C. J. et al. Obestatin stimulates Akt signalling in gastric cancer cells through β-ar-
restin-mediated epidermal growth factor receptor transactivation. Endocr. Relat. Cancer. 2009; 
16: 599-611.
i.e. EGFR (REF). In skeletal muscle, obestatin showed to cross-activate 
IGFR, one of the main regulators of muscle mass by stimulating the 
Akt/mTOR pathway140. Under these conditions there was a substan-
tial increase of the IRS-1 phosphorylation at S636/639, sites shown 
to inhibit PI3K binding to IRS-1141 and thus the Akt/mTOR signalling 
associated to IGFR. At present, it is well documented that S6K1 is im-
plicated in a negative feedback loop on IRS-1 S636/639 phosphoryla-
tion to suppress PI3K signalling142,143. Consistent with this finding, our 
results for obestatin showed that the increase of pS6K1(T389) levels 
paralleled to the enhance in pIRS-1(S636/639). Under these condi-
tions, the S6K1 activation impaired IRS-1/PI3K signalling decreasing 
Akt associated signalling to IGFR. Thus, despite the cross-activation of 
IGFR by GPR39, the negative feedback loop from S6K1 to IRS-1 rules 
out the implication of IGFR/IRS-1 in the obestatin-induced Akt/mTOR 
signalling. Therefore, obestatin induces hypertrophy independent of 
IGFR/IRS-1 activity. 
This study suggests that obestatin is an important therapeutic 
approach to stimulate muscle regeneration. The ability to increase 
muscle regeneration and hypertrophic muscle growth together with 
its role on vascularization and regulation of fibrosis, making obestatin 
a promising therapeutic candidate for treatment of trauma-induced 
muscle injuries or skeletal muscle myopathies.
140.  Glass, D. J. et al. Skeletal muscle hypertrophy and atrophy signalling pathways. Int. J. Bio-
chem. Cell. Biol. 2005;37(10): 1974-84.
141.  Um, S. H. et al. Absence of S6K1 protects against age- and diet-induced obesity while 
enhancing insulin sensitivity. Nature. 2004; 431(7005): 200-5. 
142.  Um, S. H et al. Absence of S6K1 protects against age- and diet-induced obesity while en-
hancing insulin sensitivity. Nature. 2004; 431(7005): 200-5.
143.  Zoncu, R. et al. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. 
Rev. Mol. Cell. Biol. 2011; 12(1): 21-35.
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Regulation of SCs division becomes one of the key steps in skeletal 
muscle regeneration to provide a sufficient number of cells to ensure 
the function of the newly formed muscle fibers144. However, it is now 
well established that SCs are limited in the their proliferative capacity, 
and this limitation determines the regenerative potential of the mus-
cle145. Although the proliferative limit may not be crucial during the 
normal life span of an individual, it is vital in situations where cells 
are solicited to proliferate continually. This is the case for inherited 
disorders, such us the muscular dystrophies, characterized by muscle 
weakness and wasting, due to repetitive cycles of degeneration and 
regeneration. This puts a huge and permanent demand on the pool 
of satellite cells146. The development of therapeutic interventions de-
pends on the knowledge of extrinsic and intrinsic regulatory signals 
that control the myogenic process. Previously, we identified a mecha-
nism whereby the obestatin/GPR39 system is coordinately regulated 
as part of the myogenic program and operates as an autocrine signal 
regulating skeletal myogenesis. This was followed by an analysis of 
the potential use of obestatin as a therapeutic agent for treatment of 
trauma-induced muscle injuries. This study suggested that obestatin 
might be an important therapeutic approach to stimulate muscle 
regeneration based on its ability to increase muscle regeneration and 
hypertrophic muscle growth together with its role on vasculariza-
tion and regulation of fibrosis. Based on these results, we decided to 
explore its role on SC activation taking into account its critical role for 
the development of therapeutic interventions. Data presented in the 
present Chapter showed no expression of obestatin in SCs residing 
on isolated myofibers whyle GPR39 expression was detected. Howev-
er, obestatin treatment promoted apical-basal division versus planar 
division of SCs residing in its niche as shown in ex vivo fiber culture, 
favoring SC commitment state instated of quiescent state. This data 
was confirmed after analyzing Myf5 expression on TA along the 
regeneration process, where obestatin-treated muscles increased the 
number of SCs expressing Myf5/Pax7, as well as the number of SCs 
expressing solely Pax7 or Myf5.  It was noteworthy the chemoattrant 
effect displayed by obestatin on SC-derived myoblasts.
The fact that obestatin was not expressed in SCs while GPR39 was 
expressed in SCs suggests that there is a paracrine effect on SCs. This 
is based on: (1) the expression of preproghrelin, and thus obestatin 
in healthy skeletal mucle; (2) the expression of obestatin is strikingly 
increased upon muscle injury; and, (3) silencing of GPR39 expression 
144.  Usas, A. et al. Skeletal muscle-derived stem cells: implications for cell-mediated therapies. 
Medicina. 2011; 47 (9): 469-479. 
145.  Decary, S. et al. Telomere length as a tool to monitor satellite cell amplification for cell 
mediated gene therapy. Hum. Gene. Ther. 1996; 7: 1347-50. 
146.  Renault, V. et al. Skeletal muscle regeneration and the mitotic clock. Experimental Geron-
tology. 2000; 35: 711-9.
in L6E9 myoblast cells demonstrated that this G protein-coupled 
receptor is the extracellular target for obestatin action147. We propose 
that the obestatin/GPR39 system signalling is involved in SC activa-
tion, in which obestatin exerts a paracrine function to control the SC 
activation and an autocrine action on myoblast-derived SCs to drive 
myoblast migration and fusion to reach skeletal myotube forma-
tion. In this way, the autocrine/paracrine action of obestatin would 
operate as a signal regulating skeletal myogenesis under healthy or 
injuried-skeletal muscle. 
SCs persist in muscle that is subjected to repeated cycles of 
degeneration and regeneration, suggesting that self-renewal 
or recruitment maintains the pool of these cells148. Recent 
advances have provided important insights into the role played 
by the microenvironment in regulating stem cell identity and 
the asymmetric generation of committed daughter cells. Stem 
cell polarity and spindle orientation relative to the basal lamina 
determines the fate of daughter cells149,150. Stem cell divisions in 
a planar orientation are mainly symmetric and generate identical 
daughter stem cells. By contrast, stem cell divisions in an apical-
basal orientation are predominantly asymmetric and give rise to 
a stem cell at the basal surface and a committed daughter on the 
apical surface151,152. Obestatin enhanced apical-basal versus planar 
division under ex vivo conditions, thus favoring commitment against 
stemness. It remains unclear what intrinsic mechanism is responsible 
for the orientation of divisions and how subsequent events lead to 
commitment of the apical daughter cell. However, recent insights 
into extrinsic regulators proposed that inhibition of Notch signalling 
drives satellite stem cells to commitment and differentiation153,154  
similarly to embryonic Pax7+/Myf5+ cells in the dermomyotome. 
The expression pattern of Pax7 and Myf5 in TA under obestatin 
treatment during the regeneration process fit well with SCs fate 
following division. During in vivo regeneration, SC division in the 
apical-basal orientation give rise to a committed Myf5+ SC, which is 
pushed into the apical surface, and a daughter cell, which remains 
attached to basal lamina retaining the SC identity. By contrast, planar 
147. Gurriarán-Rodríguez, U. et al. The obestatin/GPR39 system is up-regulated by muscle injury 
and functions as an autocrine regenerative system.J. Biol. Chem. 2012; 287(45):38379-89.
148.  Seale, P. et al. A new look at the origin, function, and ‘‘stem-cell’’ status of muscle satellite 
cells. Dev. Biol. 2000; 218: 115-24.
149.  Fuchs, E. et al. Socializing with the neighbors: stem cells and their niche. Cell. 2004; 116: 
769-78.
150.  Moore, K. A. et al. Stem cells and their niches. Science. 2006; 311: 1880-5.
151.  Knoblich, J. A. The Drosophila nervous system as a model for asymmetric cell division. 
Symp. Soc. Exp. Biol. 2001; 53: 75-89.
152.  Lechler, T. et al. Asymmetric cell divisions promote stratification and differentiation of 
mammalian skin. Nature. 2005; 437: 275-80.
153.  Kuang, S. et al. Asymmetric self-renewal and commitment of satellite stem cells in muscle. 
Cell. 2007; 129: 999-1010. 
154.  Conboy, I. M. et al. The regulation of Notch signalling controls satellite cell activation and 
cell fate determination in postnatal myogenesis. Dev. Cell. 2002; 3:  397-409. 
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divisions of SCs occur along the host myofiber, after which both 
daughter cells remain in contact with the basal lamina, symmetrically 
expand, giving rise to two Pax7+/Myf5- cells155. Our data showed 
in TA treated with obestatin a noteworthy increased in SCs only 
expressing Pax7, as well as the double stained population Pax7/Myf5, 
compared with non treated mice. Both populations are needed for 
fiber homeostasis, Pax7+ cells repopulate SC niche, a self-renewal 
mechanism and Pax7+/Myf5+ give rise to commitment cells. It is also 
noteworthy that obestatin increased Myf5+ cells, giving rise to a 
population of myoblasts triggered toward the differentiation process. 
These data supported the obestatin role as a dual effector on muscle 
recovery increasing the self-niche repopulation (Pax7+) and, in the 
other hand, triggering myogenesis to promote muscle regeneration 
(Pax7+/Myf5+).
Molecular characterization of SCs is providing important insights into 
the molecular mechanisms regulating their function. Our identifica-
tion of a role for the obestatin/GPR39 signal reveals a role in regu-
lating the apical expansion of SCs. This finding represents a signifi-
cant advance in understanding of satellite cell biology and muscle 
regeneration. 
155.  Wang, X. Y. et al. Satellite cells, the engines of muscle repair. Nature Reviews. 2012; 13: 
127-33.
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CHApTEr 1
1. Obestatin activated Akt and its downstream targets, 
GSK3α/β, mTOR and S6K1, in 3T3-L1 adipocyte cells. 
Simultaneously, obestatin inactivated AMPK in this cell 
model. In keeping with this, ACC phosphorylation was 
also decreased. This fact was confirmed in vivo in white 
adipose tissue (omental, subcutaneous and gonadal) 
obtained from male rats under continuous sc infusion of 
obestatin.
2. GPR39 siRNA reduced obestatin action involving this 
receptor as a extracellular target for obestatin.
3. The relevance of obestatin as regulator of adipocyte 
metabolism was supported by AS160 phosphorylation, 
GLUT4 translocation and augment of glucose uptake in 
3T3-L1 adipocyte cells. In contrast, obestatin failed to 
modify translocation of fatty acid transporters, FATP1, 
FATP4 and FAT/CD36, to plasma membrane.
4. Obestatin treatment in combination with IBMX and DEX 
showed to regulate the expression of C/EBPα, C/EBPβ, C/
EBPδ and PPARγ promoting adipogenesis.
5. Obestatin contributes to adipogenesis as an autocrine/
paracrine factor.
CHApTEr 2
1. Insulin promoted the preproghrelin expression throughout 
adipogenesis identifying mTORC1 as a critical downstream 
substrate for this profile. The role of preproghrelin-derived 
peptides on the differentiation process was supported by 
preproghrelin knock-down experiments, which revealed 
its contribution to adipogenesis. Neutralization of 
endogenous O-acyl ghrelin (acylated ghrelin), unacylated 
ghrelin, and obestatin by specific antibodies supported 
their adipogenic potential. A parallel increase in the 
expression of ghrelin-associatedenzymatic machinery, 
prohormone convertase 1/3 (PC1/3) and membrane-
bound O-acyltransferase 4 (MBOAT4), was dependent on 
the expression of preproghrelin in the course of insulin-
induced adipogenesis.
2. The coexpression of preproghrelin system and their 
receptors, GHSR1a and GPR39, during adipogenesis 
supports an autocrine/paracrine role for these peptides.
3. The results underscore a key role for preproghrelin-
derived peptides on adipogenesis through an autocrine/
paracrine mechanism.
4. Preproghrelin, PC1/3, and MBOAT4 exhibited dissimilar 
expression depending on the white fat depot, revealing 
their regulation in a positive energy balance situation in 
mice.
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CHApTEr 3
1. Obestatin and the GPR39 receptor are expressed in rat 
skeletal muscle and are up-regulated upon experimental 
injury.
2. In differentiating L6E9 cells, preproghrelin expression and 
correspondingly obestatin increased during myogenesis 
being sustained throughout terminal differentiation. 
Autocrine action was demonstrated by neutralization and 
knock-down experiments confirming the contribution of 
obestatin to the myogenic program.
3. GPR39 siRNA reduced obestatin action and myogenic 
differentiation.
4. Exogenous obestatin stimulation was also shown to 
regulate myoblast migration and proliferation. 
5. The addition of obestatin to the differentiation medium 
increased myogenic differentiation of L6E9 cells. The 
relevance of the actions of obestatin was confirmed in 
vivo by the up-regulation of Pax7, MyoD, Myf5, Myf6, 
myogenin, and MHC in obestatin-infused rats when 
compared with saline-infused rats.
CHApTEr 4
1. Obestatin activated Akt and its downstream targets, 
GSK3α/β, and S6K1, in L6E9 myotube cells. Simultaneously, 
obestatin inactivated AMPK in this cell model. In keeping 
with this, ACC phosphorylation was also decreased. 
This fact was confirmed in vivo in rat skeletal muscle, 
gastrocnemius and soleus, obtained from male rats under 
continuous sc infusion of obestatin.
2. The relevance of obestatin as regulator of adipocyte 
metabolism was supported by AS160 phosphorylation, 
GLUT4 translocation and augment of glucose uptake 
L6E9 myotube cells. Furthermore, the effect of obestatin 
in glucose up-take was also observed in gastrocnemius 
and soleus muscle.
Conclusions
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CHApTEr 5
1. The overexpression of the obestatin/GPR39 in skeletal 
muscle enhanced muscle regeneration after muscle injury
2. The intramuscular injection markedly enhances muscle 
regeneration, as evidenced by upregulation of the 
expression of the specific myogenic factors Pax7, MyoD, 
myogenin and eMHC, and, importantly, the significant 
increase of the myofiber size and the number of myonuclei 
per myofiber
3. The up-regulation of the specific satellite cells marker Pax7 
associated to the increased number of activated satellite 
cell (Pax7+) per myofiber demonstrated the actions of 
obestatin on satellite cells
4. The effective action was due to specific regulation of 
this peptide on different stages affecting myogenesis: 
proliferation, fusion and myofiber growth.
5. Added to the myogenic action, obestatin administration 
resulted in increased expression of VEGF/VEGFR2 and 
the consequent microvascularization, with no significant 
effect on collagen deposition in developing skeletal 
muscle
6. The potential inhibition of myostatin might contribute 
to the myogenic action improving muscle growth and 
regeneration.
7. The myogenic actions of obestatin were coordinated by 
a kinase hierarchy determined by the ERK1/2, CamkII, Akt 
and p38 axis. 
CHApTEr 6
1. GPR39 was expressed in SCs while no expression was 
observed for obestatin. 
2. Obestatin enhances SCs apical-basal division versus 
planar division on ex vivo myofibers.
3. Obestatin promotes ex vivo myoblast migration acting as 
chemoattrant molecule. 
4. Obestatin enhances Pax7+, Pax7+/Myf5+, Myf5+ satellite 
cells populations during muscle in vivo regeneration, 
changing the ratio and the fate of the daughter cells, thus 
favoring commitment against stemness..
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Dentro das diferentes capas xerminais, a capa mesodérmica, é a 
orixe común de varios tipos de tecidos, entre eles, o tecido adi-
poso e o muscular. Son as células mesenquimais (MSCs) prove-
nientes do mesodermo, as que tras diversos procesos de diferen-
ciación embrionaria dan lugar aos adipocitos e miotubos. Con 
todo, as MSCs non son a únicas implicadas no desenvolvemento 
embrionario e nos estadíos pre-natais, certos tecidos adultos 
manteñen pequenas cantidades de MSCs con potencial para dar 
lugar a todo tipo de células dos tecidos onde residen, de maneira 
que poden reparar ou substituír tecido, ou expandirse en respos-
ta a un exceso enerxético crónico1. Este proceso está regulado 
por mecanismos moleculares complexos, aínda non coñecidos 
na súa totalidade. Numerosas publicacións demostraron o amplo 
potencial terapéutico das MSCs, debido á súa habilidade para di-
ferenciarse en múltiples tipos celulares en condicións apropiadas 
despois do nacemento2,3,4. 
Durante a última década, os tecidos adiposo e muscular foron iden-
tificados como órganos secretores cunha función autócrina/pará-
crina5,6. De acordo con esta identificación, as citoquinas e outros 
péptidos liberados polo tecido muscular e adiposo deberían ser 
clasificados como mioquinas e adipoquinas, respectivamente. Este 
feito proporciona un novo paradigma conceptual, no cal os diferen-
tes tecidos están intercomunicados con outros órganos e xogan un 
papel global no metabolismo enerxético. Certas hormonas actúan 
a nivel local como factores parácrinos; con todo, outras teñen un al-
cance máis amplo actuando a nivel do sistema central. Esta acción 
recíproca entre mioquinas e adipoquinas representa un balance de 
positividade e negatividade, especialmente en condicións patolóxi-
cas, como a obesidade, onde os adipocitos secretan adipoquinas 
que contribúen a establecer un ambiente inflamatorio crónico que 
promove os procesos patolóxicos, tales como artereoesclerose e 
resistencia insulínica, así mesmo o músculo esquelético en con-
1.  Xiang, X. et al. mTOR and the differentiation of mesenchymal stem cells. Acta 
Biochim. Biophys. Sin. 2011; 43 (7): 501-10.
2.  Malek, A. et al. Human placental stem cells: biomedical potential and clinical rel-
evance. J. Stem Cells. 2011; 6 (2): 75-92.
3.  Ball,S. G. et al. Mesenchymal stromal cells: Inhibiting PDGF receptors or depleting fi-
bronectin induces mesodermal progenitors with endothelial potential. Stem Cells. 2013
4.  Hughey, C. C. et al. Mesenchymal stem cell transplantation for the infarcted heart: 
therapeutic potential for insulin resistance beyond the heart. Cardiovasc. Diabetol. 
2013;12(1):128.
5. Pedersen, B. K. et al. Muscle as a secretory organ. Compr. Physiol.2013;3(3):1337-62.
6.  Trayhurn, P. et al. Secreted proteins from adipose tissue and skeletal muscle - 
adipokines, myokines and adipose/muscle cross-talk. Arch. Physiol. Biochem. 
2011;117(2):47-56.
dicións de exercicio é capaz de producir mioquinas que confiren 
beneficios saudables, tales como mioquinas que contrarrestan o 
efecto daniño das adipoquinas inflamatorias.
Polo tanto o estudo de factores secretados polos tecidos de orixe 
común como o muscular e adiposo, e a súa implicación autócri-
na/parácrina no proceso de diferenciación, son de gran utilidade 
para a identificación de dianas terapéuticas, contribuíndo ao 
coñecemento e tratamento das patoloxías relacionadas con anor-
malidades nos procesos de diferenciación celular.
Como punto de partida para as nosas investigacións tomamos 
o proceso de diferenciación adipoxénica, onde unha activación 
secuencial de factores de transcrición traducen información de 
sinais intra e extra-celulares indicativas das condicións acerta-
das para a diferenciación. Numerosas moléculas endócrinas, 
parácrinas e autócrinas están asociadas con cambios dinámicos 
no tecido adiposo. Recientemente, o péptido gástrico grelina 
suscitou especial atención polo seu papel como factor regulador 
da bioloxía adipocitaria. O xene da grelina está codificado por 
un polipéptido, prepropéptido, denominado preprogrelina, que 
sofre un procesamento posterior producindo dous péptidos: a 
obestatina e a grelina. A obestatina, un peptido de 23 aminoá-
cidos, foi orixinalmente identificado e illado do estómago. Este 
péptido circulante mostra unha secreción pulsátil cunha ritmici-
dade ultradiana similar á grelina ou á hormona de crecemento. A 
acción da obestatina foi descrita inicialmente a través do receptor 
orfo GPR39, un receptor de sete dominios transmembrana per-
tencente á familia de receptores como o GHSR1a da grelina ou o 
da motilina. A pesar do entusiasmo inicial suscitado por devandi-
ta molécula, dado o potencial que posuía polos seus efectos anta-
gónicos á grelina, numerosas observacións puxeron a súa efectivi-
dade en cuestión. Consecuentemente, o estado de coñecemento 
da obestatina sofre numerosas lagoas, especialmente pola falta 
de reproducibilidade da súa actividade a nivel central. Mantendo 
separadamente a controversia sobre o seu poder anorexixénico, 
existen varias publicacións que demostran a súa actividade en 
diferentes accións biolóxicas7,8,9. Neste sentido, propuxémosnos 
7.  Pedersen, B. K. et al. Muscles, exercise and obesity: skeletal muscle as a secreto-
ry organ. Nat. Rev. Endocrinol. 2012; 8: 457-65.
8.  Zhang, J. V. et al. Obestatin induction of early-response gene expression in 
gastrointestinal and adipose tissues and the mediatory role of G protein-coupled 
receptor, GPR39. Mol. Endocrinol. 2008; 22: 1464-75.
9.  Sheng-Qiu, T. et al. Obestatin- Its physicochemical characteristics and physio-
logical functions. Peptides. 2008; 29: 639-645
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estudar a súa función nos procesos de diferenciación de orixe co-
mún, a adipoxénese e a mioxénese, así como a súa posible acción 
metabólica en ambas dianas tisulares. 
A nosa investigación parte da estimación do papel da obestatina 
sobre o control do metabolismo de preadipocitos e adipocitos 
así como da adipoxenese. Para os ensaios in vitro, empregamos 
os preadipocitos 3T3-L1 baseándonos na regulación de nodos 
clave de señalización, Akt e AMPK e as súas dianas intracelulares. 
Para os ensaios in vivo, utilizamos tecido adiposo branco de ratas 
macho baixo a administración continuada de obestatina. Este 
péptido activou Akt e as súas dianas, GSK3α/β, mTOR e S6K1, en 
adipocitos 3T3-L1. Simultaneamente, a obestatina inactivou AMPK 
neste modelo celular. En relación con esta diana, a fosforilación 
de ACC foi tamén diminuída. Estes datos comprobáronse in 
vivo en tecido adiposo branco (omental, subcutaneo e gonadal) 
obtido de ratas macho baixo a administración sc de obestatina 
durante 24 e 72h. A relevancia da obestatina como regulador 
do metabolismo adipocitario está apoiado pola fosforilación de 
AS160, pola traslocación de GLUT4 á membrana plasmatica e o 
consecuente aumento da captación de glicosa polo adipocitos 
3T3-L1. Pola contra, a obestatina non mostrou efecto significativo 
sobre a traslocación á membrana plasmática dos transportadores 
de acedos graxos FATP1, FATP4 e FAT/CD36. O tratamento con 
obestatina en combinación con IBMX e DEX regulou a expresión 
de C/EBPα, C/EBPβ, C/EBPσ e PPARγ promovendo a adipoxénese. 
De forma destacable, a expresión da preprogrelina, e polo tanto 
de obestatina, aumentou durante o proceso de adipoxénese 
sendo sostida durante a diferenciación terminal. A neutralización 
de obestatina endóxena secretada polas células 3T3-L1 mediante 
anticorpo anti-obestatina diminuíu a adipoxénese. Ademais, 
os ensaios de silenciado de preproghrelin mediante siRNA 
apoiaron os datos previos. En resumo, a obestatina promoveu a 
adipoxénese dun modo autócrino/parácrino, sendo un regulador 
do metabolismo adipocitario.
En base aos datos obtidos sobre a expresión da preprogrelina 
durante a adipoxénese, optamos por profundar no papel exercido 
polos péptidos derivados da grelina e a obestatina sobre o 
programa de diferenciación. A análise inmunocitoquímico 
de adipocitos 3T3-L1 mostrou un maior grao de expresión de 
preprogrelina en relación á súa expresión en preadipocitos. 
A insulina promoveu devandito patrón de expresión durante 
o desenvolvemento da adipoxénese identificando a mTORC1 
como un nodo intracelular de señalización clave para esta 
acción. O papel dos péptidos derivados da preprogrelina sobre 
a adipoxénese confirmouse mediante ensaios de silenciado, os 
cales revelaron a súa contribución á diferenciación adipocitaria. 
A neutralización de O-acil grelina (grelina acilada), grelina 
desacilada e obestatina mediante a utilización de anticorpos 
específicos apoiaron os datos obtidos previamente. Ademais, 
constatouse que a expresion da maquinaria enzimática asociada 
ao procesado da grelina, PC1/3 e MBOAT4, foi dependente e 
paralela á expresión da preprogrelina na adipoxénese inducida 
por insulina. A co-expresión de GHSR1a e GPR39 durante a 
adipoxénese apoiou o papel autócrino/parácrino dos péptidos 
derivados da preprogrelina. MBOAT4, PC1/3 e preprogrelina 
mostraron diferentes graos de expresión en función do 
tipo de tecido adiposo branco analizado. Nós propoñemos 
un mecanismo polo cal a insulina activa a expresión de 
preprogrelina e a consecuente secreción dos péptidos derivados 
de preprogrelina, os cales intensifican o efecto da insulina na 
activación das cascadas implicadas en adipoxénese, tales como 
Akt e as súas dianas, dun xeito autócrino en preadipocitos. 
Unha vez analizada a implicación autócrina da obestatina 
e os péptidos derivados da preprogrelina no metabolismo 
adipocitario, o noso seguinte obxectivo era estudar o papel 
autócrino da obestatina nun segundo proceso de diferenciación 
e de orixe común, a mioxénese. O mantemento e reparación do 
músculo esquelético é atribuíble a unha elaborada interacción 
entre sinais reguladoras extrínsecas e intrínsecas implicadas 
no proceso de mioxénese. Os nosos resultados mostraron 
que a obestatina e o receptor GPR39 están expresados no 
tecido muscular esquelético de rata e que a súa expresión vese 
aumentada logo da indución dun dano experimental no músculo 
esquelético. Para definir o papel do sistema obestatina/GPR39 
na rexeneración muscular, utilizamos as células L6E9 para os 
ensaios in vitro. Para os ensaios in vivo, utilizouse tecido muscular 
esquelético obtido de ratas macho trala infusión continuada 
de obestatina. En células L6E9, a expresión de preprogrelina 
e obestatina aumentou durante o progreso da mioxénese 
sendo sostida na etapa tardía do mesmo. A acción autócrina 
demostrouse mediante ensaios de silenciado de preprogrelina 
utilizando siRNA durante o progreso da mioxénese. Estes datos, 
atribuíbles á obestatina, confirmáronse trala súa neutralización 
durante a mioxénese, empregando anticorpos específicos anti-
obestatina. Ademais, o silenciado de GPR39 diminuíu a acción 
da obestatina así como o grao de progresión da mioxénese. A 
administración esóxena de obestatina mostrou regular tanto 
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a proliferación como a migración de mioblastos, así como un 
aumento da diferenciación mioxénica das células L6E9, cun poder 
hipertrófico. Estes datos foron ratificados in vivo, tras someter 
a ratas a unha infusión continua de obestatina; os resultados 
mostraron unha sobreexpresión de marcadores mioxénicos: Pax7, 
Myf5, MyoD, myogenin, Myf6 e MHC trala infusión de obestatina, 
así como de marcadores implicados na vascularización tales como 
VEGF e o seu receptor e PEDF. A análise do diámetro das fibras 
mostrou un poder hipertrófico que concordaba cos datos obtidos 
in vitro.
O conxunto de resultados obtidos demostrou o efecto autócrino 
do sistema obestatina/GPR39 sobre a mioxénese e o poder 
hipertrófico que esta exerce, así mesmo arroxaron a posibilidade 
de que o sistema obestatina/GPR39 tivese un potencial 
terapéutico no tratamento de traumas inducidos por un dano 
muscular ou o tratamento de miopatías
O aumento do diámetro das fibras, e os datos obtidos 
previamente en adipocitos que indicaban un incremento na 
captación de glicosa trala adición de obestatina, leváronnos a 
propoñer como hipótese que o maior diámetro da fibra podía ser 
debido a un aumento na captación de glicosa trala estimulación 
de obestatina.
A nivel de regulación do metabolismo do músculo esquelético, 
estudamos os nodos clave de señalización, Akt e AMPK e as súas 
dianas intracelulares de forma similar ao que realizamos no tecido 
adiposo. A obestatina activou Akt e as súas dianas, GSK3α/β, 
e S6K1, en miotubos L6E9. Simultáneamente, a obestatina 
inactivou AMPK neste modelo celular. En relación con esta 
diana, a fosforilación de ACC foi tamén diminuída. Estes datos 
comprobáronse in vivo en tecido muscular esquelético (sóleo 
e gastronemio) obtido de ratas macho baixo a administración 
sc de obestatina. A relevancia da obestatina como regulador 
do metabolismo muscular está apoiado pola fosforilación de 
AS160, e pola translocación de GLUT4 á membrana plasmática 
e consecuente aumento da captación de glicosa en miotubos 
L6E9. Este feito foi confirmado en tecido muscular esquelético. 
Estes datos demostraron que ademais da acción miogénica, 
previamente descrita, o sistema obestatina/GPR39 tamén mostra 
unha regulación sobre o metabolismo muscular a través da 
regulación da captación de glicosa.
A capacidade rexenerativa do músculo esquelético é crítica para 
o mantemento e cura de devandito tecido tanto en condicións 
normais como no caso das miopatías asociadas. Por iso, o 
desenvolvemento de intervencións terapéuticas depende en 
gran medida do coñecemento dos sinais intrínsecos e extrínsecos 
que regulan o proceso da mioxénese. En base aos resultados 
obtidos sobre o sistema obestatina/GPR39 sobre este proceso 
de diferenciación, é lóxico explorar o seu uso potencial como 
axente terapéutico para o tratamento do dano muscular inducido 
por dano. Para iso utilizamos un modelo animal de regeneración 
de músculo esquelético inducida por dano así como diferentes 
aproximación experimentais mediante o uso de células C2C12. 
Os resultados obtidos demostraron que a sobre-expresión do 
sistema obestatina/GPR39 no músculo esquelético previa á 
indución do dano muscular no TA aumentou a capacidade de 
rexeneración da zona afectada. Con todo, esta aproximación 
producía un dano consecuencia da metodoloxía aplicada, o 
que non nos permitiu diferenciar dunha forma clara a zona de 
rexeneración asociada ao dano por electroporación á zona de 
rexeneración asociada ao dano inducido. Con todo, a indución 
de dano en TA e posterior administración intramuscular local 
de obestatina demostrou de forma inequívoca un aumento 
significativo da capacidade rexenerativa do músculo. Iso 
púidose comprobar polo aumento da expresión de factores 
mioxénicos específicos como Pax7, MyoD, myogenin e eMHC. 
Este tratamento produciu ademais un aumento do tamaño 
das miofibras rexeneradas así como do número de mionúcleos 
asociados. A sobre-expresión do marcador Pax7, asociado ao 
aumento do número de células Pax7 por miofibra demostrou a 
acción da obestatina sobre a activación das células satélite (SCs). 
A acción pro-miogénica neste modelo de dano muscular está 
avalada pola regulación das diferentes etapas da mioxénese: 
proliferación, fusión e crecemento da miofibra (hipertrofia). 
Engadido á acción propia da obestatina sobre a mioxénese, 
este péptido mostrou inducir un aumento da expresión de 
VEGF/VEGFR2 e a consecuente microvascularización na zona 
de rexeneración, sen efecto significativo sobre a deposición 
de coláxeno na zona de rexeneración. A iso debemos engadir 
que a obestatina diminuíu a expresión do factor inhibidor 
do crecemento muscular, a miostatina, durante o proceso de 
regeneración. É importante sinalar que as accións mioxénicas 
da obestatina mostráronse reguladas por unha activación 
de tipo xerárquico de ERK1/2, CamkII, Akt e p38. Concluímos 
este capítulo demostrando que a obestatina regula o proceso 
multifactorial da regeneración muscular. O tratamento con 
obestatina aumenta a regeneración e a vascularización 
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necesaria para un bo restablecimiento da actividade muscular, 
sen incrementar por iso a fibrosis muscular. 
Estudos realizados en miofibras illadas obtidas das zonas 
próximas ao dano muscular, durante a regeneración, demostraron 
que as SCs eran activas de forma significativa, mostrando 
unha alta porcentaxe de división tipo apical-basal; o que 
permite afirmar que ademais da xeración de células dirixidas á 
rexeneración (Pax7+ /Myf5+ ), a obestatina garante a repoboación 
da SCs en estado quiescente (Pax7+ /Myf5-). Engadido a este 
efecto, a obestatina mostrou ademais características de molécula 
quimiatraiente sobre os miobastos derivado das SCs o que 
xustifica a súa acción sobre a migración destas células á zona 
de dano. No seu conxunto, estes resultados demostraron que a 
obestatina regula positivamente a rexeneración muscular in vivo, 
mostra, ademais, características mioxénicas importantes como 
para considerala un potencial axente terapéutico a desenvolver 
para o tratamento de patologías asociadas á rexeneración do 
músculo esquelético incluíndo a sarcopenia, a caquexia e a 
distrofia muscular.
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